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Abstract 
Osteoporosis represents an ever increasing burden to health care services world-
wide. Within the UK alone, over 500 000 fragility fractures secondary to 
osteoporosis occur each year, resulting in significant morbidity and mortality. 
Furthermore, the management of these injuries cost health care services billions 
of pounds. A revolution in the diagnosis and treatment of the disease is required 
to prevent significant suffering of future generations. 
MicroRNAs are known to regulate many key physiological processes, including 
mesenchymal stromal cell (MSC) differentiation. They have been demonstrated 
to be abnormally expressed in many musculoskeletal conditions, including 
osteoporosis. Patients who have suffered a neck of femur fracture are known to 
be at risk of, or have undiagnosed, osteoporosis. Dysregulated microRNAs have 
been identified in bone and serum samples of patients with this injury type. 
Great hope has been placed on the development of targeted therapies to 
manipulate microRNA expression and improve bone quality. 
This study has focussed on rigorously assessing the functionality of MSCs from 
patients who have suffered a neck of femur fracture. Extracellular MSC markers 
and differentiation capacity were shown to be significantly altered within this 
patient group. MicroRNA expression was analysed, and key microRNAs, 
microRNA-143 and microRNA-31, were manipulated using functionalised gold 
nanoparticles to further understand their role in MSC differentiation. 
Furthermore, the metabolomic effect of inhibiting microRNA-31 was explored to 
further understand its role in osteogenesis. To reduce the gap between in vitro 
and clinical research an optimal 3D, scaffold free, culture model was identified 
for bone marrow derived MSCs. 
These results provide further insight to the impaired MSC function of patients 
who have suffered a fragility fracture. Furthermore, the potential of microRNAs 
to be utilised as a biomarker or therapeutic target for osteoporosis has been 
reinforced. 
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Chapter 1 
  
 
 
2 
 
1.1 Osteoporosis  
Osteoporosis (OP) is a systemic skeletal disease, which is characterised by low 
bone mass and microarchitectural deterioration of bone tissue, resulting in an 
increase in bone fragility with susceptibility to fracture. The disease has become 
vastly more prevalent, and health care services and current therapies have 
failed to cope with the increasing demands (Khosla and Hofbauer, 2017). A 
revolution is required for the management of this disease, to prevent significant 
morbidity and mortality to future generations. 
1.1.1 Disease mechanism of action 
The World Health Organization utilises T scores for its diagnostic criteria of OP. 
The T score is derived by calculating the bone mineral density (BMD), via dual-
energy X-ray absorptiometry (DXA) applied to the femoral neck of a patient. OP 
is defined as a bone mineral density (BMD) of 2.5 standard deviations or more 
below the average value for a young, healthy control, with low bone mass, 
osteopaenia, defined as a T score of between -1 and -2.5  (World Health 
Organization, 2007). The disease itself is asymptomatic and it commonly remains 
undiagnosed until a fragility fracture occurs. 
As bone mass, and its loss, are intrinsic to the definition of OP, factors which 
affect the attainment of peak bone mass and the rate of its loss are therefore 
precipitators of the disease (Miller and Thompson, 2016). Peak bone mass occurs 
in the third decade of life. Bone mass is then lost faster in women, with an 
acceleration occurring after the menopause. Both sexes suffer a net decline in 
bone mass and this natural decline can result in OP. However, there are many 
other contributors which can result in OP, see Table 1-1. 
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Table 1-1 List of BMD dependent and independent factors associated with an increased risk 
of developing OP (Miller and Thompson, 2016; Ramachandran and Nunn, 2018).  
Risk Factors for Osteoporosis 
Gender Female 
Ageing With each decade there is a 1.4-1.8-fold 
increased risk of the disease 
Ethnicity Increased risk if northern European or Asian 
Sex hormone deficiency Oestrogen and testosterone 
Low Body Mass Index (kg/m2) <19 kg/m2 
Lifestyle excessive exercise, immobilisation, smoking, 
alcohol 
Chronic Disease osteogenesis imperfecta, rheumatoid arthritis 
chronic obstructive pulmonary disease, 
chronic kidney disease, liver disease 
Drugs Glucocorticoids, corticosteroids, thyroxine, 
heparin, phenytoin, antiandrogens, 
chemotherapy,  
Gastrointestinal Malabsorption, vitamin D and Calcium 
insufficiency, anorexia nervosa 
Genetic Collagen Type 1 A1, vitamin D receptor and 
oestrogen receptor genes 
Clinical previous fragility fracture, loss of height, 
strong family history of OP 
 
As disease management has improved, along with life expectancy, a greater 
number of people will be taking regular medication and secondary OP due to the 
above causes will be more frequently encountered (McClung, Baron and 
Bouxsein, 2017). Thus, its recognition and appropriate management is crucial to 
preventing fragility fractures. 
1.1.2 Bone in health 
Bone is a highly specialized connective tissue which serves several functions:  
• Reservoir of calcium and phosphate: Bone is the primary reservoir of 
calcium and phosphate in the body. 
• Haematopoiesis: Within cancellous bone the haematopoietic bone marrow 
supplies the body’s cells, tissues and organs with erythrocytes, leukocytes 
and platelets. 
• Protective and mechanical: Bone has protective and mechanical roles, 
protecting soft internal viscera and permitting movement and locomotion 
through attachment of muscles (Ramachandran and Nunn, 2018). 
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Long bones, such as the femur, tibia, radius and ulna have three anatomical 
regions, the epiphysis, metaphysis and diaphysis, Figure 1-0-1. Diaphyseal 
regions of long bones have thick cortices surrounding the intra-medullary canal.  
A
 
B  
Figure 1-0-1 Anatomy of an adult femur. Image A shows common anatomical points of a 
femur and demonstrates key regions, namely diaphyseal- blue box, metaphyseal- red boxes 
and epiphyseal- green boxes. Image B depicts the proximal femur in closer detail and the 
areas within it. Image adapted from (Jones, 2019). 
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Contrastingly metaphyseal regions of bone have thin cortical bone and a denser 
network of cancellous bone, Figure 1-0-2. Epiphyseal regions are located at the 
ends of long bones, contain the physis, also known as the growth plate, and the 
articular surface (Ramachandran and Nunn, 2018). 
 
Figure 1-0-2 Femoral head and neck from patient with osteoarthritis excised during hip 
arthroplasty, imaged during microCT experiment of research project. Coronal microCT  
imaging of the specimen, thick cortical bone in the inferior neck and inter-connected central 
cancellous bone are visible. The physis of the proximal femur is also highlighted, where 
some of the increasing limb length occurs during skeletal growth.  
  
1.1.2.1 Cortical and cancellous bone 
Cortical bone is a subtype of lamellar (mature) bone, it forms the envelope of 
cuboid bones and the diaphysis of long bones, and thus comprises approximately 
80% of the human skeleton. In comparison to cancellous bone cortical bone 
characteristically has a slower rate of turnover and is more resistant to 
compressive and tensile forces. Cortical bone has a Young’s modulus, a measure 
of a materials elasticity, of 20 Newton’s per square metre (GPa). 
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In contrast to cortical bone cancellous bone has a higher rate of remodelling and 
a lower Young’s modulus, approximately 1 GPa, resulting in more elastic 
property. Cancellous bone is formed as a loose network, and within the porous 
areas bone marrow resides (Ramachandran and Nunn, 2018). 
1.1.3 Cellular mechanisms of bone homeostasis and 
osteoporosis 
 
Figure 1 0-3 Depiction of bone homeostasis with key cells and their regulators 
demonstrated. Osteoblasts are derived from mesenchymal stromal cells (MSC), and once 
buried within the newly formed matrix become osteocytes. Sclerostin is expressed by 
osteocytes and acts to inhibit osteoblast activity. Osteoblasts express Osteoprotegrin 
(OPG) which inhibits osteoclast activity and receptor activator of nuclear factor kappa B 
ligand (RANKL) which stimulates osteoclast activity and bone remodelling, both of which 
bind to receptor activator of nuclear factor kappa B (RANK) present on osteoclasts. An 
osteoclast, derived from haematopoietic stem cells (HSC), is demonstrated on the bone 
surface with its ruffled border and known regulators are shown in the blue boxes with their 
effects indicated by the yellow arrows. Image adapted from (Qin and Hu, 2014). 
 
Osteoblasts are bone forming cells, derived from mesenchymal stromal cells 
(MSCs), which secrete matrix and can be mineralised. Osteoclasts are 
responsible for bone resorption and play a key role in tandem with osteoblasts in 
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bone remodelling, Figure 1 0-3. The change in the dynamic between these two 
cell types is key to the development of OP. 
Osteoclasts originate from haematopoietic stem cells (HSC) and are closely 
related to other HSC lineage cells such as monocytes and macrophages. The 
formation of activated multinucleated osteoclasts depends on receptor activator 
of nuclear factor kappa B-ligand (RANKL) and macrophage-colony stimulating 
factor (M-CSF). RANKL is produced by osteoblasts, bone marrow MSCs, T and B 
lymphocytes and leads to the activation of RANK, present on osteoclasts. Once 
RANKL-RANK stimulation occurs the differentiation, proliferation, 
multinucleation activation and survival of osteoclasts occurs through the action 
of regulatory transcription factors and enzymes. Resorption of bone then occurs 
(Rachner, Khosla and Hofbauer, 2011). 
During OP trabeculae within cancellous bone are thinned and decreased in 
number, with some lost entirely, leaving that bone vulnerable to injury. 
Decreased osteon size and enlarged marrow spaces are observed in osteoporotic 
cortical bone, leading to thinner cortices (Miller and Thompson, 2016; 
Ramachandran and Nunn, 2018). Microarchitectural changes result from 
increased osteoclast activity and reduced osteoblast function and thus result in a 
predisposition to fragility fractures (Brandi, 2009). 
1.1.4 Diagnosis, monitoring and fracture risk assessment 
The World Health Organization and the International Osteoporosis Foundation 
recommend DXA imaging of the femoral neck for the diagnosis of OP. This is due 
to the higher predictive value for risk of fracture at this site in comparison to 
other skeletal sites. The lumbar spine is subsequently used for monitoring 
response to initiated treatment (National Institute for Health and Care 
Excellence, 2016). Although DXA has a high specificity as a diagnostic 
investigation for OP, the majority of patients will suffer a fragility fracture with 
a T score in a non-diagnostic range for OP. 
Further tools used to help diagnosis the disease include the Fracture Risk 
Assessment Tool (FRAX). FRAX is widely used and included in multiple clinical 
guidelines. It estimates a 10-year probability of major OP fracture or hip 
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fracture alone. FRAX has been utilised clinically with and without DXA to identify 
patients requiring preventative therapy or who require further investigation 
(Compston, McClung and Leslie, 2019).  
Quantitative computed tomography can also be utilised for calculating femoral 
neck T scores and are noted to be the equivalent of DXA-derived scores (Cann et 
al., 2014). 
However, the mainstay of diagnosis and disease monitoring of OP is via DXA 
scanning, and it has its inherent limitations. BMD only partly explains bone 
strength, with bone microarchitecture increasingly becoming understood to be 
key to strength, and its insensitivity impairs the monitoring of response to 
therapy (Delmas and Seeman, 2004; Watts et al., 2005). 
1.1.5 Prevalence 
Osteoporosis represents a global burden of ever-increasing proportions. Due to 
ageing populations in societies across the world the prevalence of the disease is 
rising dramatically. The disease most commonly affects the elderly, and with 
populations ageing throughout the world the incidence of the disease and its 
complications are set to significantly rise. 300,000 OP related fractures occur 
annually in the UK alone, and this is expected to double by the year 2050. In 
addition to the detrimental effects on quality of life, the disease and its 
associated fragility fractures will cripple many healthcare budgets (National 
Institute for Health and Care Excellence, 2016; Compston et al., 2017; 
Compston, McClung and Leslie, 2019). 
The prevalence of OP increases markedly in post-menopausal women. At the age 
of 50 approximately 2% of women suffer from the disease, this rises to 50% at 80 
years of age (NICE 2011b). In the UK more than 500 000 new fragility fractures 
occur each year (Svedbom et al., 2013). Although much more common in 
women, men also suffer from the disease, and it is estimated that 1 in 5 men 
will sustain one or more OP related fractures during their lifetime (‘NOGG 2017 : 
Clinical guideline for the prevention and treatment of osteoporosis’, 2017). 
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1.1.6 Morbidity and mortality 
The morbidity of the disease is caused by fragility fractures. Due to the 
weakened status, patients’ bones are more susceptible to fracture from low 
energy trauma. A fragility fractures is defined as a fracture occurring from a fall 
from standing height or less. The most commonly occurring osteoporotic 
fractures are of the vertebrae, neck of femur and distal radius. Vertebral 
fractures may occur without a fall, or in association with bending and lifting 
(Compston et al., 2017). 
These fractures are of great importance as patients who suffer hip fractures or 
vertebral fractures have a decreased life expectancy compared with population-
based controls. Approximately 25% of the deaths that occur following a hip 
fracture are related to the fracture, and the 1 year mortality rate post hip 
fracture is 20% (Kanis et al., 2003).  
Recent research has shown that despite an increasing prevalence of these 
injuries improved post fracture outcomes have been achieved (Tucker et al., 
2017). Mortality rates after hip fracture have decreased, and this is important as 
an increasing complexity of patient is being encountered, with patients living 
longer and presenting with more comorbidities (Hannah et al., 2017). 
In addition to the high mortality rate, neck of femur fractures are also 
associated with significant morbidity. 53% of patients do not regain their 
previous level of mobility post injury and can no longer return to living 
independently (Compston et al., 2017). 
Vertebral fractures can present with acute severe back pain; however, greater 
than 50% of these pathological factures are asymptomatic. Vertebral fractures 
cause loss of height, impaired mobility and reduced respiratory function. Once a 
patient has suffered one vertebral fracture they are at great risk of suffering 
multiple (Compston et al., 2017). 
1.1.7 Economic impact 
The cost of managing fragility fractures is enormous. In the UK in 2010 it was 
estimated to have cost the NHS over £4.4 billion. These injuries are not just 
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costly, but also resource intensive with the average length of stay after a hip 
fracture in Scotland being 17 days (Scottish Hip Fracture Audit, 2019). In the UK 
alone fragility fractures are estimated to double in incidence during the next 50 
years, thus these injuries will represent a significant proportion of a healthcare 
services budget (Compston et al., 2017). 
1.1.8 Current therapies 
The primary objective of treating OP is to reduce the incidence of future 
fragility fractures. This can be achieved by reducing fall frequency, 
strengthening the skeleton, or both. All patients at risk of OP should be advised 
on good nutrition, regular physical activity, smoking cessation and appropriate 
levels of alcohol consumption (National Institute for Health and Care Excellence, 
2016; ‘NOGG 2017 : Clinical guideline for the prevention and treatment of 
osteoporosis’, 2017). 
The evidence of the efficacy of reducing fracture risk via the supplementation of 
calcium and vitamin D is inconsistent. A benefit can be seen, but for patients 
who are replete in these nutrients there appears to be little or no benefit 
(Jackson et al., 2006; Zhao et al., 2017). 
Figure 1-0-4 demonstrates the mechanism of action of the most commonly used 
class of drugs for OP currently prescribed. 
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Figure 1-0-4 X-ray of a right neck of femur fracture, a common injury in patients with 
osteoporosis. The diagrams describe the two main classes of Osteoporosis therapies and 
their effect on bone homeostasis. A negative remodelling balance is evident in age related 
bone loss due to an increase remodelling. Antiresorptive agents act to reduce the 
remodelling rate and anabolics aim to create a positive remodelling balance by increasing 
osteogenic activity. HRT- hormone replacement therapy, PTHa- parathyroid hormone 
agonist, SERM- selective oestrogen receptor modulator. Adapted from Compston et al 2019.  
 
1.1.8.1 Bisphosphonates 
Bisphosphonates are antiresorptive agents and are currently the first line of 
therapy. Following fracture risk assessment, if a patient is deemed at high risk 
of an OP fracture an oral bisphosphonate is offered. Bisphosphonates have been 
shown to reduce the risk of vertebral fracture by 40-70%, and hip fractures by 
40-50% (Scottish Intercollagiate Guidelines Network, 2009; Khosla and Hofbauer, 
2017). The mechanism of action for bisphosphonates was discovered long after 
their introduction to clinical use; osteoclast viability and function is impaired by 
inhibiting the enzyme, farnesyl pyrophosphate synthase, which generates 
isoprenoid lipids used in post-translational modifications of small guanosine 
triphosphate (GTP)-binding proteins (Khosla and Hofbauer, 2017). 
In clinical practice, initially alendronate or risedronate are trialled. Alendronate 
is approved for use in men and women and has specific requirements in its 
delivery. Patients are required to fast overnight prior to taking the medication, 
tablets should be swallowed whole with approximately 200 ml of water. The 
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patient should take the medication standing or sitting and is then required not to 
lie down for 30 minutes. If oral therapy is not tolerated an intravenous 
bisphosphonate, zolendronic acid, can be utilised (Compston et al., 2017). 
In addition to this difficult mode of taking the oral bisphosphonates, their side 
effects can be severe. They include upper gastrointestinal symptoms with oral 
therapy and flu-like symptoms with intravenous (National Institute for Health 
and Care Excellence, 2016). Osteonecrosis of the jaw is a rare, but devastating 
complication. Most concerning is the occurrence of an atypical femoral shaft 
fracture, which frequently impairs a patient’s mobility and requires surgery. The 
risk of an atypical femoral shaft fracture increases with duration of therapy, 
affecting 1 in a 1000 patients after 8 years of therapy; and they are associated 
with significant morbidity ((Shane et al., 2014; Compston, McClung and Leslie, 
2019). 
1.1.8.2 RANK ligand inhibitor 
Denosumab is a human monoclonal antibody which can be delivered by 
subcutaneous injection every 6 months to reduce the risk of vertebral, non-
vertebral and hip fractures. It causes a marked inhibition of bone remodelling, 
due to its binding and inhibition of the RANK ligand. Denosumab results in an 
increase in BMD. However, upon stopping treatment bone remodelling occurs at 
an accelerated rate before returning to the patient’s baseline level. This leads 
to an initial rapid decrease in BMD and an increased risk of vertebral fractures, 
with reports of multiple fractures occurring 3-18 months following treatment 
cessation. Thus, on stopping denosumab, a substitute antiresorptive agent 
should be prescribed (Compston, McClung and Leslie, 2019).  
Denosumab is associated with skin rashes and an increased risk of infections. 
Like bisphosphonates, denosumab is also associated with atypical femoral 
fractures (Compston, McClung and Leslie, 2019). 
1.1.8.3 Teriparatide 
A further subcutaneous injection, which is given for a course limited to 2 years, 
Teriparatide is a Parathyroid hormone receptor agonist. It has been shown to 
significantly reduce the risk of vertebral and non-vertebral fractures. 
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Teriparatide course duration is limited due to the risk of osteosarcoma and is 
also contraindicated in patients with skeletal malignancies, previous ionising 
radiation to bone or hypercalcaemia. Furthermore, its cost is prohibitive for 
regular use (Khosla and Hofbauer, 2017). 
1.1.8.4 Abaloparatide 
Abaloparatide, a synthetic analogue of parathyroid hormone-related protein, is 
not licensed for use in the UK, but similarly positive skeletal effects are seen in 
Teriparatide use. It is available in the US but due to unconvincing reduction in 
non-vertebral fractures, and increases in cardiovascular side effects, it has not 
been approved in Europe (Compston, McClung and Leslie, 2019). 
1.1.8.5 Hormone replacement therapy 
Hormone replacement therapy (HRT), in the form of oestrogen, with or without 
progesterone, has been shown to be an effective method in reducing fracture 
risk in post-menopausal women. HRT was seen to reduce the risk of vertebral 
and hip fractures by 34% in the Women’s Health Initiative study (Cauley et al., 
2003). If a patient has failed first line therapy and is early menopausal, HRT can 
be an effective therapy. Due to the risk of cardiovascular side effects this 
recommendation is limited to within 10 years of the menopause (Compston, 
McClung and Leslie, 2019). 
1.1.8.6 Selective oestrogen receptor modulators 
Raloxifine is a weak antiresorptive agent and is both an agonist and antagonist of 
oestrogen. It is observed to reduce the risk of vertebral fractures only. It is 
further limited by its side effect profile, which includes an increased risk of 
venous thrombosis, death from stroke and vasomotor menopausal symptoms 
(Compston, McClung and Leslie, 2019). 
1.1.8.7 Strontium ranelate  
The use of strontium ranelate was limited to the treatment of severe 
osteoporosis only, and it did not gain approval for use in the USA. The drug 
reduces bone resorption and increases serum markers of bone formation, 
resulting in a 41% reduction in vertebral fractures (Khosla and Hofbauer, 2017). 
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However, it is associated with several limitations, which has led to its use being 
uncommon. The drug is associated with a rise in the rates of myocardial 
infarction, heart failure and serious skin reactions, raising questions about its 
safety (Bolland and Grey, 2016). The production of the drug has been 
permanently discontinued. 
1.1.9 Duration and monitoring of Osteoporosis therapy 
There is no current evidence to support therapy for a duration longer than 10 
years. Clinicians are advised to prescribe oral bisphosphonates for an initial 
treatment period of 5 years. If the patients fulfil one of the following criteria 
they are advised to continue on therapy for a further 3-5 years: 
• hip BMD remains persistently low  
• or they suffer a further fracture  
• previously have had a vertebral or hip fracture 
• are prescribed oral glucocorticoid therapy  
• aged over 75 years  
• persistently high FRAX score  
In patients who do not fall into the above categories an assessment of their 
fracture risk should be performed after they have completed their initial 
treatment period, with a drug holiday for 2-3 years to be considered concluded 
by a further fracture assessment. Monitoring of BMD and bone turnover markers 
during the initial years of therapy remains controversial, and is not routinely 
recommended (Compston, McClung and Leslie, 2019). 
It is evident that current therapies for OP have failed to stem the tide of the 
disease. The overall aim of osteoporosis therapy is to produce a reduction in 
fracture risk. Since a patient or clinician will not know when a fracture has been 
prevented, monitoring of current therapies is not as detailed as for other chronic 
diseases such as diabetes and hypertension. New therapies which induce 
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progressive increases in BMD would produce the possibility of accurate 
monitoring, and a determination of a treatment target. However, 
bisphosphonates, the most commonly used current therapies do not produce a 
significant enough amount of BMD to be accurately quantifiable and used to 
tailor the patient’s therapy (Khosla and Hofbauer, 2017).  
Alarmingly, despite the well-known detrimental effects these injuries have on a 
patient’s life, the prescription of secondary prevention has been seen to be 
falling in several studies (Ström et al., 2011; Svedbom et al., 2013; Solomon et 
al., 2014). This trend was observed in studies conducted in different countries 
with different health service modalities. High risk patients are not being 
managed as per guidelines, with evidence to show that they are at an even 
higher risk of further fracture (Compston, McClung and Leslie, 2019). 
Several factors have been suggested for this under-treatment. This has been 
associated with the poor education of clinicians and patients, fear of side effects 
and failings of health care in managing patients with fragility fractures (Khosla 
and Hofbauer, 2017). 
This evidence shows that a revolution in the management of OP is essential. 
Improvements in diagnosis, disease monitoring and management and further 
education of clinicians and patients are all required. 
1.1.10 Future osteoporosis therapies 
It seems evident that current therapies have proven intolerable or unacceptable 
due to their side effects and associations. In developing targeted therapies, 
achieving certain criteria is the goal of future therapies. These would include: 
• Prolonged anabolic effect 
• Efficacy at > 5 years duration 
• Improve fracture healing 
• Avoid osteonecrosis of the jaw and atypical femoral fractures 
 
 
16 
• Simple drug delivery method 
Multiple different avenues are being explored for the development of targeted 
therapies for osteoporosis. 
1.1.10.1 Sclerostin inhibitors 
Sclerostin is a protein expressed by the SOST gene in osteocytes, it acts by 
inhibiting Wingless-related integration site (Wnt) signalling and results in 
reduced osteoblastogenesis. Sclerosteosis and van Buchem disease result in an 
increased bone mass and strength due to the absence of functional sclerostin 
(Hamersma, Gardner and Beighton, 2003; Van Lierop et al., 2013). This insight 
provided a therapeutic target, and sclerostin inhibition via monoclonal 
antibodies has resulted in enhanced bone strength and resistance to fractures. 
Romosozumab is under advanced clinical trials and has shown positive results for 
reducing vertebral fragility fractures. However, a reduction in non-vertebral 
fragility fractures was not seen, similar side effects to bisphosphonates were 
encountered and there was an association with cardiovascular events (Khosla 
and Hofbauer, 2017). 
1.1.10.2 Cathepsin K inhibitors.  
Cathepsin K was identified as a therapeutic target, to reduce bone resorption by 
osteoclasts but enable ongoing paracrine signalling to osteoblasts. Mature 
osteoclasts secrete cathepsin K, resulting in degradation of bone matrix proteins 
(Costa et al., 2011). 
The development of the cathepsin K inhibitor, odanacatib, was discontinued in 
2016. Despite clinical trials showing a reduction in risk of vertebral and hip 
fracture an unacceptable increase in stroke, atypical femoral fracture and skin 
reactions were encountered (Khosla and Hofbauer, 2017). 
1.1.10.3 Dickkopf-1 antibodies 
The inhibition of Dickkopf-1 (Dkk-1) has been investigated in several diseases 
which suffer from excessive bone resorption, such as multiple myeloma and 
rheumatoid arthritis and Dkk-1 inhibition has been seen to reduce osteolysis 
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(Florio et al., 2016). Due to its promise, it is being investigated for clinical use in 
OP. However, prolonged inhibition of Dkk-1 raises concerns due to the known 
association of increased Wnt signalling to diseases such as colorectal and 
hepatocellular cancer (Rachner, Khosla and Hofbauer, 2011; Khosla and 
Hofbauer, 2017).  
1.1.10.4 Stem cell therapies for OP 
Cell therapy has long been hailed as holding great potential for regenerative 
medicine, and this extends to the field of orthopaedics. The use of MSCs has 
been investigated for the treatment of many pathologies, including OA, non-
unions of fractures, tissue regeneration for defects in bone, cartilage and tendon 
and augmenting the primary healing of muscle, ligament and menisci (Chew, 
Prakash and Khan, 2017; De Albornoz et al., 2018). However, the current clinical 
picture has yet to deliver the expected outcomes. Numerous factors are involved 
in the underwhelming progress made with MSC therapy. Bone marrow and 
adipose samples to provide autologous therapy result in a low number of MSCs, 
with 0.005% to 0.01% MSCs present in the sample population respectively (Qadan 
et al., 2018). This is in stark contrast to laboratory-purified culture-expanded 
cells. Furthermore great heterogeneity is observed in cell formulations from 
different patients, reducing the observed efficacy of MSC therapy (Rodeo, 2019). 
Currently cell therapies have not proven to be a replacement to the gold 
standard treatment for many conditions, such as total hip arthroplasty for hip 
osteoarthritis. The aim must be to initiate the cell therapy after an early tissue 
diagnosis of disease, to regenerate or delay disease progression. In advanced 
disease with deformities such as osteophytes, erosions and limb malalignment, it 
is difficult to envisage cell therapy surpassing the efficacy of surgery. 
1.1.11 Mesenchymal Stromal Cells in Osteoporosis and the 
effect of ageing 
MSCs represent a population of progenitor cells with the capability of 
differentiating to produce cells of various connective tissue lineage. At least 5 in 
vivo roles have been described for MSCs, including bone, cartilage and fat 
formation and vascular and haematopoietic support (Aggarwal and Pittenger, 
2005; Dominici et al., 2006; Ball et al., 2007). 
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When considering the osteogenic potential of MSCs it is important to consider 
the donor’s age and gender. Bone formation indices peak in late teenage years 
for men and then begin a steady decline until the age of 50. In females, bone 
formation and resorption are increased after the menopause, but result in a net 
reduction in BMD (Szulc, Kaufman and Delmas, 2007). 
Due to the association of OP with age it is important to understand the effect 
aging has on the differentiation capacity of MSCs. Age related changes in MSCs 
include loss of differentiation potential, loss of proliferation potential, 
increasing senescent cell numbers and decreased osteogenic activity (Sethe, 
Scutt and Stolzing, 2006). However, this statement is made less definitive by 
several papers showing no change in the number of observed colony forming 
units in samples of donors with differing ages (Stenderup et al., 2001; Oreffo et 
al., 2002). 
A study on the effect of aging on the fitness of MSCs, in donors ranging from 5 to 
55 years of age identified significant reduction in colony forming units in donors 
aged 18 or older. MSCs from donors older than 40 showed an increased 
expression of tumour suppression protein p53 and cell-cycle regulation p21, and 
this was accompanied with a significant increase in the levels of apoptosis in 
comparison to MSC cultures from donors aged less than 18 years. Furthermore a 
significant reduction in Notch-1 receptor was observed in MSCs from donors aged 
over 40 (Stolzing et al., 2008). 
The research by Stolzing et al identified important differences occurring in MSCs 
during ageing. MSC samples were from a relatively young age group, with the 
main patient population of OP not assessed. It would be of great interest if this 
could be extended to include a further group of donors with ages greater than 65 
to further analyse these trends and to observe their rate. 
It was thought that as patients became elderly their MSCs were more prone to 
forming adipocytes instead of osteoblasts, and thus contributed to the 
development of OP, often termed senile OP (Meunier et al., 1971). This theory, 
of the loss of osteogenic potential, was termed “adipogenic switch” and has 
been investigated by many studies. Some researchers have reported an increase 
in adipogenesis in aged MSC, but this is balanced with other experiments 
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showing no change in the rate of adipocyte formation with age (Stenderup et 
al., 2003; Moerman et al., 2004; Sethe, Scutt and Stolzing, 2006; Valenti et al., 
2011). 
Sethe et al concluded that no definitive statement regarding age-related effects 
in differentiation could be made, due to differing results from multiple studies 
(Sethe, Scutt and Stolzing, 2006). It has become apparent that the cause of OP 
cannot solely be attributed to the impaired activity of MSCs, however it is likely 
that some degree of deficiency in differentiation exists.  
Thus, the cause of impaired bone formation and density cannot be just a cellular 
problem, with local and patient environmental factors playing a crucial role 
also. This has implications for future therapies as well. To effectively treat OP a 
holistic approach, focusing on more areas than just local bone marrow MSCs will 
be required. 
1.1.12 Mesenchymal stromal cell functionality in 
osteoporosis  
As discussed above, a longstanding hypothesis of the cause of OP was termed the 
“adipogenic switch”. This was described in 1971 by Meunier et al and describes 
the loss of osteogenic preponderance of MSCs within the BM environment, and a 
change to pro-adipogenesis. This was thought to account for the reduced 
osteoblast activity and an increase in marrow adiposity (Meunier et al., 1971). 
Many studies have argued against this theory of ageing and osteoporotic MSCs 
being pro-adipogenic, at the expense of osteogenesis (Stenderup et al., 2001; 
Veronesi et al., 2014). However an attenuated regenerative competence has 
been described of bone marrow MSCs in patients at risk of OP (Bidwell et al., 
2013). It appears more nuanced than to suggest that with age bone marrow MSCs 
have a propensity to the adipogenic lineage, and thus the cause of OP MSC 
dysfunction is not directly in keeping with this simplistic view. 
This is supported by Abdallah & Kassem, who disregard the simple notion of an 
inverse relationship between adipogenesis and osteogenesis in the bone marrow 
environment (Abdallah and Kassem, 2012). They state that secreted factors from 
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different MSC populations within the bone marrow exert significant regulatory 
control of differentiation. Furthermore, with regards to osteogenic 
differentiation of OP MSCs, Prall et al suggest that pre-induction, these cells 
have a reduced osteogenic state, however they maintain a sufficient 
upregulation of osteogenic differentiation on BMP-2 induction (Prall et al., 
2013). This group further identified reduced cellular migration and invasion of 
MSCs from OP patients (Haasters et al., 2014). 
The development of OP has many causes. However, determining to what extent 
the MSC or the local environment is responsible has yet to be fully understood. 
This further identifies the deficiencies of current therapies, which fail to address 
the potentially impaired functionality of MSCs (Bidwell et al., 2013). 
1.2 MicroRNAs in regenerative medicine 
1.2.1 MicroRNAs mechanism of action 
Mature microRNAs (miRNAs) are a class of naturally occurring, small non-coding 
ribonucleic acids, 18-23 nucleotides in length. They were discovered by Lee and 
colleagues and described in 1993 (Lee, Feinbaum and Ambros, 1993). MicroRNAs 
are partially complementary to one or more messenger RNA (mRNA) molecules, 
and their main function is to down regulate gene expression. This down 
regulation can occur through several different mechanisms including 
translational repression, mRNA cleavage and deadenylation (Dweep, Sticht and 
Pandey, 2011). Figure 1-0-5 demonstrates the transcription of miRNAs through to 
their cytoplasmic action. 
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Figure 1-0-5 MicroRNA biogenesis and action. MiRNAs are transcribed in the nucleus from a 
miRNA gene or intronic regions by RNA polymerase II (RNAPII), yielding the precursor 
miRNA (pri-miRNA) hairpin structure. Drosha, the endoribonuclease processes, the pri-
miRNA resulting in pre-miRNA formation. The pre-miRNA is exported to the cytoplasm, 
where Dicer binds and cleaves the pre-miRNA loop and end-regions upon an RNA-induced 
silencing complex (RISC), where double stranded miRNAs are transformed to single 
stranded mature miRNA bound to an Argonaute protein (AGO). Adapted from (Foessl, 
Kotzbeck and Obermayer-Pietsch, 2019) 
 
The regulatory effect exhibited by miRNAs does not require perfect base pairing, 
and one miRNA can bind to, and control the expression of many mRNAs. Thus, 
miRNA overlap of gene targeting can occur. MiRNAs regulate gene expression by 
their binding to the 3’ UTR (untranslated region) of the target RNA. This results 
in translational inhibition of the mRNA or destabilization resulting in cleavage 
and degradation (Lewis et al., 2003; Dweep, Sticht and Pandey, 2011). 
Several thousand miRNAs exist in humans, along with their intracellular roles 
many are detectable systemically, thus leading to great interest in their roles in 
many different diseases. Over 2500 miRNAs are found in humans. They are 
known to regulate multiple physiological processes and play an important role in 
organ development, cell proliferation, apoptosis and bone homeostasis (Kim and 
Lim, 2014). Furthermore, the dysregulation of miRNA expression has been 
observed in multiple malignancies and also cardiovascular diseases such as 
atherosclerosis, hypertension and myocardial infarction (Larrea et al., 2016; 
Samanta et al., 2016). 
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Further to this, microRNAs have been shown to be dysregulated in many 
musculoskeletal diseases,  
Osteoarthritis Osteoporosis Rheumatoid Arthritis 
   
Figure 1-0-6. They have therefore been identified as future biomarkers or 
molecular targets for many diseases (Kim and Lim, 2014). In osteoarthritis 
multiple miRNAs, including miR-9, miR-27 and mir-140 have been shown to be 
dysregulated (Nugent, 2016). Mouse models of the disease have demonstrated 
improved cartilage protection with the utilisation of a miR-218-5p inhibitor (Lu 
et al., 2017). 
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Osteoarthritis Osteoporosis Rheumatoid Arthritis 
   
Figure 1-0-6 Radiographs of three common musculoskeletal diseases and some commonly 
reported dysregulated miRNAs known to be involved in the specific disease pathogenesis. 
Yellow arrows depict up or downregulation of the expression of the microRNA within the 
disease (Li et al., 2009; Murata et al., 2013; Kim and Lim, 2014; Nugent, 2016; Liu et al., 2019). 
 
In rheumatoid arthritis, miRNAs are being investigated as both therapeutic 
targets and biomarkers. Increased miR-23b expression was demonstrated in a 
human study to represent an accurate method identifying patients with 
rheumatoid arthritis, and was detectable in both synovial and plasma samples. 
Furthermore, on treating the disease a reduction in the expression levels of miR-
23b was noted (Liu et al., 2019). 
Great research focus has been placed on increasing our understanding of their 
role in physiological and diseased states, with the aim of developing targeted 
therapies and biomarkers. 
1.2.2 MicroRNAs in Osteoporosis 
Increasing our knowledge of bone homeostasis, with the interactions between 
osteoblast and osteoclast activity has highlighted the important role miRNAs 
play. Specific miRNAs are related to osteoblastogenesis and osteoclastogenesis.  
The first miRNA that was associated with OP was miR-2861, and was reported by 
Li et al. MiR-2861 was shown to target histone deacetylase 5, which negatively 
regulates RUNX2. This was demonstrated in a clinical study of adolescents with a 
diagnosis of primary OP. They identified that a rare homozygous mutation in the 
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genomic locus that encodes miR-2861 causes familial OP. In vitro and in vivo 
experimentation with a mouse model showed that miR-2861 plays a significant 
role in bone metabolism, and the use of an intravenous antagomiR-2861 in the 
mouse model resulted in a reduction in bone mineral density, further 
highlighting the importance of this dysregulated miRNA (Li et al., 2009). 
Many more miRNAs have been identified as regulating osteogenic activity, from 
the level of the MSC through to osteocyte formation. This is demonstrated in 
Figure 1-0-7. 
 
Figure 1-0-7 Demonstration of numerous miRNA regulation sites related to 
osteoblastogenesis, occurring from MSC through to mature osteoblast and cell death. 
Adapted from (Kim and Lim, 2014). 
 
Significantly, and clinically relevant, research has focused on identifying miRNAs 
that are dysregulated in bone and serum, which have a role in disease 
progression of OP. These miRNAs are likely to be key in developing strategies for 
monitoring the disease utilising a serum sample, and avoiding ionising radiation 
(Panach et al., 2015; Weilner et al., 2015). 
MiRNAs, including miR-21, miR-23a, miR-24, miR-25 and miR-100 have been 
identified as dysregulated in serum and bone samples in patients with OP 
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(Panach et al., 2015). These miRNAs are involved in the regulation of key 
osteoblast and osteoclast differentiation genes such as osterix, bone 
morphogenic protein receptor type II, RANKL and runt-related transcription 
factor 2 (RUNX2) (Hassan et al., 2010; Sun et al., 2016).  
Furthermore, manipulating the expression of dysregulated miRNAs has been 
shown to significantly alter the osteogenic activity of MSCs (Weilner et al., 2015; 
Heilmeier et al., 2016).This highlights the possibility of developing not only a 
miRNA biomarker for OP, which could provide a quick, non-ionising and sensitive 
method of monitoring disease activity, but also targeted therapies. 
However, the non-specific nature of miRNA action makes their clinical use as a 
therapeutic target complex. Significant overlap exists between differing 
physiological systems, with miRNAs known to be important to osteoblast 
development also implicated in tumourigenesis in another tissue. Thus, 
inhibiting or upregulating the expression of a miRNA would require careful 
investigation to ensure its safety. 
This complex picture of miRNAs involved in bone homeostasis and disease clearly 
demonstrates that although they may represent a potential targeted therapy site 
for improved bone health, significant further research is required to ensure 
there is no systemic adverse effect. 
1.3 MicroCT 
1.3.1 MicroCT in orthopaedic research 
Whilst diagnosis and monitoring of OP utilises DXA scanning to assess BMD, 
further information of bone can be obtained via computed tomography (CT). It is 
not currently clinically practical to utilise CT techniques for diagnosis or 
monitoring of OP, due to the levels of ionising radiation and the requirement of 
high-resolution quantitative CT scanning. However, microCT provides great 
details of microarchitecture for in vitro samples, Figure 1-0-8. 
CT images are produced by multiple radiographic projection images taken from 
multiple different angles; this requires x-rays and relies on the differential 
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absorption of differing tissues. Transmitted photons are received by a detector 
and converted into a projection image. In clinical scenarios the emitter and 
detector are rotated, in microCT the specimen may be rotated. Cross-sectional 
images are derived via a mathematical conversion of the projections. These 
cross-sectional images can be assembled into an image stack (Hounsfield, 1973). 
MicroCT uses special scanners to achieve a higher spatial resolution. Techniques 
are utilised to reduce two commonly encountered artefacts in microCT scanning. 
Performing a scan with no specimen produces a “flat field”, which is then 
subtracted from the scan with the specimen. This compensates for ring artefact 
which occurs from variation in the sensing ability of each pixel of the detector. 
Beam hardening is a common problem of microCT and occurs due to 
differentially energized photons being emitted from the emitter. The energy of 
x-rays used increases as an object size increases, which affects the 
mathematical algorithm required for reconstruction of back projection images 
(Feldkamp, Davis and Kress, 1984). A secondary process is therefore utilised to 
remove halo effects from the algorithm; furthermore a filter can be placed 
between the emitter and the specimen to reduce the spread of the spectrum x-
rays. 
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A1  B1  
A2  B2  
Figure 1-0-8 Coronal and axial examples of microCT imaging of femoral heads. A1/ B1 
represent coronal slices and A2/B2 axial. A1/A2 are from a patient who has suffered an 
intra-capsular neck of femur fracture, B1/B2 from a patient with osteoarthritis. 
 
A balance is required to be struck between object size and resolution when 
performing microCT scanning. As a specimen size increases the detail can 
diminish, as resolution diminishes with distance from the centre of axis of 
rotation of the specimen. 
Previously histomorphometry was the gold standard for analysing bone 
specimens. A quantitative histological technique (Frost, 1958), 
histomorphometry utilises mathematical formulations to derive three 
dimensional parameters from specimens. 
MicroCT has superseded histomorphometry, allowing immediate measurement of 
bone microarchitecture without specimen destruction (Hildebrand and 
Rüegsegger, 1997; Ulrich et al., 1997) . MicroCT measurements have been shown 
to be reliable at describing trabecular structure, (Chevalier et al., 2007) and 
were often reported in combination with histomorphometry (Gielkens et al., 
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2008). Specimens acquired from biopsy, or residual tissue from surgery or post 
mortem can be imaged by microCT, furthermore in vivo scanning is also now 
available with great utilisation in small animal studies (Freitag et al., 2019). 
Many microarchitectural indices are used to assess bone via microCT and are 
described in Table 1-2. 
Table 1-2 Common microarchitectural indices that can be measured via microCT and their 
definitions. 
Micro-Architectural 
index  
 
Abbreviation Unit Description 
Percentage bone 
volume 
BV/TV % Measure of the ratio of solid to space 
within a given volume surrogate parameter 
for bone strength (Legrand et al., 2000) 
 
Trabecular thickness Tb.Th mm The width of the trabecular- important for 
determining structural integrity 
(Hildebrand and Rüegsegger, 1997; Tanck 
et al., 2009) 
 
Trabecular 
separation 
Tb.Sp mm The thickness of the marrow cavities 
Trabecular number Tb.N  The number of plates per unit length 
Structural model 
index 
SMI None Indicates relative presence of rods, plates 
or cylinders in a 3D model(Hildebrand and 
Rüegsegger, 1997). Plate 0, rod 3, sphere 
4. 
 
Degree of Anisotropy DA None Measure of how well orientated a 
microstructure is within a given 
volume(Cotter et al., 2009). 
Connectivity density Conn. D mm-3 Number of connections between trabecular 
structures in a given volume- a good 
measure of bone structure (Fajardo and 
Müller, 2001). 
 
 
Overall bone volume fraction (BV/TV) has been seen to be a key index, as 
trabecular thickness, spacing, connectivity and structural index are all 
correlated to BV/TV (Goldstein, Goulet and McCubbrey, 1993). 
1.3.2 Observed bony characteristics of Osteoporotic bone via 
MicroCT scanning 
Wolff’s law states that osseous architecture is dictated by the mechanical stress 
placed upon it (Wolff and Wolff, 1986). However trabecular structure also 
changes with age and disease. Peak bone mass occurs at different time points in 
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male and female populations. Females achieve peak bone mass early in their 
third decade of life, whereas this occurs late in the same decade for males. 
Thereafter a gradual decline occurs. Following this there is a gender dependent 
change in bone mass, with females observed to suffer a faster rate of reduction 
of bone mass which is then accelerated due to the menopause (Riggs et al., 
2004). 
Cancellous bone loss occurs earlier, in both men and women, cortical bone loss 
occurs later, post menopause for women, and is associated with increased 
porosity (Boskey and Imbert, 2017).Trabecular bone undergoes many changes 
with age in both sexes, with a reduction in thickness, number and connectivity 
observed (Seeman, 2002). Men suffer a greater reduction in trabecular 
thickness, and women a reduction in trabecular number (Farr and Khosla, 2015).  
Sex hormone deficiency results in significant architectural change to bone, with 
decreased trabecular number, increased space and a change in morphology from 
plates to rods (Ammann and Rizzoli, 2003). It is hypothesised that these 
architectural changes result in reduced strength of bone, as loss of vertebral 
bone strength precedes any observable reduction in BMD (Ammann and Rizzoli, 
2003). 
In postmenopausal women with reduced BMD, lower percentage bone volume 
(BV/TV) and trabecular thickness (Tb.Th) values are observed in comparison to 
normal elderly women (Boskey and Imbert, 2017). Furthermore, highlighting the 
importance of bone quality in OP, glucocorticoid therapy, a common secondary 
cause of OP, results in an increased fracture risk without significant changes in 
BMD. Mouse models have shown an increase in osteocyte lacunae, reduced 
BV/TV, trabecular thickness and increased trabecular separation (Lane et al., 
2006). This is also evident in humans. A study assessing key bone indices in 
premenopausal women who had sustained a distal radius fracture in comparison 
to healthy controls showed that despite comparable BMD the fracture group had 
significantly reduced trabecular thickness and number in both radius and tibia 
(Rozental et al., 2013). 
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Per decade there is a 7% reduction in ultimate stress of cancellous bone from 
femur specimens from the ages of 20-100 years (McCalden, McGeough and Court-
Brown, 1997). 
Key differences are observed in the microarchitecture of bone specimens from 
patients suffering from OA in comparison to OP. Due to the difficulty in 
obtaining bone specimens from healthy controls, patients suffering from OA are 
a common control group, because as they undergo arthroplasty for their disease 
surplus tissue can be utilised for research. Higher percentage of bone volume 
and increased trabecular number are common observations in OA specimens, 
with OP samples having reduced connectivity and more rod-like trabeculae in 
the place of plate formation (Montoya et al., 2014). This is in agreement with 
histomorphometric research by Blain et al, which showed multiple differences in 
micro-architecture of bone from the femoral necks of patients with OP in 
comparison to OA (Blain et al., 2008). Reduced cortical thickness, bone volume, 
trabecular number and thickness were all noted in the OP group. MicroCT 
provides a useful research tool to correlate in vitro experiment results to the 
observed phenotype. 
1.4 Three-Dimensional cell culture 
Historically the majority of in vitro MSC research was performed in monolayer, 
two-dimensional (2D) culture conditions. However, it is now well known that 2D 
conditions pose significant limitations in developing a model of close clinical 
relativity. 
Three-dimensional (3D) culture of MSCs results in improved inter-cell 
interactions, recreation of nutrient and oxygen gradients and generation of 
extracellular matrix (Cesarz and Tamama, 2016). Compared to 2D culture 
enhanced differentiation and self-renewal properties of MSCs are noted (Hong et 
al., 2015). The importance of the above factors has led to an understanding that 
traditional monolayer cultures do not provide optimal conditions for MSC culture 
and research (Saleh and Genever, 2011; Saleh et al., 2012). 
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1.4.1 Techniques of three-dimensional culture 
Many different strategies exist to perform 3D culture of MSCs. Broadly this can 
also be subdivided to cultures with or without a supportive scaffold. 
Cells can be grown and then implanted into a supportive scaffold, thus 
converting their culture to a 3D environment. Many different substrates can be 
utilised to form the scaffold, such as collagen, hyaluronic acid, synthetic 
biomaterials made from polymers and biologically derived from decellularized 
tissues. Scaffolds can then be implanted in vivo, to repair defects or assist in 
functions (Saleh and Genever, 2011). The disadvantage of utilising scaffolds is 
the variability in their reproduction, the potential for cell adsorption of the 
scaffold, and compromised analysis of the culture by optimal imaging (Rimann 
and Graf-Hausner, 2012). 
Sphere like in vitro aggregation of cells, referred to as spheroids, is an important 
3D culture method which can be formed without the use of a substrate or 
scaffold, Figure 1-0-9. The formation of the spheroid is dependent on 
intracellular adhesions between homotypic and heterotypic cell types (Duguay, 
Foty and Steinberg, 2003; Foty and Steinberg, 2005). 
  
Figure 1-0-9 Imaging of human MSC spheroids from osteoarthritic bone marrow, formed by 
two different techniques during this research. Image A light microscopy of spheroid formed 
by ultra low attachment (ULA) technique at 72 hours of culture. Image B scanning electron 
microscopy of a spheroid formed by magnetic nanoparticle technique at 24 hours post 
formation.  
 
Multiple and different techniques have been developed to perform 3D in vitro 
cultures. They vary in complexity and in the equipment required to perform. For 
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spheroids common techniques include the addition of viscous agents to the 
culture medium, such as methylcellulose referred to as the liquid-overlay 
method, and the hanging drop method. Dynamic culture techniques are also 
used to develop spheroids, through rotating cultures, spinner flasks and 
bioreactors (Saleh et al., 2012). Additionally, culturing cells with magnetic 
nanoparticles (MNPs), combined with an external magnetic force, has been 
shown to be a consistent method of spheroid formation, with the benefit of the 
opportunity of functionalisation of the MNPs (Lewis et al., 2017). Figure 1-0-10 
depicts these common spheroid forming techniques. 
A B 
  
C D 
  
Figure 1-0-10 Schematic representations of four commonly utilised spheroid forming 
techniques. A- ultra-low attachment- the hydrophilic, neutrally charged coating forces cells 
into a suspended state, B- hanging drop- cells in suspension sediment at the base of the 
droplet and form aggregations and later, spheroids. C- spinner + rotational flasks, both 
techniques maintain cells in suspension, prevent settling and lead to cell aggregation. D- 
magnetic nanoparticle- cells are cultured with nanoparticles with a magnetic core. Once the 
nanoparticles are internalised an external magnetic field can be applied to induce 
aggregation. 
 
Spheroids have been utilised in cancer research for several decades, and provide 
a model with similarities to the in vivo tumour environment. Similar to tumours 
they have non-proliferating cells within the core and proliferating cells on the 
periphery of the spheroid and possess oxygen and nutrient gradients which are 
relevant to a solid tumour with poor blood supply (Yamada and Cukierman, 
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2007). Their use has been extended to many other areas of research including 
tissue engineering of solid organs and high-throughput drug screening (Shea et 
al., 2000; Kunz-Schughart et al., 2004). Heterogenous spheroid cultures are also 
utilised, with particular importance to recreating in vivo microenvironments 
such as the bone marrow niche, and assessing the interaction of neighbouring 
cells to the tissue of interest (Lewis et al., 2016). 
There are drawbacks to utilising 3D research methods, with increased cost in 
comparison to monolayer culture and variability in spheroid size produced 
leading to non-uniform results being common criticisms (Tibbitt and Anseth, 
2009; Gurski et al., 2010). Furthermore, rotational methods require non-
physiological shearing forces to produce the spheroid. 
Little has been published in the literature with regards to developing a 3D OP in 
vitro model. Due to the burden OP poses, and the significant laboratory research 
required to develop improved therapies, it appears prudent to improve in vitro 
models of the disease.  
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1.5 Aims 
This thesis aims to assess the biological status and bone phenotype encountered 
in patients with neck of femur fractures. Furthermore, the effect of microRNA 
manipulation on metabolomic activity and differentiation capacity of MSCs will 
be investigated. Finally, an optimal 3D culture model will be identified for 
future in vitro research involving bone marrow MSCs.  
This will advance the field of fragility fracture research and help in the 
development of improved therapies. 
This will be achieved by assessments of the following experiments: 
• microRNA expression in MSCs from bone marrow aspirates 
o It is hypothesised that the neck of femur fracture group will 
demonstrate abnormal microRNA expression related to key 
osteoblast and osteoclast pathways in comparison to the 
osteoarthritic group. 
• extracellular MSC markers in NOF and OA patients 
o It is hypothesised that MSC markers will be differentially expressed 
across the two patient groups. 
• metabolomic effect of microRNA manipulation in MSCs 
o It is hypothesised that manipulating key microRNAs in culture of 
MSCs from neck of femur fracture patients will improve their 
differentiation potential in osteogenic and adipogenic lineages.  
• three spheroid forming techniques with bone marrow derived MSCs 
o It is hypothesised that the magnetic nanoparticle technique will 
provide a rapid method of forming spheroids with the additional 
benefits of functionalisation of available. 
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Chapter 2 
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2 Materials and Methods 
This chapter describes the materials and methods utilised to perform the 
experiments in subsequent chapters. 
2.1 Materials and reagents 
2.1.1 Cell culture reagents 
Reagent Supplier 
AccutaseTM Thermo Fisher Scientific, UK 
Ascorbate-2-phosphate (100mM) Sigma-Aldrich, UK 
Bovine Serum Albumin (BSA) Sigma-Aldrich, UK 
Dexamethasone (500ng/ mL) Sigma-Aldrich, UK 
Dulbecco’s Modified Eagle’s Medium 
(DMEM), high glucose, glutamine 
Sigma-Aldrich, UK (Product Code (PC) 
D5671) 
Ethylenediaminetetraacetic acid 
(EDTA) 
Sigma-Aldrich, UK 
Foetal Bovine Serum (FBS) Sigma-Aldrich, UK (PC F9665) 
Fungizone Ò Amphotericin B (250 µg/ 
mL) 
Gibco by Life Technologies, UK (PC 
15290-026) 
Insulin Sigma-Aldrich, UK 
Isobutylmethylxanthine Sigma-Aldrich, UK 
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Minimum Essential Medium Non-
essential Amino Acids (MEM-NEAA) 
Sigma-Aldrich, UK 
Penicillin-Streptomycin (10 mg/mL 
stock) 
Sigma-Aldrich, UK (PC 0781) 
Phosphate- Buffered Saline (PBS) Sigma-Aldrich, UK 
Sodium hydroxide (0.1 M) Sigma-Aldrich, UK 
Sodium pyruvate (100 mM) Sigma-Aldrich, UK 
Trypsin (10X solution) Sigma-Aldrich, UK 
 
2.1.2 Immunostaining reagents 
Reagent Supplier 
Biotinylated anti-goat IgG produced in 
donkey 
Vector Laboratories, UK 
Biotinylated anti-mouse IgG produced 
in horse 
Vector Laboratories, UK 
Formaldehyde Thermo Fisher Scientific, UK 
Magnesium Chloride Hexahydrate 
(MgCl2.6H2O) 
Sigma-Aldrich, UK 
Sodium Chloride VWR Chemicals 
Sucrose Thermo Fisher Scientific, UK 
Triton X-100 Thermo Fisher Scientific, UK 
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Tween 20 Sigma-Aldrich, UK 
 
2.2 Preparation of cell culture solutions 
Reagent Component Amount 
Trypsin/Versene solution NaCl 150 nM 
KCl 5 mM 
Glucose 5 mM 
HEPES 10 mM 
Phenol red solution 0.5 % (v/v) 
Trypsin 5 % (v/v) 
HEPES saline solution NaCl 150 nM 
KCL 5 mM 
glucose 5 mM 
HEPES 10 mM 
Phenol red solution 0.5 % (v/v) 
Fixative solution PBS 90 mL 
Formaldehyde 10 mL 
Sucrose 2 g 
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Permeabilisation buffer Sucrose 0.1 % (w/v) 
NaCl 50 mM 
MgCl2.6H2O 3 mM 
HEPES 20 mM 
Triton X-100 0.5 % (v/v) 
Blocking buffer PBS 100 mL 
BSA 1 % (w/v) 
ICWTM blocking buffer PBS 100 mL 
Milk powder 1 % (w/v) 
FACS buffer PBS 100 mL 
BSA 0.5 % (w/v) 
EDTA 2 mM 
 
2.3 Cell type 
One cell source was used during all experiments. At the time of hip surgery, a 
bone marrow aspirate was taken and the adherent fraction was cultured. Two 
patient groups were assessed: 
1. Osteoarthritic (OA)- patients undergoing hip arthroplasty for 
Osteoarthritis 
2. Neck of Femur fracture (NOF)- patients undergoing hip arthroplasty after 
suffering a low energy neck of femur fracture.  
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The NOF group represented a patient group at risk of developing, or having 
undiagnosed OP (Compston et al., 2017). For miRNA expression and microCT 
analysis patient samples were excluded if there was known metabolic bone 
disease, bone metastases, or if the patient was already using osteoporosis 
therapy. 
2.3.1 Ethical Approval 
Ethical approval for this research was obtained from the University of Glasgow 
and NHS Greater Glasgow and Clyde’s Biorepository Management Committee, 
application number 287. This granted approval for the sampling and 
investigation of bone marrow and femoral heads which were surplus to 
requirements during hip arthroplasty for indications of osteoarthritis or neck of 
femur fracture. 
2.4 Cell Culture 
2.4.1 Bone Marrow Extraction 
 Bone marrow samples are taken at time of surgery for total hip replacement or 
hemiarthroplasty for neck of femur fracture. After exposure of the proximal 
femur an oscillating saw is used to cut the femoral neck. A rasp is then 
introduced into the upper third of the femoral shaft, to create space for the 
femoral component of the replacement. During the rasping of the femur a 
syringe is used to aspirate bone marrow from the canal. Approximately 15 ml of 
bone marrow are obtained from each patient. 
The bone marrow is processed within 48 hours from surgery. Each bone marrow 
sample was divided into two and centrifuged for 10 minutes at 1400 rpm. The 
supernatant was then removed and the pellet was re-suspended in 10ml of fresh 
media and centrifuged again, at 1400 rpm for 10 minutes. The media was 
removed and the pellet was re-suspended in 10mL fresh media; the cell 
suspension was then slowly overlaid onto 7.5 mL of Ficoll-Paque Premium (GE 
Healthcare, UK), and then centrifuged for 45 minutes at 1513 rpm. The middle 
layer was then aspirated and resuspended in 10 mL of fresh media, followed by 
centrifugation at 1400 rpm for 10 minutes. The supernatant was then removed 
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and the pellet was resuspended in 10 mL of fresh media and then placed in a 
vented flask and incubated at 37 °C with 5% CO2. 
To expand the number of MSCs from the sample, at day 7 of culture, basal media 
containing 10% Mesenchymal stem cell growth medium 2 (PromoCell Gmbh, 
Germany) was performed utilised. Subsequent media changes were then with 
basal media.  
2.4.2 General Protocol 
The MSCs were cultured in T75 flasks with modified DMEM media at 37°C with 5% 
CO2. Upon reaching confluence the cells were washed with HEPES (Fisher 
Scientific, UK) solution and then detached from the surface using 
trypsin/versene, 2 minutes at 37 °C, (Sigma-Aldrich, UK). Fresh media was then 
added to the flask to neutralise the active trypsin, the cell suspension was then 
centrifuged for 4 minutes at 1400 rpm. After centrifugation the supernatant was 
removed leaving a cell pellet. The cells were then re-suspended in fresh media 
and seeded into appropriate wells for experiments. MSCs were used between 
passage a number of 1-3. 
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2.4.3 Cell Culture Media 
In addition to basal and expansion media, pro-osteogenic and adipogenic media 
were utilised to induce MSC differentiation. The constituents of the media are 
detailed in Table 2-1 Constituents of media used for cell culture., with the 
adipogenic and osteogenic induction media as per Alakpa et al (Alakpa et al., 
2018). 
Table 2-1 Constituents of media used for cell culture. 
Name Constituents 
Basal media DMEM with 10% FBS with 2% antibiotic 
mixture, 1% Non essential Amino Acids 
and 1% sodium pyruvate 
Osteogenic media DMEM, 10% FBS with 2% antibiotic 
mixture, Ascorbate-2-phosphate 350 
µM, dexamethasone 0.1 µM 
Adipogenic induction media DMEM, 10% FBS with 2% antibiotic 
mixture, 1 µM Dexamethasone, 1.7nM 
insulin, 200µM indomethacin, 500 µM 
isobutylmethylxanthine 
Adipogenic maintenance media DMEM, 10% FBS with 2% antibiotic 
mixture, 1.7nM insulin 
Expansion media DMEM, 10% FBS with 2% antibiotic 
mixture, 1% Non essential Amino Acids 
and 1% sodium pyruvate, 10% 
Mesenchymal stem cell growth 
medium 2 (Promocell Gmbh, 
Germany)  
 
2.4.4 Freezing cells for storage 
MSCs from some patient samples, obtained as described above, were frozen and 
stored at -80 °C for future experiments. The cells were detached with 
trypsin/versene and centrifuged. The pellet was then resuspended in dimethyl 
sulfoxide ((DMSO) Sigma-Aldrich, UK)/foetal bovine serum ((FBS) Sigma-Aldrich, 
UK) and stored at -80 °C. 
2.4.5 Thawing cells from storage 
Cells were revived from storage at -80 °C by rapidly thawing in a 37 °C water 
bath. The cells were then transferred into 10 ml of warmed culture media and 
centrifuged for 5 minutes at 445 x g. The subsequent cell pellet was re-
suspended in basal culture media and transferred to a T75 flask. 
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2.5 Cell Culturing Methods 
2.5.1 Differentiation culture 
Growing MSCs were utilised and detached from their flask via tryspin/versene. A 
cell count was performed and the cells plated on cover slips in basal media at a 
density of 2000 thousand per cm2. After 24 hours the media was exchanged for 
differentiation media. For osteogenic differentiation osteogenic media was used 
for all culture exchanges for the remainder of the experiment. For adipogenic 
differentiation culture media alternated between adipogenic induction media 
for 7 days and adipogenic maintenance media for 7 days, for the remainder of 
the experiment. The differentiation medias are described in Table 2-1. The 
constituents of the adipogenic and osteogenic media were as per (Alakpa et al., 
2018).  
2.5.2 MicroRNA Culture 
Cultures of MSCs with miRNA mimics and inhibitors were performed. The miRNA 
mimics/inhibitors were delivered via functionalised gold nanoparticles (GNPs). 
The thiolated sequences  were obtained from Dharmacon and functionalised with 
GNPs at the Universidade NOVA de Lisboa’s Life Sciences department. The 
synthesis is as described by McCully et al’s paper on nanoparticle-antagoMiR 
based targeting of miR-31 (McCully et al., 2018). Table 2-2 details the GNP 
physical properties utilised during the miRNA manipulation experiments. 
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Table 2-2 The physical properties of the functionalised GNPs used in miRNA manipulation 
studies. Polyethylene glycol (PEG) was used to passivate the NPs (percent saturation 
indicated); SPR- corresponds to surface plasma resonance, used to determine nanoparticle 
aggregation. 
Name miR (nM) 
on GNPs 
PEG Size 
(nm) 
SPR Acronym- 
used in 
chapter 
Au-NPs- 30% 
PEG miR-143 
66 857 22.45 522 miR-143 
mimic 
Au- NPs-30% 
PEG-
AntagomiR-31 
90 857 26.4 522 AntagomiR-
31 (AmiR-31) 
Non-targeting NA 857 19.5 520 Non-T 
 
As previously, cultured MSCs were utilised from both patient groups and 
detached from their flask via tryspin/versene. A cell count was performed and 
the cells were cultured in 24 well plates in basal media at a density of 2000 
thousand per cm2. After 24 hours the media was exchanged for the conditions 
described in Table 2-3. The nanoparticle conditions were cultured at a 
concentration of 50nM per 500 µl of media. 
Table 2-3 Details of culture conditions for miRNA manipulation studies. 
No Particles Non-targeting miR 
Basal media Basal media and Non-
targeting nanoparticles 
 
Basal media and 
AntagomiR-31/miR-143 
nanoparticles 
 
Adipogenic media Adipogenic media and 
Non-targeting 
nanoparticles 
 
Adipogenic media and 
AntagomiR-31/miR-143 
nanoparticles 
 
Osteogenic media Osteogenic media and 
Non-targeting 
nanoparticles 
 
Osteogenic media and 
AntagomiR-31/miR-143 
nanoparticles 
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After 48 hours of incubation with the above conditions, the media was 
exchanged, and for the remaining time in culture media without nanoparticle 
supplementation was used. 
2.6 Spheroid formation 
2.6.1 Hanging drop spheroid formation 
MSCs were detached from a T75 flask. Cell suspensions of MSCs were prepared at 
concentrations of 5 x 103, 1 x 104 and 2 x 104 cells per 40 µl. A GravityPLUSTM 
(Perkin Elmer, Waltham, MA, USA) 96 well plate was used, with 40 µl pipetted 
into each well. The cells were cultured in the presence of a humidifier pad, to 
reduce water evaporation from the droplet. After 24 or 72 hours of culture an 
additional 70 µl of media was added to the cell suspension droplet and the 
spheroid was transferred to a non-adherent GravityTRAPTM (Perkin Elmer, 
Waltham, MA, USA) plate placed below, for long term culture.  
 
 
Figure 2-1 Depiction of the Hanging drop technique. A droplet is formed with MSCs in 
suspension (black dots), with time they are seen to coalesce to aggregates (black circles) 
and finally a singular spheroid.  
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2.6.2 Ultra-low attachment spheroid formation 
MSCs were detached and cell suspensions of concentrations of 5 x 103, 1 x 104 
and 2 x 104 cells in 200 µl of media were created. 200 µl of each cell suspension 
was then pipetted, per well, into a CellCarrier Spheroid ULA 96-well microplate 
(Perkin Elmer, Waltham, MA, USA). These plates have round-bottomed wells and 
a non-adherent coating. 100 µl of media was exchanged every 72 hours. 
 
 
Figure 2-2 Depiction of the Ultra-low attachment. MSCs (black dots) are in suspension, and 
unable to adhere to the round bottomed, non-adherent well. With progressive time the MSCs 
form aggregates (black circles) and finally a singular spheroid. 
 
2.6.3 Magnetic Nanoparticle Uptake into Cells 
MSCs were seeded at a concentration of 1x104 cells/cm in a 24 well plate and 
left 24 hours to adhere (37 °C/5% CO2). The media was removed and exchanged 
for 1mL of magnetic nanoparticles (mNPs) diluted in fresh DMEM media at a 
concentration of 0.1mg/ml. This was followed by a 30-minute incubation (37 
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°C/5%CO2) in the presence of a magnetic field of 350 mT (24 magnet array 
placed beneath the 24 well plate, Chemicell). 
2.6.4 MNP Spheroid culture in media 
Following incubation with the MNPs, the cells (1x104 cells/cm) were detached 
with AccutaseTM cell detachment solution (Stemcell Technologies, UK), and 
centrifuged at 1400 rpm for 4 minutes. The cells were then resuspended in fresh 
media and 0.5 ml of cell suspension was added to 4 ml of fresh media in a 6 well 
plate. A single magnet (13 mm diameter, 350 mT) was placed on top of the well 
and the plate was incubated at 37 °C with 5% CO2 for the remainder of the 
experimental duration. 
 
 
Figure 2-3 Depiction of Magnetic nanoparticle spheroid formation technique. MNPs (brown 
hexagons) are incubated with adherent MSCs, leading to internalisation of the MNPs. The 
MSCs are then detached and resuspended in fresh media. The MSCs in suspension (black 
dots) are then placed in a new well with an external magnetic force applied above. With time 
the external magnet encourages aggregate and spheroid formation (large black circle). 
 
2.7 Flow cytometry 
2.7.1 Flow cytometry staining 
Cells for flow cytometric analysis were harvested from passage 2 cultures of 
patient samples from both groups. Cells were detached from flasks via 
incubation with AccutaseTM, and centrifuged at 400 x g for 5 minutes. They were 
then resuspended in 800 µl 0.5% BSA in phosphate buffered solution ((PBS) 
Sigma-Aldrich, UK) containing 2 mM EDTA (FACS buffer). They were washed 
again, following the same protocol. Staining with appropriate antibodies was 
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then performed in 100 µl volumes, using pre-determined dilutions of antibodies 
for 30 minutes on ice, protected from light. Details of antibodies utilised in flow 
cytometric analysis are displayed in Table 2-4. They were washed 2 further 
times and suspended in 200 µl FACS buffer. They were then run on a 
ThermoFisher Attune NXT analyser. An unstained control sample was utilised to 
set the voltage for each channel and an isotype control sample was also used to 
determine background binding of the antibodies. 
Table 2-4 Details of antibodies used in flow cytometric analysis experiments. 
Manufacturer Marker Clone Fluorochrome 
eBioscience CD13 WM15 PE 
eBioscience CD29 TS2/16 FITC 
eBioscience CD31 WM59 PE-CY7 
eBioscience CD34 4H11 PE 
eBioscience CD44 IM7 PE-CY7 
eBioscience CD45 H130 FITC 
eBioscience CD73 AD2 FITC 
eBioscience CD105 SN6 PE 
eBioscience CD106 STA PE-Cy7 
Biolegend CD140b 18A2 PE 
Biolegend CD146 P1H12 PerCP-Cy5.5 
eBioscience CD166 3A6 PerCP-eFluor710 
Biolegend CD271 ME20.4 PE-Vio770 
eBioscience HLA-ABC W6/32 PE 
eBioscience HLA-DR L243 FITC 
  
Cells were run using a ThermoFisher Attune NXT flow cytometer. Unstained 
controls were used to set the voltage for each of the fluorescent channels used. 
Isotype controls for each channel were used with cells as negative controls, thus 
allowing the non-specific background signal to be differentiated from the 
specific antibody signal. 
2.7.2 Flow cytometry compensation 
UltraComp eBeadsTM (ThermoFisher Scientific, UK) were used to perform 
fluorescence compensation by correcting for spectral overlap. 1 drop of beads 
was added to a 5 ml conical tube, and 2 µl of fluorescently labelled antibody was 
added, and incubated for 30 minutes at 4°C. Centrifugation at 600 x g for 5 
minutes was then performed. The pellets were resuspended in 500 µl FACS 
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buffer and the samples were run in the cytometer. Spectral overlap settings 
were set automatically, by the accompanying software. 
2.7.3 Flow cytometry gating strategy and analysis 
With assistance from Dr Ewan Ross, University of Glasgow, gating strategy work 
was conducted using the FlowJoTM software. Forward scatter area (FSC-A) versus 
side scatter area (SSC-A) was calculated to identify the population of viable 
cells. This population was then assessed for its expression of specific antibodies, 
Figure 2-4. Positive expression was determined by a fluorescence signal that was 
higher than the isotype background control. 
A B 
  
Figure 2-4 Image A demonstrates flow cytometry gating strategy for identification of viable 
MSCs with a forward scatter versus side scatter plot. The viable, single cell population, with 
doublet exclusion are highlighted, sample data is from the OA group. Image B demonstrates 
antibody staining observed, with positive expression of CD90 identified in OA (Red) and 
NOF (Blue) in comparison to Isotype control (Grey). 
 
The mean fluorescence intensity (MFI) of each sample was calculated and the 
fold change of antibody expression between the NOF and OA groups was 
determined. This was assessed for statistical significance by a two-tailed Mann 
Whitney test. 
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2.8 Histochemical staining 
2.8.1 Oil Red O staining 
Oil Red O staining was utilised to assess differentiation of MSCs to mature 
adipocytes. At the end of culture ,cells were washed in PBS and fixed via a 15 
minute incubation with 4% formaldehyde, 2% sucrose in PBS at 37 °C. A 0.3% 
stock solution of Oil Red O (Sigma Aldrich, UK) was prepared and diluted 3:2 in 
distilled water. The fixative was removed and the samples washed in distilled 
water. A wash in 60% isopropanol was then performed. The dilute Oil Red O 
solution was then added to the samples through a syringe filter, and incubated 
at 15-20 °C for 15 minutes. The solution was removed from the samples and 
washed twice with water. PBS was then placed on the coverslips and brightfield 
microscopy was performed. 
2.8.2 Von Kossa staining 
At the end of culture cells were washed in PBS and fixed, as described 
previously. The samples were then immersed in 5% silver nitrate and exposed to 
UV light for 20 minutes. The samples were then rinsed in deionized water. 5% 
sodium thiosulphate was added to the samples for 10 minutes at 15-20 °C and 
then washed for 5 minutes in tepid water, followed by a further wash in 
deionized water. The samples were then counterstained in nuclear fast red for 5 
minutes and rinsed three times in deionized water and finally with 70% ethanol. 
Samples were allowed to dry and then observed by brightfield microscopy was 
performed. 
2.9 MicroRNA extraction 
MiRNAs were extracted from MSC cultures of both patient groups for analysis. A 
TRIzol (ThermoFisher Scientific) extraction method was utilised. Cells were 
detached from flasks via Trypsin and centrifuged at 1400 rpm for 4 minutes. The 
cell pellet was resuspended in 1ml of basal media and transferred to an RNase 
free Eppendorf tube, and centrifuged at 1445 x g for 5 minutes. The supernatant 
was removed and the pellet was resuspended in 1ml TRIzol. The sample was 
mixed via vortex for 30 seconds and incubated at 15-20 °C for 5 minutes. 200 µl 
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chloroform was added and the sample was vortexed again for 30 seconds 
followed by 2 minutes of incubation at 15-20 °C. The sample was then 
centrifuged at 14848 x g for 10 minutes. After centrifugation the uppermost 
clear layer of liquid was transferred to a new RNase free Eppendorf. Isopropanol 
was then added, 70% of the volume of sample. The sample was mixed and then 
centrifuged at 14848 x g for 10 minutes. The supernatant was removed, the 
pellet was washed in 200 µl 80% ethanol, and centrifuged for 5 minutes at 14848 
x g. This was repeated and the pellet was then allowed to dry at 15-20 °C. 25 µl 
RNase free water was added and the sample resuspended. The RNA 
concentration of the sample was assessed by NanoDropTM (ThermoFisher 
Scientific) and the samples were then stored at -80 °C. 
2.10 MicroRNA analysis 
The miRNA samples were analysed at the University of Glasgow’s Polyomics 
Department. Next Generation sequencing was performed utilising the NextSeqTM 
500 platform. 3 patient samples per group were analysed, with 3 technical 
replicates for each patient sample. 
MiRNA expression was tested for differential expression and statistical 
significance by the DESeq2 package (Bioconductor). P adjusted value of <0.1 was 
considered statistically significant. 
2.11 Immunostaining for In Cell WesternTM 
At set time points cells were fixed for 15 minutes at 37 °C, (with 4% 
formaldehyde, 2% sucrose in PBS) and incubated in permeabilising buffer (10.3g 
sucrose, 0.292g NaCl, 0.06g MgCl2 (hexahydrate), 0.476 HEPES, 0.5 ml Triton X 
(Sigma-Aldrich, UK) in 100 ml PBS, pH 7.2) for 5 minutes at 4°C. The 
permeabilising buffer was then removed and 150 µl PBS/1% milk protein was 
added. The plate was placed on a shaker at 15-20 °C for 90 minutes. The 
blocking solution was removed and the primary antibody, diluted in 150 µl 
PBS/1% milk protein, was added and incubated for 2.5 hours at 15-20 °C. The 
antibody was removed and 5 washes were performed with diluted Tween 20, (1 x 
PBS + 0.1% Tween 20 solution (Sigma-Aldrich, UK)), with 5 minutes of shaking per 
wash. Secondary antibody solution was then incubated for 1 hour on a shaker at 
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15-20 °C protected from light. The secondary antibody solution was made up to 
150 µl and contained 1:800 secondary antibody, 1:500 Li-Cor Cell Tag 700 stain 
(Li-Cor, UK) and 0.2% Tween 20. 5 further washes in diluted Tween 20 were 
performed, with the samples protected from light throughout. The final wash 
buffer was removed, the coverslips were transferred to a new 24 well plate, 
protected from light, and stored at 4°C until dry. Table 2-5 displays the primary 
and secondary antibodies used during In Cell Western TM (ICW) analysis. 
Table 2-5 Details of primary and secondary antibodies utilised in In Cell Western 
experiments. 
Primary 
Antibody 
Manufacturer Dilution Secondary 
Antibody 
Osterix Santa Cruz, 
Biotechnologies, 
Dallas TX, USA 
1:100 Rabbit 
PPARg Santa Cruz, 
Biotechnologies, 
Dallas TX, USA 
1:100 Donkey 
 
2.12 RNA extraction  
RNA extractions from cell pellets were performed utilising Qiagen RNeasy mini 
kits, according to the manufacturer’s protocol. All centrifuge runs were at 8000 
x g for 15 seconds unless stated otherwise. Pellets were either used immediately 
after cell harvest or after storage at -80 °C. Four wells were combined to 
provide one replicate, with 350 µl of buffer RLT added to each well and the 
sample homogenised with pipetting. 1400 µl of 70% ethanol was added to the 
lysate, and mixed via pipetting. Samples were then transferred to an RNeasy 
MinElute spin column, and centrifuged. The flow through was discarded and 350 
µl of buffer RW1 were added to the spin column and centrifuged. 80 µl of DNase 
I in buffer RDD were added directly to the spin column membrane, and 
incubated at 20 °C for 15 minutes. 350 µl of buffer RW1 were added, and the 
column was centrifuged, the collection tube was then replaced. 500 µl of buffer 
RPE was added and the column was centrifuged. 500 µl of 80% ethanol was then 
added and the column centrifuged for 2 minutes at 8000 x g. The collection tube 
was then discarded. The spin column was then placed in a new collection tube 
and centrifuged at 16,000 x g for 5 minutes to dry the membrane. The column 
was then placed into a 1.5 ml collection tube, and the previous collection tube 
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was discarded. 14 µl of RNase-free H2O were added to the centre of the spin 
column membrane and the RNA was eluted by a further centrifugation at 16,000 
x g for 1 minute. 
2.13 Reverse Transcription 
Reverse transcription was performed using a QuantiTect Reverse Transcription 
Kit, according to the manufacturer’s protocol. RNA samples were thawed on ice. 
The kit reagents, gDNA Wipeout Buffer, Quantiscript Reverse Transcriptase, 
Quantiscript RT Buffer, RT Primer Mix and RNasefree water, were thawed at 
room temperature (15-25 °C). The solutions were mixed and centrifuged. All 
subsequent reactions were performed on ice. RNA content was normalised to 500 
ng total in each reaction, if possible from the sample. If not achievable, when 
assessed by Nanodrop quantification, the total volume of RNA elute was used. 
Genomic DNA elimination reaction was performed with 2 µl of gDNA Wipeout 
Buffer appropriate volume of RNA sample to yield 500 ng made up to 14 µl with 
RNase-free water. This reaction was incubated at 42 °C for 2 minutes then 
placed on ice. Reverse transcription was then performed with 1 µl Quantiscript 
Reverse Transcriptase, 4 µl Quantiscript RT buffer, 1 µl RT primer mix and 14 µl 
sample RNA from the genomic DNA elimination reaction. An incubation step at 
42 °C for 15 minutes, followed by 3 minutes at 95 °C to inactivate the 
Quantiscript Reverse Transcriptase was performed. The complete reverse 
transcription reaction samples were then stored at -20 °C. 
2.14 Analysis of quantitative real-time-PCR (qRT-PCR) 
Samples were removed from storage and assessed by qRT PCR. A master mix for 
each gene to be analysed was prepared. Table 2-6 demonstrates the constituents 
of the master mix. 2 µl of cDNA at a concentration of 2.5 ng/µl was added to 
each well, with each sample analysed in duplicate. A negative control, was also 
placed in a known location on the 96 well plate. The wells were then sealed 
firmly with a thin film of plastic. The primers used to assess the samples are 
displayed in Table 2-7. 
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Table 2-6 Constituents of wells for qRT-PCR analysis. 
Reagent Volume required per 
well (µl) 
SYBR-Mix (Qiagen) 10 
100 µM Primer Forward 
(0.1 µl) 
0.1 
100 µM Primer Backward 
(0.1 µl) 
0.1 
H2O 7.8 
Total 18 
 
Table 2-7 Details of primers utilised in qRT-PCR experiments 
Gene Forward primer Reverse primer Manufacturer 
GAPDH TCAAGGCTGAGAACGGG
AA 
TGGGTGGCAGTGATGGCA Eurofins 
Osterix GGCAAAGCAGGCACAAA
GAAAG 
AATGAGTGGGAAAAGGGAG
GG 
Eurofins 
RUNX2 CAGACCAGCAGCACTCC
ATA 
CAGCGTCAACACCATCATTC Eurofins 
PPARg TGTGAAGCCCATTGAAG
ACA 
CTGCAGTAGCTGCACGTGT
T 
Eurofins 
FABP4 ACAAACCACCGCACAACA
G 
CGCCTGCACTTTTGGGTA Eurofins 
 
The 7500 Real Time PCR system was used to perform the amplification and 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as the reference 
gene. The expression of the target genes was assessed in comparison to GAPDH. 
For quantification the 2-DDCt method was used to determine gene expression and 
amplification of the negative control samples was also assessed against the 
sample conditions.  
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2.15 Electron Microscopy 
On day 3 of spheroid formation spheroid samples were prepared for scanning 
electron microscopy (SEM) and transmission electron microscopy (TEM). The 
spheroids were fixed in 2.5% glutaraldehyde in 0.1 M sodium cacodylate (SC) 
buffer for 1 hour. The spheroids were then washed 3 times in 0.1 M SC and 
incubated for 1 hour in 1% osmium tetroxide. The spheroids were then rinsed 3 
times in distilled water prior to a 1 hour incubation in 0.5% aqueous uranyl 
acetate in the dark. The spheroids were then washed 2 times further in distilled 
water and then subjected to dehydration through an alcohol series, prior to 
being critical point dried. SEM samples were then mounted on to stubs and 
sputter coated in gold prior to microscopy. TEM samples were embedded in resin 
and sectioned prior to imaging.  
2.16 Cell Viability Staining 
Viability of the cells within the spheroid was determined using an ethidium 
homodimer/calcein AM viability kit (Life Technologies, Carlsbad, CA, USA), 
which stains live cells green and dead cells red. At time points of 24 hours, 7 
days and 28 days after spheroid formation culture media containing 1 μL/ml of 
each stain was added to the spheroids. After 1-hour incubation at 37 °C the cells 
were washed with warmed media and immediately imaged using a fluorescence 
microscope. 
2.17 MicroCT scanning of femoral head samples 
Femoral heads were obtained from 3 patients undergoing total hip replacement 
for osteoarthritis and 3 for hemiarthroplasty for patients who had sustained 
osteoporotic type intracapsular neck of femur fractures. The sample was stored 
in formalin at 4 °C until scanning was performed. 
MicroCT scanning was undertaken with a Skyscan 1172 microCT scanner (Bruker 
microCT, Kontich, Belgium). Shadow projection images were taken at 0.34 
degree steps for a 180-degree rotation. The pixel resolution was 34 µm. To 
reduce signal noise a random motion of 5 was used with 3 frames averaged. 
Beam energy was 100 kilovolts and an aluminium filter was used to reduce beam 
 
 
56 
hardening. Acquired images were reconstructed into axial slices using NRecon 
(version 1.6, Skyscan Ltd, Belgium). Orientation of the images was performed on 
the DataViewer software and further analysis was performed using the software 
package CTAn (version 1.11, Bruker-microCT, Belgium). 
2.18 Metabolomic analysis 
At defined culture time points media was removed from wells, and the cells 
were washed in chilled PBS. All PBS was then removed from the wells. Chilled 
extraction solvent (1:3:1 of chloroform, methanol and water) was added to the 
wells, the plate was sealed by parafilm, and placed on a rotary shaker at 4 °C 
for 1 hour. The solution was then pipetted from the well and centrifuged for 3 
minutes at 13000 x g at 4 °C. The supernatant was transferred to a fresh 
Eppendorf tube. A control, pooled sample was taken with 10 µl from each well 
of the experiment per biological replicate. The samples were stored at -80 °C, 
until they were subjected to liquid chromatography by the Glasgow Polyomics 
Facility at the University of Glasgow. For each patient sample 1 replicate was 
used from each condition. 
The liquid chromatography mass spectrometry (LCMS) was carried out by staff at 
the Glasgow Polyomics. LCMS allows the isolation of individual metabolites from 
the mixture produced in each sample, and separated them relative to their 
mass:charge (m/z/) ratio. An UltiMate 3000 RSCLC featuring a 20 mm x 2.1 mm 
ZIC-pHILIC analytical column running at 300 µl/minute, coupled to an Orbitrap 
Q-Exactive (Thermo Fisher) was used. Standards comprising known metabolites 
were also processed in this manner and their respective retention times in the 
chromatography column were used to identify sample metabolites. 
2.19 Statistical Analysis 
Statistical tests were performed using GraphPad Prism 6 software. Data sets 
were analysed for normality by the Shapiro-Wilk test. If normal distribution of 
data existed, then analysis of variance (ANOVA) was performed using one-way 
ANOVA test, followed by a Tukey post-hoc test. If data was not normally 
distributed then non-parametric tests were used, namely Mann Whitney and 
Kruskal-Wallis, with multiple comparisons.  
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The statistical significance of the results was determined by calculating the 
probability of a null hypothesis being true, using a pre-specified threshold (p-
value). The null hypothesis was rejected and the result was classed as being 
statistically significant if the p-value was < 0.05. 
2.20 Research Colleagues 
Dr Ewan Ross assisted with conducting flow cytometry. Dr Robert Wallace, 
University of Edinburgh, operated the microCT scanner for imaging of the 
femoral heads. TEM samples were sectioned by Margaret Mullin, Electron 
Microscopy Facility, University of Glasgow. Next Generation sequencing of RNA 
samples and metabolomic analysis was performed at the University of Glasgow’s 
Polyomics department. 
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Chapter 3 
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3 An analysis of microRNA expression and 
functional capacity of mesenchymal stromal 
cells from patients with neck of femur fractures 
3.1 Introduction 
Decreasing the burden OP poses to future generations is an important goal. To 
achieve this more must be known of the condition, and its associated fragility 
fractures to improve the development of biomarkers and therapies. 
It is also imperative to improve primary preventative therapies, and their 
monitoring, to successfully reduce the significant morbidity and economic effect 
of OP (Compston, McClung and Leslie, 2019). 
MSCs have long been heralded for their promise and importance in regenerative 
medicine (Rodeo, 2019). The ageing effect on MSCs has been explored; however, 
defining characteristics present in BM MSCs from patients with OP has not been 
thoroughly investigated (Sethe, Scutt and Stolzing, 2006; Abdallah and Kassem, 
2012). 
Determining the multipotent potential of MSCs from NOF patients will further 
elucidate their role in the development of OP. It will also identify their 
usefulness as a source for in vitro research. It is hypothesised that MSCs from the 
NOF group will have deficient multipotent potential. Improving our 
understanding of MSCs from patients with, or at risk of OP, will result in more 
relevant research with the aim of optimising the development of future 
therapies.  
MicroRNAs hold great promise as biomarkers and targets for many diseases. This 
hope extends to musculoskeletal diseases including OP (Cheng et al., 2019). 
Studies have shown dysregulated microRNAs in both serum and bone marrow, 
and it is hoped that microRNA therapies can be developed which can improve 
bone density (Heilmeier et al., 2016). Due to their non-specific binding each 
microRNA can play a variety of roles in vivo, and thus rigorous investigation of 
potential therapeutic candidates is required. 
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MicroCT scanning of femoral heads provides a means of assessing the phenotype 
produced in the OA and NOF groups. MicroCT has previously shown significant 
differences in these patient groups (Jenkins et al., 2013), and will act as a 
means of corroborating the deficiencies produced by dysregulation of MSC 
function and microRNA expression. 
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3.2 Objectives  
This chapter aims to rigorously characterise bone and BM MSCs from the two 
patient groups within the study, namely osteoarthritic and neck of femur 
fracture. The cell phenotype of BM MSCs from each group will be interrogated 
and the bone phenotype produced assessed. This will be achieved by the 
following experiments.  
1. Extracellular surface marker analysis by flow cytometry 
2. Culture within conditioned media to determine differentiation capacity 
3. microRNA expression analysis of BM MSCs 
4. Analysing bone micro-architectural indices via microCT scanning of 
femoral heads 
  
 
 
62 
Materials and Methods 
3.2.1 Patient samples 
Bone marrow and femoral head samples of the same patients were utilised for 
the microCT and microRNA experiments. All of the patients were of the same 
gender, with no statistical difference in mean age between the NOF and OA 
group, P = 0.9 (Mann Whitney test). 
3.2.2 Cell Culture 
In this chapter bone marrow extraction was performed from the OA and NOF 
groups, and culture of MSCs in monolayer was as described in section 2.4.  
3.2.3 Flow Cytometry 
To characterise and identify MSC markers in cells extracted from BM from both 
patient groups, flow cytometric analysis was performed as described in section 
2.7. Antibodies used for phenotyping are listed in section 2.7.1. 
3.2.4 Differentiation media 
Culture of MSCs of both patient groups was performed in conditioned media. This 
was performed as described is section 2.5.1, to induce adipogenesis and 
osteogenesis. The cells were seeded from growing flasks at a concentration of 
2000 cells per cm2 and after allowing 24 hours of attachment to the coverslip the 
media was exchanged for basal, adipogenic or osteogenic media. Every 7 days 
the adipogenic media was substituted from induction to maintenance or vice 
versa. 
3.2.5 Histochemical staining and imaging 
Histological analysis was performed to observe and quantify differentiation of 
MSCs from both patient groups. MSCs were seeded onto coverslips and after 24 
hours differentiation media was applied. The cells were cultured for 21 days, 
with feeding every 72 hours. The cells were fixed and stained with Oil red O or 
von Kossa to assess adipogenesis and osteogenesis, respectively. MSCs grown in 
monolayers were utilised as a control.  
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3.2.5.1 Oil Red O staining 
As described in section 2.8.1, Oil Red O staining was utilised to observe the 
deposition of lipids and neutral triglycerides as an indication of adipogenic 
differentiation.  
3.2.5.2 Von Kossa staining 
Von Kossa staining demonstrates mineralization, and thus evidence of osteogenic 
differentiation within a culture. Samples were prepared as described in section 
2.8.2.  
3.2.5.3 Quantification of histochemical staining 
After histochemical staining samples were imaged by light microscopy at 10x 
magnification. For each patient 3 technical replicates were utilised, and 5 
images were taken of each coverslip at specified areas, see Figure 3-1. 
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Figure 3-1 Example of areas imaged for analysis during histochemical staining. For both Oil 
red O and von Kossa staining coverslips were assessed by light microscopy and in 5 pre-
determined areas, demonstrated by crosses in the above depiction, images of the observed 
staining recorded. 
 
The obtained images were than processed in ImageJ and quantified as follows: 
Oil Red O quantification: Images were converted to an 8-bit image and 
thresholding was performed to identify the areas of the cover slip positively 
stained by Oil Red O. The basal media was used as a control, the mean threshold 
value was calculated for this condition, and this value was then applied as a 
threshold for staining to the adipogenic media group, and the area of positive 
staining calculated, and utilised in statistical analysis.  
von Kossa quantification: all images were converted to an 8-bit image. Manual 
thresholding to identify positive areas of mineralization was performed. The 
area of positive staining was utilised in statistical analysis. 
3.2.6 MicroRNA expression 
As described in section 2.9 RNA extraction from MSCs was performed via a TRIzol 
method for both groups. Next Generation Sequencing was performed on the 
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extracted RNA, via the University of Glasgow’s Polyomics department. Three 
patient samples from each group were analysed. Three technical replicates were 
used for each patient. 
3.2.7 MicroCT scanning 
3 femoral heads from both the NOF and OA group were imaged via microCT 
scanning with a pixel resolution of 34µm. Acquired images were reconstructed 
into axial slices, and orientated by identification of the calcar and physeal scar. 
The mid axial scan image of each femoral head was identified. A virtual sphere 
was then drawn fitting the diameter of the femoral head. The centre of this 
sphere was utilised as the location of the first volume of interest (VOI), from 
which all other VOIs were calculated Figure 3-2. The VOIs were cuboidal, 
measuring 7.5mm3. Each VOI was separated from VOI 1 by 2mm, in their 
respective directions. All bone characteristic data analysed was from these VOIs. 
A1
 
B1
 
C1
 
A2
 
B2
 
C2
 
Figure 3-2 MicroCT images of femoral heads demonstrating the 7 VOIs. Images A1/B1/C1 are 
representative of the OA group, images A2/B2/C2 are representative of the NOF group. 
Images A1/A2 show centre axial slices where 5 VOIs were analysed. Images B1/B2, C1/C2 
show upper and lower slices respectively where 1 central VOI was analysed. 
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3.3 Results 
3.3.1 Flow Cytometry 
The phenotype of the NOF and OA patient groups was assessed by flow 
cytometry. The expression of specific surface antigens used to define MSC 
populations was assessed. Surface antigens, known to characterise 
haematopoietic stem cells, were also evaluated, to determine the heterogeneity 
of the cell population. 
Displayed in Table 3-1 both patient groups positively expressed markers of MSCs, 
namely CD105, CD73 and CD90. Importantly both groups did not express surface 
antigens known to represent HSC populations, CD45, CD34, CD14, CD79 and HLA-
DR, which would have been suggestive of co-culture conditions. Results from the 
flow cytometric analysis confirmed the adherent fraction of the BM was 
producing a cell population containing MSCs, which was consistent to both 
patient groups.  
Table 3-1 Phenotyping demonstrates positive and negative expression of MSC markers on 
flow cytometric analysis. 
 OA NOF 
CD 105 + + 
CD 73 + + 
CD 90 + + 
CD45 - - 
CD34 - - 
CD14 - - 
HLA-DR - - 
CD79 - - 
 
Differential expression between the two groups was observed, however this only 
reached statistical significance for three markers, CD90, CD13 and CD166, Figure 
3-3. In each case, these markers were reduced in NOF MSCs compared to OA 
MSCs. 
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Figure 3-3 Flow cytometric assessment of antibody expression, CD90, CD13 and CD166 with 
fold change of antibody expression between the NOF and OA groups determined. Statistical 
significance assessed by a two-tailed Mann Whitney test, P=0.0286. N=4. These MSC 
markers were all reduced in NOF MSC cell populations in comparison to the OA group. 
 
No statistically significant difference was observed in the expression of the 
remaining antibodies, Figure 3-4. 
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Figure 3-4 Flow cytometric assessment of antibody expression, with fold change of 
antibody expression between the NOF and OA groups determined. N=4 for all antibodies 
except CD140a and CD140b N=3. 
 
Examples of the observed antibody expression is demonstrated in Figure 3-5,  
with data from one patient of from each group demonstrated.  
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Figure 3-5 Demonstration of histograms antibody expression by flow cytometry. One patient 
from OA and NOF group with isotype controls as negative controls displayed. Solid blue- 
NOF patient, Solid red- OA. Dotted red and blue- isotype controls. Data normalised to allow 
comparison between samples. 
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3.3.2 Differentiation Potential of Bone Marrow Mesenchymal 
Stromal Cells from NOF and OA patients 
A 21-day culture in differentiation media was performed to assess the 
multipotency capacity of each group. Two differentiation lineages were 
selected, adipogenesis and osteogenesis. 
3.3.2.1 Adipogenesis 
Small areas of positive Oil Red O staining were observed in both patient groups 
in the basal media condition, Figure 3-6, however by day 21 adipocytes were not 
observed in this control condition. Both the OA and NOF group were able to form 
mature adipocytes, see Figure 3-7, when cultured in adipogenic media. Clusters 
of adipocytes were observed in both patient groups when cultured in adipogenic 
media. 
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B 
 
Figure 3-6 Brightfield microscopy of Oil Red O staining at Day 21 of MSC culture in basal 
medium. Image A represents OA group, B NOF group. Scale bar = 10µm.  
 
A 
 
B 
 
Figure 3-7 Brightfield microscopy of Oil Red O staining at Day 21 of MSC culture in 
adipogenic medium. Image A represents OA group, B NOF group. Scale bar = 10µm. 
 
An increase in positive Oil Red O staining was seen in both groups in the 
adipogenic media at day 21. A statistically significant increase in Oil Red O 
staining was observed in the OA group, however this was not observed in the 
NOF group, Figure 3-8. The NOF group displayed a trend of increasingly positive 
Oil Red O staining in the adipogenic media, however this did not reach statistical 
significance. This may correlate to a more adipogenic state for NOF MSCs in 
basal media noting that staining revealed no evidence for this, or, perhaps more 
likely, a reduced capacity of differentiation from MSCs from the NOF group. 
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Figure 3-8 Level of Oil Red O staining in OA (A) and NOF (B) MSCs at day 21 in basal and 
adipogenic culture medium. For each group 3 patient samples were used with 3 cover slips 
per culture condition analysed. 5 images were taken per coverslip resulting in 45 images per 
group and condition. Mean grey value with standard deviation is displayed. Statistical 
analysis by Mann Whitney test, group A, P<0.0001, group B P= 0.637.  
 
3.3.2.2 Osteogenesis 
Von Kossa staining was performed to assess the presence of mineralization as a 
marker of osteogenesis. Microscopy revealed the monolayer formation of MSCs 
with evidence of mineralization in the basal media in both patient groups, Figure 
3-9. 
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A  B  
Figure 3-9 Brightfield microscopy of von Kossa staining at Day 21 of MSC culture in basal 
medium. Image A represents OA group, B NOF group. Scale bar = 10µm. 
 
A  B  
Figure 3-10 Brightfield microscopy of von Kossa staining at Day 21 of MSC culture in 
osteogenic medium. Image A represents OA group, B NOF group. Scale bar = 10µm. 
 
When cultured in osteogenic media, clustering of cells and larger mineral 
deposition was evident by microscopy, with positive staining visible in both 
groups, Figure 3-10. The OA group again appeared to show a greater potential 
for differentiation. 
The overall trend of expression was similar between the two groups, Figure 3-11, 
with both patient groups showing a statistically significant increase in von Kossa 
staining when cultured in osteogenic media. Greater variation was observed in 
the NOF group, with a wider spread of mean gray values. A direct comparison 
was not made between the groups as staining and imaging was not performed on 
the same day for all samples. 
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Figure 3-11 Level of von Kossa staining in OA (A) and NOF (B) MSCs at day 21 in basal and 
osteogenic culture medium. Mean grey value with standard deviation is displayed. 
Statistical analysis by Mann Whitney test, group A and B p < 0.0001. 
 
3.3.3 microRNA expression in NOF and OA 
Over 2000 microRNAs were screened in MSCs from both patient groups. This 
revealed significant variations in expression levels of microRNAs known to be 
involved in the pathogenic process of OP (Kim and Lim, 2014; Heilmeier et al., 
2016; Mäkitie et al., 2018). Figure 3-12 demonstrates the 105 significantly 
abnormally expressed microRNAs observed in the NOF group in comparison to the 
OA group. This shows an approximately even distribution of over and under-
expressed miRNAs when comparing the NOF patients to the OA group. 
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Figure 3-12 Volcano plot of microRNA expression in the NOF group in comparison to the OA 
group. X axis represents log2 of the fold change and Y axis represents the p value. Red dots 
demonstrate miRNAs which are significantly dysregulated with a p adjusted value of <0.1. 
Statistical analysis by DESeq2.  
 
Principal component analysis (PCA) was performed to assess the clustering of 
microRNA expression within patient samples and groups, Figure 3-13. A weak 
pattern of separation was observed between the two patient groups. Replicates 
of patient samples were seen to cluster better in the OA group with more 
variance seen in the NOF group.  
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Figure 3-13 PCA plot of log transformed microRNA expression in NOF and OA groups. Red 
circles represent OA group patients and blue circles NOF group patients. Intra-patient 
samples were seen to cluster closely. The OA group demonstrated a greater distribution 
along both X and Y axes. A weak pattern of clustering was evident within the NOF group.  
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Of these dysregulated microRNAs the most increased and decreased, and their 
log fold change are displayed in Table 3-2 and Table 3-3. 
Table 3-2 Top 20 microRNAs with increased expression in NOF group vs OA group, with log 
2-fold change. 
 
 
 microRNA Log 2-Fold Change 
1 hsa-miR-146a-3p 2.25 
2 hsa-miR-4662a-5p 2.17 
3 hsa-miR-1304-3p 2.13 
4 hsa-miR-935 1.83 
5 hsa-mir-2114 1.75 
6 hsa-mir-3671 1.67 
7 hsa-mir-549a 1.62 
8 hsa-miR-4653-5p 1.35 
9 hsa-miR-4286 1.11 
10 hsa-miR-99a-5p 1.16 
11 hsa-miR-100-5p 1.00 
12 hsa-miR-3200-3p 0.92 
13 hsa-miR-598-3p 0.84 
14 hsa-miR-125b-2-3p 0.80 
15 hsa-miR-212-5p 0.75 
16 hsa-miR-31-5p 0.75 
17 hsa-let-7a-2-3p 0.71 
18 hsa-miR-500a-3p 0.69 
19 hsa-mir-491 0.56 
20 hsa-miR-29a-3p 0.53 
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Table 3-3 Top 20 microRNAs with decreased expression in NOF group vs OA group, with log 
2-fold change. 
 
 
 microRNA Log 2-Fold Change 
1 hsa-mir-4467 -2.42 
2 hsa-miR-124-3p -2.37 
3 hsa-mir-124-2 -2.20 
4 hsa-miR-133a-3p -2.04 
5 hsa-mir-1-2 -1.98 
6 hsa-miR-16-1-3p -1.69 
7 hsa-mir-3167 -1.66 
8 hsa-mir-150 -1.61 
9 hsa-mir-6868 -1.53 
10 hsa-miR-18a-5p -1.12 
11 hsa-miR-2355-3p -1.11 
12 hsa-miR-299-3p -1.08 
13 hsa-miR-143-5p -1.07 
14 hsa-mir-3182 -1.03 
15 hsa-miR-106a-5p -1.01 
16 hsa-miR-455-5p -0.99 
17 hsa-miR-3529-3p -0.97 
18 hsa-miR-7-5p -0.97 
19 hsa-miR-7-2 -0.97 
20 hsa-miR-20a-5p -0.95 
 
Several pathways were highlighted as being predicted to be altered due to this 
expression profile of microRNAs in the NOF group. Figure 3-14 demonstrates a 
network centred on AGO2, a member of the Argonaute family crucial to RNA 
silencing. This network was observed by IPA to be related to organismal injury. 
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Figure 3-14 Network 1, demonstrating an abnormally regulated pathway in the NOF group 
relative to the OA group, centred upon the cytoplasmic actions of AGO2, generated via IPA 
software. Red represents predicted increased expression, and green decreased. N = 3 
patient samples, with 3 technical replicates each. Solid line represents direct, and dotted 
line indirect, effect. 
 
Figure 3-15 demonstrates another IPA generated network observed to be 
dysregulated in the NOF group. The main functions of the network were cellular 
movement, development, growth and proliferation. The down-regulation of miR-
143 is observed to target Transgelin (TAGLN), observed to control differentiation 
via regulating cytoskeleton organization (Elsafadi et al., 2016), B-cell lymphoma 
2 (BCL2), known to promote cell survival and regulate mitochondrial activity 
(Pantschenko et al., 2005) and smooth muscle actin, observed in active 
osteoblasts (Kinner and Spector, 2002). Furthermore, there is reduced 
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expression of miRNAs involved in the regulation of molecules related to 
osteogenesis such as Wingless-type MMTV integration site family, member 2 
(Wnt2), Wingless-type MMTV integration site family, member 3A (Wnt3A) and 
bone morphogenic protein 2 (BMP2) (Liu et al., 2013). 
 
Figure 3-15 Network 2 demonstrating an abnormally regulated pathway in the NOF group, 
relative to the OA group, with effects on molecules related to cellular growth, proliferation 
and movement. Red represents predicted increased expression, and green decreased. N = 3 
patient samples, with 3 technical replicates each. Solid line represents direct, and dotted 
line indirect, effect. 
 
Figure 3-16 shows a third network IPA generated network, with dysregulation of 
cell death and survival and cell cycle regulation. Abnormalities in inflammatory 
response are observed in the NOF group. MiR-31-5p upregulation is noted. MiR-
31-5p indirectly regulates CXCL5 and IL1B, known inflammatory regulators 
(Lange et al., 2010; Sepuru, Poluri and Rajarathnam, 2014). 
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Figure 3-16 Network 3 Demonstrating a dysregulated miRNA network in the NOF group, 
relative to the OA group, with abnormalities of cell death and survival and cell cycle 
regulation predicted. Red represents predicted increased expression, and green decreased. 
N = 3 patient samples, with 3 technical replicates each. Solid line represents direct, and 
dotted line indirect, effect. 
 
Figure 3-17 illustrates network 4 which was again identified by IPA to be 
abnormally regulated in the NOF group, with effects on cellular growth, 
organismal injury noted. Furthermore, notch signalling via the notch receptor 
protein was noted to be implicated, via NOTCH1 and NOTCH2. Both have been 
shown to have roles in osteoblast differentiation (Hilton et al., 2008; Regan and 
Long, 2013). 
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Figure 3-17 Network 4 displays predicted abnormalities in cell growth, organismal injury and 
cancer pathways in the NOF group, relative to the OA group. Red represents predicted 
increased expression, and green decreased. N = 3 patient samples, with 3 technical 
replicates each. Solid line represents direct, and dotted line indirect, effect. 
 
3.3.4 MicroCT Characteristics of femoral head samples from NOF 
and OA 
MicroCT scanning was performed to assess multiple bony characteristics of 
femoral head samples from both patient groups. Femoral heads were from the 
same patients as utilised in the microRNA expression analysis. 
Seven volume of interests (VOI) were plotted within the femoral head. VOI 1 was 
determined from the mid axial scan image, the other VOIs were determined 
respective to its position, see Figure 3-2 for further description of the VOIs 
locations.  
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Multiple indices were assessed within the VOIs, to obtain a comprehensive 
overview of the microarchitecture of each sample. BV/TV was a key index that 
was assessed and is displayed by group, Figure 3-18, and by patient, Figure 3-19 
and Figure 3-20. The highest BV/TV value was observed in VOI 1 in the NOF 
group. The lowest BV/TV value was seen in VOI 4 of the OA group. BV/TV was 
seen to be statistically significantly varied in the OA group when comparing VOI 
1 vs VOI 4 only. 
A
 
B
 
Figure 3-18 Mean BV/TV % with SD observed in each VOI, in group A (OA) and B (NOF). N=3. 
Statistical analysis by Kruskal Wallis test with Dunn’s multiple comparison showed 
significant variation in VOI 1 vs VOI 4 in group A (OA) only. 
 
Figure 3-19 and Figure 3-20 show the individual patient BV/TV values in each 
VOI. This demonstrates no uniform pattern of BV/TV throughout the femoral 
head, with individual trends observed in both patient groups. 
   
Patient 1 OA BV/TV Patient 2 OA BV/TV Patient 3 OA BV/TV 
Figure 3-19 Range of BV/TV (%) observed in patient samples from OA group in each VOI. 
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Patient 1 NOF BV/TV Patient 2 NOF BV/TV Patient 3 NOF BV/TV 
Figure 3-20 Range of BV/TV (%) observed in patient samples from NOF group in each VOI. 
 
Trabecular thickness, Figure 3-21, was also assessed and demonstrated similar 
trends to BV/TV in both groups. In keeping with the BV/TV data, trabecular 
thickness was greatest in VOI 1 in both groups. Marked variation in the remaining 
VOIs was observed in NOF group in comparison to the OA group.  
A
 
B
 
Figure 3-21 Mean trabecular thickness with standard deviation at the 7 Volume of Interest 
sites within the femoral heads of in group A (OA) and B (NOF). n=3 
 
It is evident that a more uniform trabecular thickness is observed in the OA 
group with very large variation seen in the NOF group, Figure 3-21. 
Similar mean values of trabecular separation were observed in the two groups, 
Figure 3-22, with VOI 1 showing the shortest distance between trabeculae. This 
was statistically significantly different in comparison to VOI 4 in the OA group. 
VOI 2 and 4 in both groups showed large separation of trabeculae. Little 
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difference is noted in VOI 6 and 7 in the NOF group, whereas a suggestion of 
more closely associated trabecular is observed in VOI 6 in the OA group. 
A  B  
Figure 3-22 Mean trabecular separation/mm with SD observed in each VOI, in group A (OA) 
and B (NOF). N=3. Statistical analysis by Kruskal-Wallis test with Dunn’s multiple 
comparison showed significant variation in VOI 1 vs VOI 4 in group A only, (P=0.0467). 
 
Trabecular number, assessed in all seven VOIs, is demonstrated in Figure 3-23. 
The OA group showed a significant difference of mean trabecular number in VOI 
1 in comparison to VOI 4, which were observed to have the highest and lowest 
trabeculae number respectively. Similar peak trabecular number was observed in 
the two groups in VOI 1, however little variation in mean trabecular number was 
demonstrated in the remaining VOIs in the NOF group. In both groups, VOI 7, the 
most inferior VOI in the femoral head showed a lower mean value than VOI 6. 
A  B  
Figure 3-23 Mean trabecular number with SD observed in each VOI, in group A (OA) and B 
(NOF). N=3. Statistical analysis by Kruskal-Wallis test with Dunn’s multiple comparison 
showed significant variation in VOI 1 vs VOI 4 in group A only, (P=0.0339). 
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The SMI values across the seven VOIs was observed to follow a similar pattern in 
the NOF and OA group, Figure 3-24. Large variation in the SMI values in each VOI 
was noted in the NOF in contrast to the OA group.  
A
 
B
 
Figure 3-24 Mean structural model index with SD at the 7 VOIs sites within the femoral 
heads of in group A (OA) and B (NOF). n=3. 
 
Variation in degree of anisotropy was seen throughout the femoral heads in both 
groups, Figure 3-25. This reached statistical significance in the OA group only. 
VOI 2 contained the lowest DA in the OA group, suggestive of containing the 
most plate like-trabeculae. VOI 4 in the NOF group contained the lowest DA 
value but this was not significant likely due to high variance in the NOF samples. 
Similar trends were observed in both groups. 
A  B  
Figure 3-25 Mean degree of anisotropy with SD observed in each VOI, in group A (OA) and B 
(NOF). N=3. Statistical analysis by Kruskal-Wallis test showed significant variation in group 
A only, (P=0.0380). 
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Figure 3-26 demonstrates mean connectivity density, with a similair trend, but 
with lower values in the NOF group. Intra-VOI variability was greatest again in 
the NOF groups suggesting large patient-patient variability. A more uniform 
degree of connectivity density was noted in th OA group. 
A
 
B
 
Figure 3-26 Mean Connectivity density with SD observed in each VOI, in group A (OA) and B 
(NOF). N=3. 
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3.4 Discussion 
These experiments sought to rigorously assess the MSC characteristics of the two 
groups and also to identify any phenotypic differences from bone samples. 
3.4.1 Flow cytometry confirms cell populations contain MSCs 
MSCs have long held great hope for greater understanding of diseases and 
providing a therapeutic source. There are multiple tissue sources of MSCs and 
furthermore there are many different techniques used for their isolation. This 
variation causes difficulties when comparing research outcomes, and predicting 
future areas of investigation. 
In order to minimise this heterogeneity criteria have been set for defining MSCs 
(Dominici et al., 2006). In 2006 the International Society for Cellular Therapy 
proposed the following criteria to define the human MSC; 
 
1. Adherence to plastic 
2. Specific Antigen expression 
a. Expression of CD 105, CD 73, CD 90 
b. Lack of expression of CD45, CD34, C14, CD11b, CD79α, CD19 and 
HLA-DR 
3. Multipotent in vitro differentiation potential 
a. Adipogenic 
b. Osteogenic 
c. Chondrogenic 
 
Culturing MSCs from the adherent fraction of bone marrow aspirates has been 
used extensively. However, a comparison of extracellular markers between 
these two groups is relatively unexplored. It was important to assess the 
population of cells being utilised in experiments, to ensure the presence of MSCs 
and the absence of HSCs. 
Results from the flow cytometric analysis confirmed the adherent fraction of the 
bone marrow samples was producing a cell population containing MSCs, which 
was consistent to both patient groups. Importantly both groups did not express 
surface antigens known to represent HSC populations, which would have been 
suggestive of co-culture conditions. The percentages of expression of these 
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extracellular markers was not calculated which could be performed, to fully 
comply with the above criteria, in future experiments. 
Co-cultures have their role in MSK research, with a particular importance when 
assessing osteoclast/osteoblast interactions (Young et al., 2015; Silverwood et 
al., 2016). The focus of experiments in this project, however, was MSC 
differentiation and thus it was favourable to have populations not containing 
HSCs or their progeny. 
3.4.2 MSCs from neck of femur fracture patients show reduced 
stemness 
A trend of reduced expression of markers of MSC naivety and potency was 
observed in the NOF group. A reduction in the expression of CD90 was observed 
in the NOF group. CD90 is a cell surface protein originally discovered as a 
thymocyte antigen, and is also known as Thy-1 (Williams and Gagnon, 1982). 
CD90 has been used as a marker of many cell types, including mature neurons, it 
is notably utilised as one of the characteristic markers of MSCs (Dominici et al., 
2006; Rege and Hagood, 2006). CD90 has also been strongly linked to 
differentiation. Studies have assessed the osteogenic effect of increased or 
decreased expression of CD90 (Moraes et al., 2016). Demonstrations of increased 
osteogenesis in both in vitro and in vivo experiments has been observed with 
high CD90 expression, which is in keeping with the flow cytometry results 
displayed in Figure 3-3, suggesting an impaired osteogenic capacity of MSCs from 
the NOF group (Chung et al., 2012). 
CD13 expression was also observed to be significantly downregulated in the NOF 
group. CD13 is well expressed by many cell types, but has been shown to have an 
important role in MSC function (Iaffaldano et al., 2013). CD13 plays a significant 
role in MSC adhesion, migration and angiogenesis, CD13 knockout studies have 
shown impaired tissue repair (Rahman et al., 2014). The reduced expression of 
CD13 within the NOF group is, again, suggestive of impaired MSC function. It can 
be postulated that this would contribute to impaired fracture healing in vivo and 
thus could be a significant barrier to successful management of fragility 
fractures occurring secondary to OP. 
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Activated leukocyte cell adhesion molecule (ALCAM), also known as CD166, is an 
immunoglobulin with important roles in cell adhesion, migration, haematopoiesis 
and tumour progression (Xu et al., 2016). It is described to play an important 
role in osteoblastic support of HSC function and maintenance (Chitteti BR, Cheng 
Y-H, Kacena MA, 2014). The decreased expression observed in the NOF group, 
Figure 3-3, is suggestive of an impaired bone marrow niche environment. This 
could contribute to poorer osteoblast function and bone deposition. 
3.4.3 Mesenchymal stem cells from NOF patients have impaired 
functionality 
As discussed earlier part of Dominici et al’s criteria of defining an MSC 
population is the ability to differentiate through osteogenic, adipogenic and 
chondrogenic lineages (Dominici et al., 2006). I chose to focus on osteogenesis 
and adipogenesis as differential regulation of these processes have been 
associated with OP (Abdallah and Kassem, 2012; Bidwell et al., 2013). 
The differentiation capacity of MSCs from the two patient groups was assessed 
by culture in differentiation media. This was to assess the multipotency of each 
group, and to determine whether MSCs from the NOF group remained as active. 
It was hypothesised that the NOF group would be relatively more adept at 
differentiating to adipocytes, and have poorer osteogenic differentiating 
capacity. 
Both patient groups were able to differentiate to osteoblasts and adipocytes in 
the presence of differentiation media. When compared to a basal control media 
both groups demonstrated a statistically significant increase in von Kossa 
staining, evidence of osteogenic differentiation. It was predicted that the NOF 
MSCs would show a reduced ability to form osteoblasts in comparison to the OA 
group, however this was not evident. 
The impaired adipogenic activity from the NOF MSCs suggests more about the 
potency of the cells than it does explain a propensity to form osteoblasts in 
favour of adipocytes. The OA group showed a much greater ability to form 
mature adipocytes with positive Oil Red O staining, which was statistically 
significant. The inability of the OP group to produce a statistically significant 
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increase in Oil Red O staining even with induction suggests that the OP MSCs may 
be less reactive to differentiation stimuli. 
The source of MSCs may have been implicated in the multipotency of the MSCs. 
This study utilised MSCs from bone marrow. It has been suggested that these 
have an osteogenic propensity in comparison to other sources, including adipose 
tissue derived MSCs (Xu et al., 2017; Mohamed-Ahmed et al., 2018). 
As discussed in section 1.1.12 the literature remains in equipoise with regards to 
the ability of OP MSCs to form osteoblasts in comparison to control populations 
(Bidwell et al., 2013). The previous hypothesis of ageing and osteoporotic MSCs 
being pro-adipogenic, at the expense of osteogenesis, was refuted by many 
studies (Stenderup et al., 2001; Veronesi et al., 2014). It appears more nuanced 
than to suggest that with age bone marrow MSCs have a propensity to the 
adipogenic lineage and thus the cause of OP MSC dysfunction is not directly in 
keeping with this simplistic view. 
This is supported by Abdallah & Kassem, who disregard the simple notion of an 
inverse relationship between adipogenesis and osteogenesis in the bone marrow 
environment (Abdallah and Kassem, 2012). They state that secreted factors from 
different MSC populations within the bone marrow exert significant regulatory 
control of differentiation. Furthermore, with regards to osteogenic 
differentiation of OP MSCs, Prall et al suggest that pre-induction these cells have 
a reduced osteogenic state, but maintain a sufficient upregulation of osteogenic 
differentiation on BMP-2 induction (Prall et al., 2013). This group further 
identified reduced cellular migration and invasion of MSCs from OP patients 
(Haasters et al., 2014). 
The development of OP has many factors. However, determining to what extent 
the MSC or the local environment is responsible has not yet been addressed. 
These experiments show a trend of reduced potency of MSCs from patients at 
significant risk of OP. This identifies limitations of therapies, as a reduced 
differentiation effect will be exerted in MSCs from this population. 
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3.4.4 MicroRNA expression in NOF patients shows significant 
dysregulation 
105 microRNAs were observed to be significantly dysregulated between the two 
patient groups as illustrated by Figure 3-12. Of the significantly dysregulated 
microRNAs in the NOF group, 63 were seen to be downregulated and 42 
upregulated. 
PCA is a method of identifying patterns from large datasets. The key data is 
depicted by principle components and are used to demonstrate the variation 
within the samples of an experiment. Figure 3-13 displays the PCA plot of the OA 
vs NOF group and identifies a weak pattern of differential expression between 
the two groups. It is evident that within each group there is variation, with the 
NOF samples grouping less tightly and showing the greater degree of variation. 
3.4.4.1 Abnormal expression of known microRNAs related to bone fragility 
is observed in the NOF group 
The microRNA expression profiles observed in the NOF group show overlap with 
known fracture related and OP profiles. 
The miR-125 family is seen to be highly conserved in humans and be involved in 
multiple pathways (Sun, Lin and Chen, 2013). It has been extensively linked to 
OP and also highlighted as a potential biomarker of the disease (Kelch et al., 
2017). In keeping with this miR-125b-2-3p was seen to be significantly 
overexpressed in the NOF group. 
MiR-29a was also seen to be significantly upregulated in the NOF group, and has 
been shown to be pro-osteogenic, and linked to low bone mass states, (Ko et al., 
2015; Materozzi et al., 2018). Within this experimental context it appears to be 
upregulated to stimulate osteoblastogenesis, rather than supressed as seen in OP 
linked states such as glucocorticoid therapy. Furthermore, miR-20a was 
significantly downregulated in the NOF group, with its known action of 
increasing osteoblast markers and regulators such as bone morphogenic protein-2 
(BMP2), Runt-related transcription factor 2 (RUNX2), osterix (OSX), osteocalcin 
(OCN) and osteopontin (OPN) (Zhang et al., 2011; Sun et al., 2016). 
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Conversely miR-21 was significantly down-regulated in the NOF group. Previous 
research has shown elevated expression post fracture, but it is also known as a 
marker of OP (Nugent, 2017). MiR-21 has been shown to be down-regulated in 
both serum and bone samples of patients with OP and is observed to play an 
important role in osteoblast differentiation from MSCs (Zhao et al., 2018). 
Unexpectedly, miR-99a-5p and miR-100-5p were seen to be significantly 
upregulated within the NOF group. They have been documented in the literature 
previously to be significantly down-regulated in OP, and have been shown to be 
regulators of osteoclast activity (Mandourah et al., 2018; Zhou et al., 2019). The 
observed up-regulation in this experiment is in keeping with an expectant 
picture post fracture. 
MiR-31 has been observed to have significance in the development of OP and 
potentially as a biomarker, (Materozzi et al., 2018). It has been noted to be 
upregulated in the serum of female and male patients with OP in comparison to 
controls, as seen in this study. MiR-31 has been shown to have a pro-osteoclastic 
effect, by targeting RhoA (Mizoguchi et al., 2013). Furthermore, inhibiting or 
antagonising miR-31 activity has been shown to be osteogenic (Weilner et al., 
2016). 
MiR-143 is reported to be involved in several pathways which are of significance 
to OP. Firstly it was known as a positive regulator of adipogenesis, with 
increased expression shown in differentiating adipocytes, reported to act 
through ERK5 (Esau et al., 2004). More recently a Finnish study has shown miR-
143 to be down regulated in OP and has identified it as being key to a genetic 
form of the disease (Riikka Mäkitie et al., 2018). Additionally, MiR-143 is seen to 
suppress osteogenesis through several pathways. MiR-143 is seen to inhibit the 
nuclear factor kappa B (NF-kB) signalling pathway in dental pulp stem cells 
(Zhang et al., 2018). MiR-143 has also been identified as a negative regulator of 
OSX, with its up-regulation resulting in decreased osteogenesis (E. Li et al., 
2014). 
A comparison of the significantly dysregulated microRNA expression in the NOF 
group was made to the post fracture state. The literature was reviewed, with 
many studies published on microRNA expression post skeletal injury (Nugent, 
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2017). MiR-106a is known to inhibit osteoblast differentiation and promote 
adipogenesis. In keeping with the literature, it was observed to be down-
regulated in the NOF group (Inose et al., 2009; Li et al., 2013). MiR-133 has been 
shown to inhibit RUNX2, and thus osteogenic activity, it has been observed in 
several studies, and within this experiment to be down-regulated, supporting a 
pro-osteogenic state (Huang et al., 2010). 
MicroRNAs often observed to be dysregulated in osteosarcoma were notably 
dysregulated in both the over and under expressed in the NOF group. No patient 
had a known diagnosis of a bone tumour, and these profiles are suggestive of the 
pro-osteogenic state occurring post fracture. MicroRNAs such as miR-3200 have 
been shown to be overexpressed in osteosarcoma (Li et al., 2018).  
However, low expression of miR-598 is associated with invasiveness and 
progression of osteosarcoma (Liu et al., 2017), whereas an increased expression 
was observed in the NOF group. MiR-150 and miR-6868 were down regulated in 
this dataset and have been shown to be overexpressed in osteosarcomas (Lulla et 
al., 2011; Xie et al., 2017). In addition. miR-18a-5p was seen to be reduced in its 
expression, which similarly has been reported to be overexpressed in 
osteosarcoma (Lu et al., 2018). Therefore, it appears a pro-osteogenic but not 
malignant state is being produced post fracture, with regulation occurring 
through different miRNAs. 
The NOF group also contained dysregulation of microRNAs related to 
inflammation and injury, which corresponds well to the clinical situation in 
comparison to the OA group. The OA group had not suffered any trauma, so 
should not have had a pro-inflammatory response on culture of their MSCs. This 
is evident in the upregulation of miR-146a-3p, observed to be crucial to immune 
and inflammatory responses (Li, Chen and Li, 2010). Furthermore, miR-150 was 
significantly down-regulated in-keeping with a known inflammatory regulatory 
mechanism (Sang et al., 2016). 
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3.4.4.2 Comparison of microRNA expression profile in the NOF group to 
previous OP research reveals a varied picture 
A review of the literature regarding fragility fractures and the pathogenesis of 
OP was performed. The miRNAs previously noted to be of importance were cross-
referenced with the expression data in the NOF and OA group. This is displayed 
in Table 3-4. 
Table 3-4 Table showing previsously identified abnormally regulated microRNAs related to 
OP and their action and the observed expression level in the NOF group within this study. 
LTFx- low trauma fracture, Fx- fracture, Ý- denotes increased expression, ß decreased 
expression and NS= not statistically significant. 
microRNA Source Experimental 
setting 
Effect Action This 
study 
Let-7g-5p Weilner 
(2015) 
LTFx vs 
control ß 
Promotes 
osteogenic 
differentiation 
ß NS 
miR-100-
5p 
Seeliger 
(2014) 
OP Fx vs non-
OP Fx Ý 
Inhibits 
osteogenic 
differentiation 
Ý * 
(1.0) 
miR-10b-
5p 
Weilner 
(2015) 
LTFx vs 
control 
Ý 
Up-regulated 
during 
osteogenic 
differentiation 
Ý NS 
miR-122a Seeliger
(2014) 
OP Fx vs non-
OP Fx 
Ý 
Mechanism 
unknown 
Ý NS 
miR-124a Seeliger
(2014) 
OP Fx vs non-
OP Fx 
Ý 
Inhibits 
Osteoclast 
differentiation 
via NFATc1 
ß NS 
miR-125b Seeliger
(2014) 
OP Fx vs non-
OP Fx Ý 
Inhibits 
osteogenic 
differentiation 
ÝNS 
miR-133b Li 
(2014), 
Weilner 
(2015), 
LTFx vs 
control/Low 
BMD vs normal 
BMD 
ß/Ý 
Inhibits 
osteogenic 
differentiation 
via RUNX2 
Ý NS 
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miR-328-
3p 
Weilner 
(2015) 
LTFx vs 
control ß 
Represses Wnt 
inhibitor SFRP-
1 
Ý NS 
miR-148a-
3p 
Seeliger
(2014) 
OP Fx vs non-
OP Fx 
Ý 
Promotes 
osteoclast 
differentiation 
via MAFB 
ß NS 
miR-21-5p Li 
(2014), 
Seeliger
(2014), 
Weilner, 
(2015) 
 OP Fx vs non-
OP Fx, Low 
BMD vs normal 
BMD, LTFx vs 
control 
Ý/ß 
Promotes 
osteogenic and 
impairs 
adipogenic 
differentiation 
ß NS 
miR-22-3p Weilner 
(2015) 
LTFx vs 
control 
ß 
Up-regulated 
during 
osteogenic 
differentiation. 
Targets Wnt 1, 
Tcf7, Ep300. 
ß NS 
miR-23a-
3p 
Seeliger
(2014) 
OP Fx vs non-
OP Fx 
Ý 
Inhibits 
osteogenic 
differentiation 
via SATB2 
Ý NS 
miR-24-3p Seeliger
(2014) 
OP Fx vs non-
OP Fx 
Ý 
Inhibits 
osteogenic 
differentiation 
via SATB2 
Ý NS 
miR-93-5p Seeliger
(2014) 
OP Fx vs non-
OP Fx Ý 
Attenuates 
osteoblast 
mineralization 
ß NS 
 
Within the literature differing, and often, opposing profiles are observed. There 
are several factors which could attribute to this. Whilst all the studies aimed to 
research miRNA expression in patients with OP, the patients used from the 
samples often differed. For example, some studies had patients in the OP group 
diagnosed with a DXA scan (H. Li et al., 2014; Seeliger et al., 2014), whereas 
others had a clinical diagnosis with a low energy NOF (Weilner et al., 2015). The 
tissue source used may also be of interest, as some studies assessed serum 
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samples (H. Li et al., 2014), and Weilner et al utilising adipose tissue as a source 
of MSCs. These differences in patient samples and tissue source may account for 
the varied expression profiles observed, which would be in-keeping with this 
study using of patients without a formal diagnosis of OP. 
Identifying miRNAs consistently dysregulated in both local, disease relevant 
tissue and serum samples is of importance to identify a diagnostic or biomarker 
miRNA, which could be of great clinical benefit. Providing a rapid, non-ionising 
diagnosis of OP would allow quicker initiation of therapy and an improved use of 
health care resources. 
3.4.4.3 Dysregulated microRNA networks 
The analysis software used for miRNA expression data predicted several 
networks to be dysregulated in the NOF group, Figure 3-14, Figure 3-15, Figure 
3-16 and Figure 3-17. These pathways were often reported to be linked to 
organismal injury, in keeping with these patient samples coming from patients 
who had suffered a fall and fracture. 
Figure 3-14 shows a dysregulated network centred upon Argonaute2 (AGO2). 
AGO2 is part of the argonaute family of proteins, which are essential 
components of miRNA and small interfering RNA mediated post transcriptional 
gene-silencing pathways. AGO2 is known to be crucial to the RNA-induced 
silencing complex (RISC) that endonucleolytically cleaves mRNA of 
complementary sequence (Martinez and Gregory, 2013). Multiple miRNAs are 
implicated in this network suggestive of the widespread differences in microRNA 
expression in the two groups. 
Molecules intrinsic to bone physiology were also implicated, with reduced miR-
143 and miR-145-5p having an indirect effect on Transgelin (TAGLN). TAGLN has 
been identified as being upregulated during osteoblastic and adipocytic 
differentiation of MSCs in vitro, and deficiency is also noted to lead to reduced 
cell motility (Elsafadi et al., 2016). This is in keeping with the NOF group having 
poorer differentiation potential.  
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Furthermore, Figure 3-15 also shows the dysregulation of key osteogenic 
molecules in the NOF group. Wnt 2, Wnt 3A and bone morphogenic protein were 
all implicated within this network (Liu et al., 2013). 
Network 3, Figure 3-16, was implicated in the NOF group showing abnormalities 
in cell death and survival and cell cycle regulation. The upregulation of MiR-31-
5p was predicted to indirectly effect CXCL5, and IL1B, which are known to be 
important pro-inflammatory chemokine and cytokines (Lange et al., 2010; 
Sepuru, Poluri and Rajarathnam, 2014). This network was centred around BCL2L1 
which acts as an apoptotic regulator by controlling outer mitochondrial 
membrane channels (VDAC). VDAC controls the production of reactive oxygen 
species and cytochrome C which induce apoptosis. BCL2 in bone has been 
observed to play an important role in bone strength, and its reduction has been 
observed to be related to glucocorticoid-induced bone loss (Pantschenko et al., 
2005). Furthermore, BCL2L1 was shown to be important in osteoblast 
differentiation and proliferation, with its overexpression leading to reduced 
osteoblast apoptosis (Moriishi et al., 2016). 
Figure 3-17 depicts network 4, which was predicted to have dysregulation of 
pathways related to cellular growth and organismal injury. Interestingly NOTCH 
1 and NOTCH2 were identified, which are known regulators of osteoblast 
differentiation (Hilton et al., 2008; Regan and Long, 2013). 
The miRNA expression data identified dysregulation of key bone related miRNAs. 
There was correlation to miRNA profiles of previous OP and of post fracture 
studies, showing that this group was not specific to either. However, this 
provides key information for patients at risk of developing OP. 
From the above miRNA expression data miR-31 and miR-143 were identified for 
further investigation into their roles in MSC differentiation and osteogenesis. 
3.4.4.4 MicroCT data 
The microCT analysis produced somewhat unexpected results upon comparisons 
of the two groups. The highest BV/TV and trabecular thickness values were 
observed in the NOF group, in patients at risk of, or suffering from OP. OP is 
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known as a quantitative bone condition, and it was hypothesised that the 
microCT data would demonstrate thinner, less dense trabecular bone within the 
femoral heads.  
A similar, but not exact, trend of BV/TV was observed in the VOIs of both 
patient groups. VOI 1 corresponded to the area of greatest BV/TV in both patient 
groups. Corresponding to the centre of the femoral head, this result is in keeping 
with the expected higher areas of density.  
VOI 4 was observed to have the lowest BV/TV in the OA group, corresponding to 
the most lateral area of the femoral head, at a transition point to the femoral 
neck. This was statistically significant in the OA group when comparing VOI 1 and 
VOI 4. When further analysing the groups, the more heterogeneous nature of the 
NOF group becomes apparent, Figure 3-20. A greater range of BV/TV is observed 
in the VOIs, with notable inter-patient variability. Large discrepancies are 
observed from the VOI with the highest BV/TV value to the VOI with the lowest. 
This is in contrast to the OA group, Figure 3-19, with a reduced range of BV/TV 
values within the VOIs in each sample.  
In keeping with the BV/TV data the greatest trabecular thickness values were 
observed in the NOF group, again associated with large inter-sample variability 
in the NOF group. Neither group demonstrated significant variation in trabecular 
thickness throughout the femoral head. 
Figure 3-22 demonstrates the trabecular separation observed within each VOI of 
the femoral head samples. The OA group was seen to have significant variation 
in distance between trabeculae, between VOI 1 and 4. A similar trend was 
observed in the NOF group. However, this did not reach statistical significance. 
As expected, the trabeculae were most widely spread in VOI 4, which 
corresponds to the most lateral portion of the femoral head. It is at this area 
where the femoral head blends with the femoral neck. 
In both groups VOI 1 was seen to have the most closely associated trabeculae, in 
keeping with a dense area of bone. VOI 1 corresponds to the most central 
portion of the femoral head, and this data correlates well to macroscopic 
observations of the specimens. VOI 6 represents the upper central portion of 
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bone analysed in the femoral heads which is thought to represent a low-density 
region within the femoral head. Within the NOF group VOI 6 demonstrated 
greater trabecular separation in keeping with previous research (Jenkins et al., 
2013). This is of importance for surgical procedures, where metalwork is 
inserted to the femoral head, and areas of strong bone are sought to prevent 
failure of the implant (Baumgaertner et al., 1995; Parmar et al., 2005). 
Figure 3-23 demonstrates the trabecular number observed in VOIs in both 
groups. In keeping with the separation analysis, VOI 1 contained the greatest 
number of trabeculae in both groups. In the OA group a statistically significant 
increase in trabecular number was observed when comparing VOI1 to VOI 4. The 
overall trend was similar in the two groups, however in the NOF group the 
lowest trabecular number was observed in VOI 2, and no significant variation was 
observed. The OA group demonstrated variation in trabecular number 
throughout the femoral head, whereas a more consistent level was observed in 
the NOF group, with the exception of VOI 1. 
Variation in degree of anisotropy was seen throughout the femoral heads in both 
groups, Figure 3-25. This reached statistical significance in the OA group only. 
VOI 2 contained the lowest DA in the OA group, suggestive of containing the 
most plate like-trabeculae. Interestingly the lowest DA value in the NOF group 
was observed in VOI 4, the most lateral area assessed. Similar trends were 
observed in both groups, with a greater variability evident in the NOF group. 
This is in keeping with previous research into variation of DA in femoral heads of 
patients with OP (Jenkins et al., 2013). 
Structural model index (SMI) and connectivity density values failed to reach 
statistically significant variation throughout the VOIs. SMI values followed a 
similar pattern in the femoral head in both groups, with the OA group 
demonstrating predominantly higher values. VOI 1 in both groups showed the 
lowest value, indicative of dense, plate like orientation of bone in this region. 
Connectivity density values were lower in the NOF group, again with great inter-
sample variability, which is in keeping with previous findings (Zupan et al., 
2013). This is suggestive of improved inter-connections between trabeculae in 
the OA group throughout the femoral heads, with the exception of VOI 4. 
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These results demonstrate a variability in micro-architectural characteristics 
throughout the adult femoral head. Despite the presence of disease, the OA 
group demonstrated more consistent results throughout the patient samples and 
demonstrated the only statistically significant results. It is interesting to note 
that when analysing trabecular characteristics in the NOF group a more uniform 
picture is observed across the VOIs. It was hypothesised that a variation in 
trabecular characteristics would be seen throughout the femoral head, as per 
Wolff’s law (Wolff and Wolff, 1986), due to bone deposition being relative to the 
stress produced within that VOI. However, in the NOF group this was not 
observed. Osteoporosis is known to produce thinner and defective trabeculae 
and this data may suggest that patients at risk of the disease have globally 
impaired trabeculae within the femoral head. 
A limitation of the microCT data was the restriction of the analyses to only 
trabecular bone within the femoral head. It is known that significant cortical 
thinning is present in patients with proximal femoral fractures (Bell et al., 
1999). This may be more responsible for the propensity to hip fractures which 
patients with OP suffer than changes in trabecular size and number. 
Unfortunately, samples within the NOF group only included the femoral head, 
and therefore analyses on the cortices of the femoral neck could not be 
performed.  
The microCT data was not as hypothesised, with the NOF group having similar 
mean levels of micro-architectural indices, indicative of strength and density. 
However, these patients are at high risk of developing OP and by definition have 
already suffered a fragility fracture. This NOF group is still representative of this 
patient population, who after suffering such an injury are known to be at high 
risk of, or have undiagnosed, OP. Furthermore, the miRNA expression profiles of 
the NOF group, again, are associated with OP profiles observed in the literature, 
providing more evidence that this group is representative and relevant to 
patients at risk of OP. 
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Conclusion 
A thorough assessment of the bone biology of both groups has been undertaken 
in this chapter. Flow cytometric analysis revealed the consistent MSC expression 
and lack of HSC expression in both patient groups. Furthermore, a reduction in 
expression of key MSC markers linked to cell mobility and differentiation was 
observed in the NOF group. In keeping with the flow data, the propensity of 
MSCs from the NOF group to differentiate in conditioned media was significantly 
reduced. These experiments highlight an impaired functionality of MSCs from 
patients at risk of OP. 
The dysfunction of MSCs in the NOF group was further highlighted by multiple 
abnormally expressed miRNAs which have key roles in differentiation and 
osteogenesis. MicroCT analysis of the NOF group revealed large variations in 
bone indices within the group, in comparison to a more uniform picture within 
the OA group. 
These results provide insight to the impaired bone health of patients at risk of 
OP and will help direct future research into therapeutic targets. 
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Chapter 4 
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4 An assessment of mesenchymal stromal cell 
differentiation following microRNA manipulation 
4.1 Introduction 
Increasingly miRNAs are being investigated for their therapeutic potential in 
many diseases (Hanna, Hossain and Kocerha, 2019). Clinical trials are underway 
for their use in many pathological conditions within several different organ sites, 
such as miR-16 for mesothelioma, miR-92 for heart failure and miR-29a in tendon 
injury (van Zandwijk et al., 2017; Watts et al., 2017; Bonneau et al., 2019). 
There is great hope that they can be utilised in diseases such as OP. 
In this chapter, the effect the miRNA mimic 143 has on adipogenesis with MSCs 
from two patient groups, OA and NOF, group will be assessed. AntagomiR-31 will 
be cultured with MSCs to assess if it can increase osteogenesis in both patient 
groups, and be a potential target for improving bone quality in patients at risk of 
fragility fractures. 
MicroRNA-31 has been shown previously to significantly influence osteogenesis, 
and when impaired, can result in improved mineralisation (Weilner et al., 2016). 
Furthermore, it is known to be upregulated in patients with OP (Materozzi et al., 
2018). Manipulating the function of MiR-31 has a potentially important role in 
developing new therapeutics for the treatment of impaired bone quality. 
Previously published in the literature, and evident here in the miRNA array, MiR-
143 is dysregulated in patients with OP and recent fragility fractures (Mäkitie et 
al., 2018). Its role has previously been linked with adipogenesis (Esau et al., 
2004), more recently a negative regulatory role of osteogenesis has been 
described (E. Li et al., 2014). As such it is of importance to understand more 
about its role in MSC function and bone fragility. 
Differentiating cells have been shown to have heightened metabolic activity, 
while quiescent stem cells have relatively inactive metabolism (Chung et al., 
2007; Yanes et al., 2010). The increase in metabolism has been previously 
reported to occur rapidly (Reyes et al., 2006) and metabolomic studies are being 
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increasingly utilised in bioengineering research to gain greater insight into the 
effect on MSCs. Several key areas of metabolism are commonly assessed to 
determine a manipulation of differentiation (Tsimbouri et al., 2012). Amino acid 
metabolism, with the presence of an increased abundance of amino acids 
correlated to differentiation (Sampath et al., 2008), carbohydrate metabolism 
and respiration shown to be enhanced during MSC differentiation (Varum et al., 
2011) and lipid metabolism, with specific lipids observed to be depleted during 
osteogenesis (Alakpa et al., 2016), are key metabolic pathways to be 
interrogated to understand differentiation induced by miRNA manipulation. 
Due to the cost implications of performing metabolomic analysis only miR-31 will 
be investigated by this technique. 
4.2 Objectives 
This chapter has three main objectives 
1. To manipulate adipogenesis via a miR-143 mimic and to determine the 
effect on differentiation at a gene and protein level 
2. To manipulate osteogenesis via a miR-31 inhibitor and to determine 
the effect on differentiation at a gene and protein level 
3. To identify the mechanism of miRNA manipulation on osteogenic 
differentiation at a metabolite level 
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4.3 Materials and Methods 
4.3.1  Cell Culture 
In this chapter bone marrow extraction was performed from the OA and NOF 
groups, and culture of MSCs in monolayer was as described in section 2.4.1. The 
cells were seeded from growing flasks at a concentration of 2000 cells per cm2 
and after allowing 24 hours of attachment the media was exchanged for the 
conditions described in Table 2-3. After 48 hours of incubation the media were 
exchanged and for the remaining time in culture did not include nanoparticles. 
Cells were cultured for 7 days. 
 
4.3.2 Nanoparticles 
MicroRNA-143 mimic and AntagomiR-31 (AmiR-31) were delivered on gold 
thiolated nanoparticles. Non-targeting nanoparticles were also utilised. See 
section 2.5.2 for further information. 
4.3.3  Differentiation Media 
In addition to basal media, differentiation media, to stimulate differentiation, 
was used to act as a positive control in both experiments, Section 2.4.3 
describes their constituents. 
4.3.4   Quantitative real-time (qRT)-PCR 
qRT-PCR was utilised to quantitatively assess gene expression at day 7 with 
regards to osteogenesis and adipogenesis in the AmiR-31 and miR-143 mimic 
cultures respectively. Full details of the qRT-PCR process is described in sections 
2.12 - 2.14. 
4.3.5  In Cell WesternTM (ICW) 
Described in full in section 2.11, immunostaining and analysis by ICW was 
performed at day 7. Samples were scanned with detection in the 800 nm channel 
for the protein of interest, and in the 700 nm channel for the detection of 
CellTag fluorescence, which was indicative of observed cell number. 
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Fluorescence units in the 800 nm channel were divided by the 700 nm channel to 
determine levels of expression within each culture condition.  
4.3.6 Metabolomic analysis 
An IDEOM excel interface file was generated by the University of Glasgow 
Polyomics facility. Metabolites were identified from this IDEOM file in 
conjunction with the Kyoto Encyclopaedia of Genes and Genomes (KEGG) 
database (Kanehisa et al., 2012). Data relating to specific metabolism areas, 
such as amino acid, carbohydrate and lipid, were exported from the IDEOM 
interface and further analysed using Metaboanalyst. Metaboanalyst was utilised 
to generate principal component analysis plots (PCA) and heatmaps (Xia et al., 
2015). 
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4.4 Results 
4.4.1 MicroRNA-143 mimic culture 
4.4.1.1 qRT-PCR analysis 
MiR-143 mimic was cultured with MSCs from both patient groups, in basal and 
adipogenic media. At Day 7 the effect on PPARg expression was analysed by qRT-
PCR. This is displayed in Figure 4-1, and demonstrates the positive effect of the 
adipogenic induction media. In both patient groups an increase in PPARg 
expression was evident with the positive control culture medium; however no 
statistically significant increase was observed in any condition. In the basal 
conditions, no appreciable difference in PPARg expression was observed. 
A 
 
B 
 
Figure 4-1 qRT-PCR analysis of PPARg at day 7 culture of OA and NOF MSCs in miR-143 
experimentation. Ratio of expression in comparison to reference gene GAPDH. The addition 
of adipogenic media resulted in increase in PPARg expression in both patient groups, 
without responding to one condition specifically. A = OA group, B = NOF group. Basal no 
part = basal media; Basal non T = basal media and non targeting nanoparticles; Basal miR-
143 = basal media and miR-143 mimic nanoparticles; Adipo no part = adipogenic induction 
media; Adipo non T = adipogenic induction media and non targeting nanoparticles; Adipo 
miR-143 = adipogenic induction media and miR-143 mimic nanoparticles. Each culture 
condition represents 3 patients with 2 technical replicates. Results are mean with standard 
deviation. No statistical significance reached upon Kruskal-Wallis analysis. 
 
FABP was also assessed at day 7, and displayed in Figure 4-2. No statistically 
significant difference in FABP expression was noted in any condition in both 
patient groups. Intra-group variation within each condition was notable in both 
patient groups.  
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A 
 
B 
 
Figure 4-2 qRT-PCR analysis of FABP at day 7 culture of OA and NOF MSCs in miR-143 
experimentation. Ratio of expression in comparison to reference gene GAPDH. No clear 
increase in FABP expression was noted upon additon of miR-143 mimic or adipogenic 
media in either patient group. A = OA group, B = NOF group. Basal no part = basal media; 
Basal non T = basal media and non targeting nanoparticles; Basal miR-143 = basal media 
and miR-143 mimic nanoparticles; Adipo no part = adipogenic induction media; Adipo non T 
= adipogenic induction media and non targeting nanoparticles; Adipo miR-143 = adipogenic 
induction media and miR-143 mimic nanoparticles. Each culture condition represents 3 
patients with 2 technical replicates. Results are mean with standard deviation. No statistical 
significance reached upon Kruskal-Wallis analysis. 
 
4.4.1.2 In Cell WesternTM analysis miR-143  
In Cell Western analysis was used to determine the protein expression of PPARg 
at day 7, Figure 4-3. The OA group demonstrated a positive adipogenic response 
to the induction media, with the highest expression observed in the Adipo-miR-
143 group. No appreciable trend of increased PPARg expression in the NOF group 
was noted. 
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A 
 
B 
 
Figure 4-3 In Cell WesternTM analysis of PPARg protein expression of OA and NOF MSCs in 
miR-143 experimentation. Within the OA group the addition of adipogenic media resulted in 
increased expression of PPARg most notably with the addition of miR-143 mimic. No 
appreciable trend of increased expression was noted in the NOF group. A = OA group, B = 
NOF group. Basal no part = basal media; Basal non T = basal media and non targeting 
nanoparticles; Basal miR-143 = basal media and miR-143 mimic nanoparticles; Adipo no 
part = adipogenic induction media; Adipo non T = adipogenic induction media and non 
targeting nanoparticles; Adipo miR-143 = adipogenic induction media and miR-143 mimic 
nanoparticles. Each culture condition represents 3 patients with 4 technical replicates. 
Results are mean with standard error of mean. Statistical analysis by Kruskal-Wallis, * P = £ 
0.05, ** P = £ 0.01.  
 
4.4.2 AntagomiR-31 culture 
4.4.2.1 qRT-PCR analysis 
AmiR-31 was cultured with MSCs from both patient groups, in basal and 
osteogenic media. At day 7, the effect on osteogenic differentiation was 
assessed by analysing Osterix and RUNX2 expression by qRT-PCR. This is 
displayed in Figure 4-4 and Figure 4-5. 
At day 7 of culture no statistically significant increase in either gene were 
observed in either group or condition. RUNX2 expression in the NOF group 
demonstrated a trend of increased expression in the osteogenic media 
conditions.  
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B 
 
Figure 4-4 qRT-PCR analysis of Osterix at day 7 culture of OA and NOF MSCs in AntagomiR-
31 experimentation. Ratio of expression in comparison to reference gene GAPDH. Minimal 
increase in Osterix expression was observed in the OA group within the osteogenic media 
conditions, with the NOF group showing no consistent tend. A= OA group, B = NOF group. 
Basal no part = basal media; Basal non T = basal media and non targeting nanoparticles; 
Basal AmiR-31 = basal media and AmiR-31 nanoparticles; Osteogenic no part = osteogenic 
induction media; Osteogenic non T = osteogenic induction media and non targeting 
nanoparticles; Osteogenic AmiR-31 = osteogenic induction media and AmiR-31 
nanoparticles. Each culture condition represents 3 patients with 2 technical replicates. 
Results are mean with standard deviation. No statistical significance reached upon Kruskal-
Wallis analysis. 
 
A 
 
B 
 
Figure 4-5 qRT-PCR analysis of RUNX2 expression at day 7 culture of OA and NOF MSCs in 
AntagomiR-31 experimentation. Ratio of expression in comparison to reference gene 
GAPDH. A trend to increased RUNX2 expression was observed in the NOF group. No 
change was evident in the OA group. A = OA group, B = NOF group. Basal no part = basal 
media; Basal non T = basal media and non targeting nanoparticles; Basal AmiR-31 = basal 
media and AmiR-31 nanoparticles; Osteogenic no part = osteogenic induction media; 
Osteogenic non T = osteogenic induction media and non targeting nanoparticles; 
Osteogenic AmiR-31 = osteogenic induction media and AmiR-31 nanoparticles. Each culture 
condition represents 3 patients with 2 technical replicates. Results are mean with standard 
deviation. No statistical significance reached upon Kruskal-Wallis analysis. 
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4.4.2.2 In Cell WesternTM analysis AntagomiR-31 
Figure 4-6 demonstrates the day 7 Osterix protein expression levels. A trend of 
increased osteogenic activity was observed in the OA group within the AmiR-31 
conditions, reaching statistical significance in the Osteo + AmiR-31 condition in 
comparison to basal media alone. A similar trend is visible in the NOF group, but 
did not reach statistical significance. 
A 
 
B 
 
Figure 4-6 In Cell WesternTM analysis of Osterix protein expression of OA and NOF MSCs in 
AntagomiR-31 experimentation. The addition of AmiR-31 to basal media resulted in 
increased Osterix expression, with an increased effect evident in the osteogenic media with 
AmiR-31. This was notable in both patient groups, but statistically significant only in the OA 
group. A = OA group, B = NOF group. Basal no part = basal media; Basal non T = basal 
media and non targeting nanoparticles; Basal AmiR-31 = basal media and AmiR-31 
nanoparticles; Osteo media = osteogenic media; Osteo non targeting = osteogenic media 
and non targeting nanoparticles; Osteo + AmiR-31 = osteogenic media and AmiR-31 
nanoparticles. Each culture condition represents 3 patients with 4 technical replicates. 
Results are mean with standard error of mean. Statistical analysis by Kruskal-Wallis, ** P = £ 
0.01. 
 
4.4.2.3 Metabolomics 
The metabolomic effect on MSCs was assessed at Day 7 in the AmiR-31 culture 
experiment. All 6 culture conditions were assessed in 3 patients from the OA and 
NOF group. 
Heatmaps are utilised in the following figures to allow easy recognition of fold 
changes in the abundance of metabolites present in each culture condition. The 
metabolites are ranked from hot (shown as dark red colours, indicating increased 
Ba
sa
l M
ed
ia
Ba
sa
l +
 no
n t
arg
eti
ng
Ba
sa
l +
 Am
iR 
31
Os
teo
 M
ed
ia
Os
teo
 + 
no
n t
arg
eti
ng
Os
teo
 + 
Am
iR 
31
0.0
0.2
0.4
0.6
0.8
1.0
Condition
Re
lat
ive
 le
ve
l o
f e
xp
re
ss
ion
 of
 O
SX **
Ba
sa
l M
ed
ia
Ba
sa
l +
 no
n t
arg
eti
ng
Ba
sa
l +
 Am
iR 
31
Os
teo
 M
ed
ia
Os
teo
 + 
no
n t
arg
eti
ng
Os
teo
 + 
Am
iR 
31
0.0
0.5
1.0
1.5
Condition
Re
lat
ive
 le
ve
l o
f e
xp
re
ss
ion
 of
 O
SX
 
 
113 
abundance) to cold (shown as dark blue colours, indicating decreased 
abundance). 
Principal component analysis (PCA) plots are also utilised in the following 
figures, which use scatter plots to demonstrate variance within data sets. 
Finally, networks demonstrating the potential effect of the change in 
metabolites observed in the treatment conditions were generated through the 
use of IPA software. 
4.4.2.4 Amino acid metabolism 
The heat map in Figure 4-7 demonstrates the variation in amount of amino acid 
metabolites present in the specific culture conditions. Most notably a high 
abundance of amino acid metabolites were present in the AmiR-31 culture 
condition with the addition of osteogenic media. This was present both in the OA 
and NOF group, with 2 patients in each group showing a strong response. 
Low levels, indicated by blue colouring in the heatmap, indicative of a more 
quiescent culture environment, were observed more frequently when the AmiR-
31 nanoparticles and osteogenic media were not present. 
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OA Group
 
Figure 4-7 Amino Acid metabolite profile of OA MSCs at day 7 of culture in AntagomiR-31 
experimentation. The heatmap demonstrates the greatest increase in abundance of amino 
acid metabolites in the osteogenic AmiR-31 culture condition. Decreased abundance was 
commonly seen in the basal culture conditions. B No Part = basal media; B Non T = basal 
media and Non-targeting nanoparticles; B AmiR31 = basal media and AntagomiR-31 
nanoparticles; O No Part = Osteogenic media; O Non T = Osteogenic media and Non-
targeting nanoparticles; O AmiR31 = osteogenic media and AntagomiR-31 nanoparticles. 3 
patient samples per group with 1 technical replicate per condition. Red colours are 
indicative of fold increases in metabolite abundance, and blue colours of fold decreases. 
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NOF Group
 
Figure 4-8 Amino Acid metabolite profile of NOF MSCs at day 7 of culture in AntagomiR-31 
experimentation. The heatmap demonstrates the greatest increase in abundance of amino 
acid metabolites in the osteogenic AmiR-31 culture condition in all 3 patients. B No Part = 
basal media; B Non T = basal media and Non-targeting nanoparticles; B AmiR31 = basal 
media and AntagomiR-31 nanoparticles; O No Part = Osteogenic media; O Non T = 
Osteogenic media and Non-targeting nanoparticles; O AmiR31 = osteogenic media and 
AntagomiR-31 nanoparticles. 3 patient samples per group with 1 technical replicate per 
condition. Red colours are indicative of fold increases in metabolite abundance, and blue 
colours of fold decreases. 
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Figure 4-9 displays the PCA plot of amino acid metabolism and displays overlap 
between the conditions, evident in both patient groups. However, in both groups 
the osteogenic AmiR-31 group is seen to differ most in comparison to the other 
culture conditions, suggestive of a drive towards osteogenesis. The remaining 
conditions clustered closely in the NOF group. 
 
Figure 4-9 PCA plot of amino acid metabolites detected at day 7 of MSC culture in the OA 
group AntagomiR-31 experimentation. Within the OA group variation between basal and 
osteogenic conditions was noted with the Osteogenic media and AmiR-31 condition 
showing large differences. Data sets were derived from putative amino acid metabolites 
identified within the different culture conditions at day 7 of culture. B No Part = basal media; 
B Non T = basal media and Non-targeting nanoparticles; B AmiR31 = basal media and 
AntagomiR-31 nanoparticles; O No Part = Osteogenic media; O Non T = Osteogenic media 
and Non-targeting nanoparticles; O AmiR31 = osteogenic media and AntagomiR-31 
nanoparticle. Points represent individual samples of each condition. 3 patient samples per 
group with 1 technical replicate per condition. The coloured ellipses represent the spatial 
borders associated with each condition, to a 95% confidence interval. 
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Figure 4-10 PCA plot of amino acid metabolites detected at day 7 of MSC culture in the NOF 
group AntagomiR-31 experimentation. Within the NOF group the Osteogenic media and 
AmiR-31 condition lead to the greatest variation, with clustering of the remaining conditions 
observed. Data sets were derived from putative amino acid metabolites identified within the 
different culture conditions at day 7 of culture. B No Part = basal media; B Non T = basal 
media and Non-targeting nanoparticles; B AmiR31 = basal media and AntagomiR-31 
nanoparticles; O No Part = Osteogenic media; O Non T = Osteogenic media and Non-
targeting nanoparticles; O AmiR31 = osteogenic media and AntagomiR-31 nanoparticles. 
Points represent individual samples of each condition. 3 patient samples per group with 1 
technical replicate per condition. The coloured ellipses represent the spatial borders 
associated with each condition, to a 95% confidence interval. 
 
4.4.2.5 Carbohydrate metabolism 
Carbohydrate metabolism was observed to differ greatly in the OA group. This is 
striking in the PCA plot, Figure 4-11. The greatest decrease in both PC1 and PC2 
was noted in the OA Osteogenic AmiR31 condition. No overlap is observed in the 
basal and osteogenic media PCA in the OA group. The NOF group showed closer 
groupings on PCA analysis, with the largest divergence between the NOF Basal 
AmiR31 and Osteogenic AmiR31. 
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Figure 4-11 PCA plot of carbohydrate metabolites detected at day 7 of MSC culture in the 
OA group AntagomiR-31 experimentation. Large separation was observed in the osteogenic 
media conditions in the OA group. The osteogenic media and AmiR-31 condition differed 
most notably from the other conditions. Data sets were derived from putative carbohydrate 
metabolites identified within the different culture conditions at day 7 of culture. B No Part = 
basal media; B Non T = basal media and Non-targeting nanoparticles; B AmiR31 = basal 
media and AntagomiR-31 nanoparticles; O No Part = Osteogenic media; O Non T = 
Osteogenic media and Non-targeting nanoparticles; O AmiR31 = osteogenic media and 
AntagomiR-31 nanoparticles. Points represent individual samples of each condition. 3 
patient samples per group with 1 technical replicate per condition. The coloured ellipses 
represent the spatial borders associated with each condition, to a 95% confidence interval. 
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Figure 4-12 PCA plot of carbohydrate metabolites detected at day 7 of MSC culture in the 
NOF group AntagomiR-31 experimentation. A trend of separation is noted in the osteogenic 
media conditions in comparison to the basal. Data sets were derived from putative 
carbohydrate metabolites identified within the different culture conditions at day 7 of 
culture. B No Part = basal media; B Non T = basal media and Non-targeting nanoparticles; B 
AmiR31 = basal media and AntagomiR-31 nanoparticles; O No Part = Osteogenic media; O 
Non T = Osteogenic media and Non-targeting nanoparticles; O AmiR31 = osteogenic media 
and AntagomiR-31 nanoparticles. Points represent individual samples of each condition. 3 
patient samples per group with 1 technical replicate per condition. The coloured ellipses 
represent the spatial borders associated with each condition, to a 95% confidence interval. 
 
The above PCA findings are corroborated by the accompanying heatmap, shown 
in Figure 4-13. In both patient groups the greatest abundance of carbohydrate 
metabolites was observed in the osteogenic AmiR-31 condition. In the OA group 
a clear increase in carbohydrate metabolite presence was observed in all 
osteogenic conditions in comparison to basal media. These findings were also 
observed, but more subtly in the NOF group. 
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OA group
 
Figure 4-13 Carbohydrate metabolite profile of OA group MSCs at day 7 of culture in 
AntagomiR-31 experimentation. The heatmap demonstrates a trend to increased abundance 
of carbohydrate metabolites in the osteogenic conditions, the strongest observed in the 
osteogenic and AmiR-31 culture condition. B No Part = basal media; B Non T = basal media 
and Non-targeting nanoparticles; B AmiR31 = basal media and AntagomiR-31 nanoparticles; 
O No Part = Osteogenic media; O Non T = Osteogenic media and Non-targeting 
nanoparticles; O AmiR31 = osteogenic media and AntagomiR-31 nanoparticles. 3 patient 
samples per group with 1 technical replicate per condition. Red colours are indicative of 
fold increases in metabolite abundance, and blue colours of fold decreases. 
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NOF group 
 
Figure 4-14 Carbohydrate metabolite profile of NOF MSCs at day 7 of culture in AntagomiR-
31 experimentation. Increased abundance of carbohydrate metabolites in the osteogenic 
conditions is seen in all patients, with the strongest observed in the osteogenic and AmiR-
31 culture condition demonstrated in 2 of the patient samples. B No Part = basal media; B 
Non T = basal media and Non-targeting nanoparticles; B AmiR31 = basal media and 
AntagomiR-31 nanoparticles; O No Part = Osteogenic media; O Non T = Osteogenic media 
and Non-targeting nanoparticles; O AmiR31 = osteogenic media and AntagomiR-31 
nanoparticles. 3 patient samples per group with 1 technical replicate per condition. Red 
colours are indicative of fold increases in metabolite abundance, and blue colours of fold 
decreases. 
 
4.4.2.6 Lipid metabolism 
On assessing lipid metabolism, the culture conditions showed large overlap in all 
replicates in the OA and NOF group, Figure 4-15. The OA group showed more 
evidence of localising by media type, with some variation evident on comparing 
the basal to the osteogenic media. This was not present in the NOF group. 
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Figure 4-15 PCA plot of lipid metabolites detected at day 7 of MSC culture in the OA group 
AntagomiR-31 experimentation. Large overlap, with no clear clustering by condition was 
observed. Data sets were derived from putative lipid metabolites identified within the 
different culture conditions at day 7 of culture. B No Part = basal media; B Non T = basal 
media and Non-targeting nanoparticles; B AmiR31 = basal media and AntagomiR-31 
nanoparticles; O No Part = Osteogenic media; O Non T = Osteogenic media and Non-
targeting nanoparticles; O AmiR31 = osteogenic media and AntagomiR-31 nanoparticles. 
Points represent individual samples of each condition. 3 patient samples per group with 1 
technical replicate per condition. The coloured ellipses represent the spatial borders 
associated with each condition, to a 95% confidence interval. 
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Figure 4-16 PCA plot of lipid metabolites detected at day 7 of MSC culture in the NOF group 
AntagomiR-31 experimentation. No clustering by condition was noted. Data sets were 
derived from putative lipid metabolites identified within the different culture conditions at 
day 7 of culture. B No Part = basal media; B Non T = basal media and Non-targeting 
nanoparticles; B AmiR31 = basal media and AntagomiR-31 nanoparticles; O No Part = 
Osteogenic media; O Non T = Osteogenic media and Non-targeting nanoparticles; O AmiR31 
= osteogenic media and AntagomiR-31 nanoparticles. Points represent individual samples 
of each condition. 3 patient samples per group with 1 technical replicate per condition. The 
coloured ellipses represent the spatial borders associated with each condition, to a 95% 
confidence interval. 
 
In keeping with the PCA data, the heatmaps demonstrate a slight trend of 
increased abundance of lipid metabolites in the osteogenic AmiR31 culture 
condition, Figure 4-17. However, this was not uniformly seen across all 
replicates, and was most pronounced in the OA group. 
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OA Group
 
Figure 4-17 Lipid metabolite profile of OA MSCs at day 7 of culture in AntagomiR-31 
experimentation. Increased abundance of metabolites was observed across the culture 
conditions, with the greatest increase noted in the osteogenic conditions. B No Part = basal 
media; B Non T = basal media and Non-targeting nanoparticles; B AmiR31 = basal media 
and AntagomiR-31 nanoparticles; O No Part = Osteogenic media; O Non T = Osteogenic 
media and Non-targeting nanoparticles; O AmiR31 = osteogenic media and AntagomiR-31 
nanoparticles. 3 patient samples per group with 1 technical replicate per condition. Red 
colours are indicative of fold increases in metabolite abundance, and blue colours of fold 
decreases. 
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NOF Group 
 
Figure 4-18 Lipid metabolite profile of NOF MSCs at day 7 of culture in AntagomiR-31 
experimentation. Both basal and osteogenic media conditions resulted in an increased 
abundance of metabolites. B No Part = basal media; B Non T = basal media and Non-
targeting nanoparticles; B AmiR31 = basal media and AntagomiR-31 nanoparticles; O No 
Part = Osteogenic media; O Non T = Osteogenic media and Non-targeting nanoparticles; O 
AmiR31 = osteogenic media and AntagomiR-31 nanoparticles. 3 patient samples per group 
with 1 technical replicate per condition. Red colours are indicative of fold increases in 
metabolite abundance, and blue colours of fold decreases. 
 
4.4.2.7 Alteration in metabolic networks initiated by AntagomiR-31 
An assessment on the effect the AmiR-31 nanoparticle had on metabolic 
networks was undertaken via the IPA software. The basal no particle condition 
was utilised as a control, with the remaining culture conditions compared to it. 
IPA predicted alteration in many canonical pathways in both patient groups. 
Displayed in Figure 4-19 and Figure 4-20 are the top altered canonical pathways 
in conditions of basal media and AmiR-31, osteogenic media and AmiR-31 and 
osteogenic media with no particles. This consistently demonstrated the same 
canonical pathways as being the most altered. These canonical networks were 
transfer RNA charging, citrulline metabolism and arginine, citrulline and 
glutathione biosynthesis. Whilst the pathways were the same, differences 
occurred in the number of upregulated and downregulated molecules for each 
condition. Within the NOF group the Osteogenic media with AmiR-31 was 
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predicted to upregulate more molecules than the other two conditions. Within 
the OA group similar trends were predicted, however the basal media with 
AmiR-31 was predicted to have a greater number of downregulated molecules in 
comparison to the other conditions. 
NOF- Basal media and 
AmiR-31 
 
NOF- Osteogenic media 
and AmiR-31 
 
NOF- Osteogenic media 
no particles 
 
 
Figure 4-19 Predicted altered canonical pathways in the NOF group culture conditions in 
comparison to basal media. The osteogenic media with AmiR-31 is predicted to upregulate 
more molecules in each pathway with similar expression in the remaining two conditions. 
Top 7 pathways displayed with the number of molecules involved in each pathway noted 
above each bar. Green colour represents downregulation, red upregulation and clear no 
overlap within the dataset. 3 patient samples per group with 1 technical replicate per 
condition. 
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OA- Basal media and 
AmiR-31 
 
 
OA- Osteogenic media 
and AmiR-31 
 
OA- Osteogenic media 
no particles 
  
 
 
 
Figure 4-20 Predicted altered canonical pathways in the OA group in comparison to basal 
media. The osteogenic media with AmiR-31 is predicted to upregulate more molecules in 
each pathway in comparison to the other two conditions. The basal media and AmiR-31 
condition led to a greater number of downregulated molecules within the pathways than the 
other two conditions. Top 7 pathways displayed with the number of molecules involved in 
each pathway noted above each bar. Green colour represents downregulation, red 
upregulation, grey no change and clear no overlap within the dataset. 3 patient samples per 
group with 1 technical replicate per condition. 
 
Moving to network analysis, Figure 4-21 and Figure 4-22 display network 1, an 
IPA predicted network, centred upon extracellular signal-regulated kinases 1/2 
(ERK 1/2) and glutathione of the NOF and OA groups in conditions of osteogenic 
media and basal media with AmiR-31 in comparison to basal no particles as a 
control. The addition of osteogenic media led to similar levels of molecule 
expression in both groups, Figure 4-21 . 
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A
 
B
 
Figure 4-21 Metabolomic Network 1 at day 7 of culture in osteogenic media in comparison to 
basal media. The addition of osteogenic media leads to similar patterns of expression in 
both patient groups. A = OA group, B= NOF group. 3 patient samples per group with 1 
technical replicate. Red = increased expression, Green = decreased expression.  
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Strong upregulation of glutathione continued in the NOF group in the basal 
media and AmiR-31 condition. In contrast, the addition of AmiR-31 to the OA 
group lead to a decrease in glutathione expression, Figure 4-22. 
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A
 
B
 
Figure 4-22 Metabolomic pathway Network 1 at day 7 of culture in basal media and AmiR-31 
in comparison to basal media. Glutathione expression was decreased in the OA group and 
increased in the NOF group. A = OA group, B= NOF group. 3 patient samples per group with 
1 technical replicate. Red = increased expression, Green = decreased expression. 
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Network 2 was centred upon protein kinase B (AKT), protein phosphatase 2 
(PP2A) and AMP activated protein kinase Figure 4-23. Inverse expressions were 
again observed in the two patient groups upon addition of AmiR-31. 
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A
 
B
 
Figure 4-23 Metabolomic pathway Network 2 at day 7 of culture in basal media and AmiR-31 
in comparison to basal media. Large increases in expression of regulators of this network 
were observed in the NOF group only. A = OA group, B= NOF group. 3 patient samples per 
group with 1 technical replicate. Red = increased expression, Green = decreased 
expression. 
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Upon analysis of Network 2 in the osteogenic media only, weaker change in 
regulation of molecules is predicted in both groups, Figure 4-24, in comparison 
to the basal media and AmiR-31 condition, Figure 4-23. However, the NOF group 
continues to have more molecules upregulated in comparison to the OA group, 
as observed in the AmiR-31 condition. 
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B
 
Figure 4-24 Metabolomic pathway Network 2 at day 7 of culture in osteogenic media in 
comparison to basal media. A greater number of molecules are predicted to be upregulated 
in the NOF group, without evidence of strong up or downregulation. A = OA group, B= NOF 
group. 3 patient samples per group with 1 technical replicate. Red = increased expression, 
Green = decreased expression. 
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Network 4, Figure 4-25, centred upon adenosine triphosphate, and involving 
nuclear factor Kappa-light-chain-enhancer of activated B cells (NF kB), 
demonstrated variance between the two patient groups. Upon addition of AmiR-
31 in the NOF group a large increase in the expression of adenosine triphosphate 
is observed. Conversely, a reduced expression of adenosine triphosphate was 
noted in the OA group. 
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B
 
Figure 4-25 Metabolomic pathway Network 4 at day 7 of culture in basal media and AmiR-31 
in comparison to basal media. Large increases in expression of adenosine triphosphate 
were predicted in the NOF group only, with reduced expression in the OA group. A = OA 
group, B= NOF group. 3 patient samples per group with 1 technical replicate. Red = 
increased expression, Green = decreased expression. 
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4.5 Discussion 
4.5.1 MicroRNA manipulation influences differentiation 
The in vitro monolayer culture results presented above show miRNA 
manipulation lead to trends of affect in both adipogenic and osteogenic 
differentiation. Whilst the qRT-PCR results did not show the hypothesised 
effects, the ICW and metabolomic data suggested that the miRNA mimic and 
inhibitor cultures were leading to change within the MSCs. 
The miR-143 culture demonstrated that adipogenesis can be stimulated utilising 
the miR-143 nanoparticle mimic. This required the addition of adipogenic 
induction media, and was only evident on ICW protein analysis and within the OA 
group. This is in keeping with the impaired differentiation potential observed in 
this patient group in chapter 3. The NOF group was seen to be stimulated 
towards adipogenesis on qRT-PCR analysis, but not specifically increased by the 
addition of the miR-143 mimic. Several studies have demonstrated the 
adipogenic inductive nature of miR-143, interestingly Xie et al demonstrated in 
an in vivo experiment that although a potent driver of adipogenesis, in the obese 
state miR-143 expression is low (Esau et al., 2004; Xie, Lim and Lodish, 2009). 
MiR-143 was chosen due to its high level of dysregulation in the microRNA 
expression data and its observed role in inherited forms of OP (Mäkitie et al., 
2018). Furthermore, miR-143 has been more recently identified as an osterix 
expression regulator, and therefore osteogenesis. Li et al showed that the 
induction of osteogenesis in a mouse osteoblast cell line led to a reduced 
expression of miR-143, when cultured with a miR-143 mimic a significant 
decrease in alkaline phosphatase and osteocalcin expression was observed after 
2 days of culture (E. Li et al., 2014). 
MiR-143 is evidently an important regulator of MSC differentiation. It has been 
described to play critical roles in both adipogenesis and osteogenesis. However, 
its role in bone formation is yet to be fully understood. By upregulating the 
expression of miR-143 this experiment attempted to restore the differentiation 
potential of the NOF group with regards to adipogenesis. MiR-143 was evidently 
a stimulator of adipogenesis in the OA group, where the MSCs are theorised to be 
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of improved stemness, but the mimic nanoparticle failed to return the 
differentiation level to comparable levels in the NOF group in comparison to OA. 
Performing further experimentation into the effects miR-143 mimic has on bone 
formation in the NOF group would be of significant interest. 
Identifying methods to improve the activity of MSCs from patients at risk of OP is 
important. Improving the functionality of the MSCs would hopefully lead to an 
increase in bone quality and quantity. 
MiR-31 was chosen due to its known role in osteogenesis and its dysregulation in 
the NOF group in the miRNA expression data. Previous research has shown that 
miR-31 targets key markers of osteogenesis, such as osteopontin, osteocalcin 
and osterix, furthermore reducing miR-31 expression results in increased 
osteogenesis (Deng et al., 2013; McCully et al., 2018). Although MiR-31 
dysregulation in OP is well documented, little has been published with regards to 
its manipulation of bone marrow MSCs from at risk of fragility fractures (Weilner 
et al., 2016; Mäkitie et al., 2018). 
An increase in osterix protein expression at day 7 was observed on ICW analysis 
in both OA and NOF patient groups, with the addition of differentiation media 
again leading to an additive effect with the miRNA nanoparticle (Figure 4-6). 
This increase in osteogenesis was not clearly evident on qRT-PCR, with a trend 
to increase expression in all osteogenic conditions in the NOF group the main 
finding (Figure 4-4). 
The disappointing qRT-PCR results may have been impaired due to the timepoint 
of analysis, with day 7 representing an early timepoint for adipogenesis and 
osteogenesis. More clear results between the culture conditions would be 
expected at a later timepoint (Tsimbouri, 2015; Young et al., 2015). With only 
having 3 patients per group, the results may have suffered due to variability 
between patients. Increasing the patient number, and replicate number 
analysed may also reduce the variability observed in the qRT-PCR data.  
These experiments have examined the effect on one form of MSC differentiation 
after the manipulation of a single miRNA. Due to the non-specific binding of 
miRNAs viewing these results in isolation would be ill-advised. Both miRNAs have 
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been shown to be abnormally expressed in other diseases. Upregulation of miR-
31 is observed in squamous cell cancers of the lung, head and neck and 
oesophagus, post myocardial infarction, with reduced expression in sepsis and 
cancers of breast, prostate, and ovarian cancers tissue (Van Der Heide et al., 
2016; Martinez et al., 2017; T. Yu et al., 2018). The wide ranging, multiple 
tissue type sites regulated by MiR-31 are due to it targeting genes related to cell 
proliferation, apoptosis and cell motility (Stepicheva and Song, 2016). With 
regards to miR-143 it has been implicated in cardiovascular disease, the 
development of type 2 diabetes mellitus and many malignancies such as 
colorectal and pancreatic cancer (B. Yu et al., 2018; Li, Fan and Chen, 2018; Li 
et al., 2019; Xie et al., 2019). 
Thus, the implications of delivering a systemic miRNA therapy, to induce 
osteogenesis and improve bone density, on other physiological systems may be 
far ranging. Analysis of the miRNA manipulation on other cell lines, or disease 
models would be imperative before upscaling to in vivo experimentation. 
Furthermore, the crossover between osteogenesis and adipogenesis in the 
function of miR-143 highlights that targeting a single miRNA in attempt to 
provide a therapeutic effect may be ineffective.  
Developing our understanding of miRNAs in bone pathophysiology is of great 
therapeutic importance. This experiment provides insight to the potential role 
miR-31 and miR-143 could play in preventing or treating OP. These results have 
importance due to the limited published results of studies utilising bone marrow 
MSCs from patients with, or at risk of, OP. 
4.5.2  Metabolomic analysis displays manipulation of 
differentiation 
Metabolomic data shows interesting findings, providing a clearer insight into the 
mechanisms of osteogenic differentiation induced by AmiR-31. The conclusions 
are limited by the small-scale experiment, with only one technical replicate per 
biological replicate, i.e. 3 patients per condition. However, interesting 
summations can still be drawn. 
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4.5.2.1 Analysis of heatmaps and PCA plots 
Metabolomic experiments generate vast amounts of data, which is a feature that 
is both lauded and criticised of this technique (Daviss, 2005). Therefore, key 
pathways are required to be selected, relevant to the research question. 
Analysis within this experiment was focused on the metabolism of amino acids, 
carbohydrates and lipids.  
On assessing the metabolic profile of the culture conditions during the AmiR-31 
experiment, large differences were evident in several areas associated with MSC 
activity and osteogenesis. 
Displayed in the heatmaps, Figure 4-7, Figure 4-13 and Figure 4-17, the 
osteogenic AmiR-31 condition frequently produced several fold-change in 
metabolite abundance, most notably in the amino acid and carbohydrate 
metabolite dataset. These metabolomic pathways have been linked to 
osteogenesis and MSC differentiation (Sampath et al., 2008). A quiescent MSC 
state is associated with low abundance of metabolites in these pathways (Chung 
et al., 2007), again indicative of both patient groups undergoing differentiation 
and proliferation. This effect was demonstrated in both the OA and NOF group, 
again showing the potential of MSCs from the NOF group to undergo 
differentiation upon the correct stimulus. 
The heat maps and PCA plots of amino acid and carbohydrate metabolism in 
Figure 4-7, Figure 4-9, Figure 4-11 and Figure 4-13 demonstrate a low abundance 
of metabolites in the basal conditions. The addition of osteogenic media causes 
notable increases, however the strongest expression in both groups is observed 
upon addition of AmiR-31 to the osteogenic media. Encouragingly this effect was 
seen in the NOF group. This is suggestive that at an early time point to observe a 
large increase in osteogenic differentiation stimulated by AmiR-31 a positive 
control condition is required. The stark difference in effect may have lessened 
at a later time point, i.e. with longer culture the osteogenic effects of AmiR-31 
may have become more apparent and less reliant on the osteoinductive 
conditioned media. 
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The lipid profile produced less clear results, the PCA plot in Figure 4-15 shows 
significant overlap in all conditions. The heatmaps in Figure 4-17 demonstrate 
mixed increased and decreased fold changes in lipid metabolites in the AmR-31 
condition. Changes in lipid metabolism have been described in the process of 
osteogenic differentiation, however the effects in this experiment were not 
clearly in keeping with these (Alakpa et al., 2016). It may be that a longer 
culture duration would provide greater insight to the effect AmiR-31 has on lipid 
metabolism and osteogenesis. 
4.5.2.2 Network analysis 
The IPA software predicted AmiR-31 to lead to up and downregulation of several 
pathways, with often opposing effects in the OA and NOF group.  
The previous analysis in the heatmaps suggested the osteogenic media and AmiR-
31 condition to be the most active, however the strongest levels of change of 
expression occurred in the NOF basal media and AmiR-31 condition. This is 
evident in Figure 4-22 of network 1. In network 1 the addition of osteogenic 
media produced similar changes to the pathway, but the extent of change in 
expression was less strong than in the basal media and AmiR-31 condition. 
Glutathione was noted to be a crucial part of Network 1. Glutathione is known to 
be involved in osteogenic differentiation and its redox status also key to 
osteoclastogenesis (Romagnoli et al., 2013). It is thought to be pivotal to bone 
remodelling. Glutathione expression was predicted to increase in both patient 
groups on culturing with osteogenic media, Figure 4-21. The addition of the 
AmiR-31 to basal media was predicted to produce an increase in glutathione 
expression in the NOF group but a decrease in the OA group, Figure 4-22. This 
difference is intriguing as supplementing levels of glutathione are associated 
with osteogenesis, however glutathione levels are known to decrease during 
osteogenesis induced by differentiation media (Romagnoli et al., 2013). It is 
encouraging to see it highlighted in the IPA network, but intriguing to observe a 
strong difference between the patient groups. 
Network 2, Figure 4-23, was centred upon AKT, PP2A and AMPK. This network is 
intrinsic to cell survival, and tissue growth, with AKT a regulator of apoptosis. 
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Furthermore, AKT is a known regulator of osteogenic differentiation, the 
inhibition of AKT function is seen to impair osteoblast differentiation and 
maturation (Mukherjee and Rotwein, 2009; Baker, Sohn and Tuan, 2015). Due to 
the regulation AKT plays in osteogenesis, it is of interest to note this pathway to 
be predicted to be upregulated in the NOF group, suggesting the positive 
differentiation stimulus provided by AmiR-31. This result was not replicated in 
the OA group, with molecules targeting AKT predicted to be decreased in 
expression. 
The final network analysed in Figure 4-25, network 4 surprisingly predicted large 
differences in adenosine triphosphate (ATP) expression. ATP is a crucial 
metabolite which plays fundamental roles as an energy transfer molecule, a 
phosphate donor and in intracellular signalling (Tantama and Yellen, 2014). The 
NOF group was predicted to have high levels of expression of ATP on addition of 
AmiR-31. The OA group was observed to have predicted low expression of ATP. 
ATP function has also been linked to MSC differentiation, with pre-treatment of 
ATP during in vitro cultures leading to enhanced adipogenesis and osteogenesis 
(Ciciarello et al., 2013), and its role in osteogenesis recently described to be 
dependent on intracellular calcium pathways (Stovall et al., 2019). This network 
provides further confirmation of the positive differentiation stimuli provided by 
AmiR-31. 
The above networks demonstrated intriguing results in the NOF group, suggestive 
of a pro-differentiation state induced by AmiR-31. The results in the OA group 
did not mirror these trends, despite in previous chapters showing improved 
differentiation capacity. The time point utilised of the metabolomic analysis 
thus may be questioned. The effect of the addition of Amir-31 could be 
temporal, and potentially delayed in the NOF group, with an earlier increase 
present in the OA group, not captured at this timepoint of day 7. It would be 
important to interrogate these findings further with future experiments. 
It would be of interest to analyse the miR-143 mimic in similar metabolomic 
experiments to elucidate its role in MSC differentiation and osteogenesis further. 
Due to the financial constraints of this project it was unable to be performed 
within this study. These experiments will hopefully be conducted within the 
laboratory group in future research projects. 
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4.6 Conclusion 
This chapter demonstrates the potential for miRNA targeting therapies. Utilising 
nanoparticles osteogenic and adipogenic differentiation was manipulated. This 
effect was scrutinised by several modalities, and adds new information to the 
scientific literature with a metabolomic assessment of miRNA-31 manipulation. 
The data displayed in this chapter also paves a clear path for future work into 
the development of targeted therapies for the prevention of fragility fractures. 
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Chapter 5 
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5 Optimising Bone Marrow Derived MSC Spheroid 
Formation 
5.1 Introduction 
Developing consistent and credible 3D in vitro techniques for bone research is 
crucial to producing future translational work. They will allow improved analysis 
of basic science and more clinically relevant platforms for drug screening. 3D cell 
culture is more physiologically relevant than traditional 2D monolayer culture due 
to the recreation of physiological features such as a supportive matrix, tissue 
gradients and cell-cell interactions (Saleh et al., 2012). Such models therefore 
provide an improved approach for assessing drug therapies, and predicting their 
effect, prior to animal models and clinical trials. To this end, the utilisation of 3D 
models reduces the use of animal models, by bridging the gap between in vitro 
and in vivo conditions. In addition, the use of 3D human-physiologically relevant 
bioengineered models reduces the risk and cost of running clinical trials, thereby 
reducing financial waste in the Pharma sector (Saleh and Genever, 2011). 
Culturing cells as spheroids, a method of 3D cell culture, has been practiced in 
non-musculoskeletal research for several decades. Multiple different techniques 
exist for the formation of spheroids, which all share the same goal of reproducing 
the in vivo environment as closely as possible (Metzger et al., 2011; Saleh and 
Genever, 2011). The Hanging Drop technique (HD) has been successfully employed 
for several decades with multiple cell types (Han, Asano and Hsu, 2019). A small 
aliquot of a single cell suspension is utilised, after seeding the aliquots are 
converted to a droplet, which is kept in place due to surface tension. The cells 
accumulate at the tip of the droplet, at the liquid-air interface, and are prevented 
from monolayer formation. After proliferation the spheroid is transported for 
ongoing culture in a non-adherent well (Breslin and O’Driscoll, 2013).  
A second reputable technique is the Ultra-Low Attachment (ULA) method, which 
utilises a non-adherent coating to round bottomed wells. This is a form of the 
liquid overlay technique, also known as forced floating, and can be achieved by 
various techniques which prevent the cells from attaching to a vessel, including 
coating the plates with a substance such as 0.5% poly-2-hydroxylethyl 
methacrylate or the addition of 1.5% agarose to the culture medium (Ivascu and 
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Kubbies, 2006; Friedrich et al., 2009). This technique prevents cells from adhering 
to the tissue culture plastic and promotes cell-cell contacts, resulting in cell 
aggregation and spheroid formation. Multiple different cell types have been 
utilised for this techniques, with extensive use in cancer research due to its ability 
to allow high throughput screening and large scale production of spheroids (Costa 
et al., 2018). 
Finally, there is the magnetic nanoparticle (MNP) method (Souza et al., 2010; 
Lewis et al., 2015). Here, cells are loaded with super paramagnetic iron oxide 
nanoparticles, prior to being detached, and the resultant cell suspension pipetted 
into a well below a magnet. This causes cell levitation towards the magnet, 
encouraging aggregation of the cells, resulting in spheroid formation. This 
technique has also been applied to several cell types, and benefits from the ability 
of functionalisation of the nanoparticles. However, the success of the MNP 
technique in an unselected adherent fraction of BM MSCs has not been thoroughly 
investigated. Previous work in our group has used STRO-1 selected mesenchymal 
stromal cells and proprietary mesenchymal stromal cells, namely PromoCell 
human mesenchymal stem cells (PromoCell GmbH, Germany). 
Scaffold free techniques of spheroid formation were chosen for further analysis in 
this chapter. Scaffold techniques utilise a non-adhesive matrix, produced from 
substances such as collagen or hyaluronic acid, within the culture setting to 
promote spheroid formation. However, the use of scaffolds for spheroid based 
research has been criticised for its poor reproducibility, impaired analysis by 
optical techniques due to the scaffold size or transparency and finally therapeutics 
may be adsorbed by the scaffold instead of the cells, thus confounding the 
therapeutic effect (Gurski et al., 2009; Rimann and Graf-Hausner, 2012). 
Due to the multiple options available for spheroid culture, with varying degrees 
of complexity and cost, it is important to identify and optimise a technique. This 
will facilitate, and enhance, future in vitro research of musculoskeletal conditions 
utilising BM MSCs. 
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5.2 Objectives 
This chapter aims to thoroughly assess three established spheroid-forming 
techniques when used with BM MSCs. The hanging drop, ultra-low attachment and 
magnetic nanoparticle techniques will be assessed with BM MSCs from 
osteoarthritic donors and the spheroids produced will be assessed as follows. 
1. Assessment of spheroid size and effect on increasing seeding density. 
2. Determination of cell viability over time in 3D spheroid culture.  
3. Spheroid and cell morphological analysis via electron microscopy 
  
 
 
148 
Materials and Methods 
5.2.1 Cells and Spheroid forming techniques 
MSCs were cultured from BM samples from patients with OA, undergoing hip 
arthroplasty, as described in section 2.4.1. Three spheroid forming techniques 
were assessed: 
1. Hanging drop  
As described in section 2.6.1 MSCs were detached from a T75 flask and cell 
suspensions were prepared at concentrations of 5x103, 1x104, 2x104 cells per 40 
µl. A GravityPLUSTM (Perkin Elmer, Waltham, MA, USA) 96 well plate was used. 
After 24 or 72 hours of culture, the spheroid was transferred to a non-adherent 
plate placed below, GravityTRAPTM (Perkin Elmer, Waltham, MA, USA) for long 
term culture. Day 0 was on pipetting the cell suspension to the GravityPLUSTM  96 
well plate. 
2. Ultra-Low Attachment 
Described in 2.6.2 MSC cell suspensions were prepared at concentrations of 5x103, 
1x104, 2x104 cells per 100 µl. CellCarrier Spheroid ULA 96-well microplates (Perkin 
Elmer, Waltham, MA, USA) were used, which have round-bottomed wells and a 
non-adherent coating. Day 0 was on pipetting the cell suspension into the ULA 96-
well microplate. 
3. Magnetic nanoparticle levitation 
Described in detail in section 2.6.4, MSCs were seeded at concentrations of 5x103, 
1x104, 2x104 cells in a 24 well plate. The media was exchanged for basal media 
containing 0.1mg/ml 200nm diameter magnetic nanoparticles (mNPs) (Chemicell, 
GmbH, Berlin, Germany), followed by an incubation period in the presence of a 
magnetic field of 350mT. After this incubation period the cells were washed, 
detached and re-suspended in 4ml of media within a 6 well plate, with a magnet 
placed above; this was taken as day 0 in spheroid culture. 
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5.2.2 Light microscopy 
Spheroids were imaged at defined time points, days 3 and 21, to quantify their 
diameter. A minimum of 3 spheroids were imaged at each timepoint. The maximal 
diameter was measured and the mean diameter was utilised for each cell seeding 
concentration and technique. 
5.2.3 Viability staining 
Cell viability within the spheroid was determined at time points of day 7 and 21, 
using an ethidium homodimer/calcein AM viability kit (Life Technologies, 
Carlsbad, CA, USA). This technique is described in full in section 2.16. Fluorescent 
microscopy was then performed, utilising a Zeiss Axiovert 200M fluorescent 
microscope.  
A representative cross-section of the spheroid was assessed to evaluated the 
presence of necrosis, utilising ImageJ software. FITC and TRITC signals from the 
cross-section were then plotted. The FITC channel represented live cells and the 
TRITC dead cells, indicative of necrosis.  
5.2.4 Electron Microscopy 
As fully described in 2.15 at 24 hours of spheroid formation, samples were 
prepared for scanning electron microscopy (SEM) and transmission electron 
microscopy (TEM). SEM samples were mounted on to stubs and sputter coated in 
gold prior to microscopy. TEM samples were embedded in resin and sectioned prior 
to imaging.  
5.2.5  Statistical analysis 
To determine the presence of a statistically significant difference in spheroid size 
produced, spheroid diameters from differing seeding densities were compared 
with the Kruskal-Wallis test with Dunn’s multiple comparison. 
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Results 
5.2.6 Hanging Drop (HD) Technique 
5.2.6.1 Cell number and spheroid size 
The effect of spheroid seeding density was assessed in the HD method and 
significant differences were observed, Figure 5-1. At day 3, a defined, stable 
structure morphology was observed, with a significant increase in size with 
increasing cell number. At day 21 of culture the diameter size had reduced in all 
seeding densities. A statistically significant increase in spheroid diameter was 
maintained when comparing the lowest and highest seeding density groups. 
A
 
B
 
Figure 5-1 Mean spheroid diameter measured at day 3 (A) and day 21 (B) by the HD 
technique with different cell seeding densities. A: N=3 for all seeding densities. p = 0.0036. 
B: 5 x 103 N=10, 1 x 104 N= 8, and 2 x 104 N= 6. p = 0.0249. 
 
5.2.6.2 Hanging Drop Spheroid Viability 
High levels of cell viability were noted for HD spheroids at day 7, Figure 5-2. Where 
irregular shaped spheroids were observed at 24 hours with SEM (Figure 5-4), by 
day 7, spheroids demonstrated improved morphology, generating spherical and 
robust spheroids. At day 21, there was evidence of dead cells, particularly at the 
higher seeding density, but the spheroids remained mainly viable, Figure 5-3. A 
round morphology was maintained, but the spheroid size was greatly decreased, 
supporting the measurement graphs (day 3 and day 21). 
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Figure 5-2. Day 7 viability staining- the cross-sectional viable (green; FITC) and dead (red; 
TRITC) fluorescent signal after calcein/ethidium staining in HD spheroids with different cell 
seeding densities. Peaks in the graph represent increasing signal. Scale bar 200 µm. 
 
 
Figure 5-3 Day 21 viability- the cross-sectional viable (green; FITC) and dead (red; TRITC) 
fluorescent signal after calcein/ethidium staining in HD spheroids with different cell seeding 
densities. Peaks in the graph represent increasing signal. Scale bar 100 µm. 
 
5.2.6.3 Electron microscopy 
Electron microscopy was performed at 24 hours. Figure 5-4 represents the SEM, 
whilst Figure 5-5 the TEM images obtained. SEM images showed the multicellular 
aggregate formation of MSCs at 24 hours, with true spheroid formation not yet 
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visible. Increasing the cell number at seeding was shown to increase the spheroid 
size, Figure 5-4. In addition, an irregular border and shape of the spheroid was 
observed via SEM. 
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Figure 5-4 Scanning electron microscopy of spheroids formed by the HD technique at 24 
hours with different cell seeding densities. A1-A3 scale bar 100 µm, B1-B3 10 µm and C1-C3 
2 µm. 
 
TEM allowed the observation of individual cells within the spheroids at all seeding 
densities. Cell-cell gap junctions were noted at all seeding densities. Organelles 
were also visible with the presence of the nuclear membrane evident in all seeding 
densities, Figure 5-5. 
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Cell number HD spheroids at 24 hours 
5 x 103 
  
1 x 10 4 
  
2 x 10 4 
  
Figure 5-5 Transmission electron micrographs of HD spheroids at 24 hours, with different 
cell seeding densities. Blue arrows demonstrate nuclear membranes and red arrows inter-
cellular connections. Scale bar 1 µm. 
 
5.2.7 Ultra-Low Attachment Technique 
5.2.7.1 Cell number and spheroid size 
Adjusting the spheroid seeding number significantly increased the spheroid 
diameter using the ULA technique, Figure 5-6. At both days 3 and 21, the size of 
spheroid produced was consistent, with a small range of diameters observed in 
each of the seeding groups. However, a reduction in spheroid size was noted with 
time in culture. 
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A
 
B
 
Figure 5-6 Mean spheroid diameter measured at day 3 (A) and day 21 (B) by the ULA 
technique with different cell seeding densities. N= 6. p < 0.0001. 
 
5.2.7.2 Ultra-Low Attachment Spheroid Viability staining 
ULA generated highly viable spheroids at day 7 across the seeding densities, Figure 
5-7. A uniform, round morphology was observed. At day 21 of culture the lowest 
seeding density spheroids remained mainly viable, however dead cells were 
evident at higher seeding density, Figure 5-8. A robust, round morphology was 
maintained at day 21. 
 
Figure 5-7 Day 7 viability staining-the cross-sectional viable (green; FITC) and dead (red; 
TRITC) fluorescent signal after calcein/ethidium staining in ULA spheroids, with different 
cell seeding densities. Peaks in the graph represent increasing signal. Scale bar 200 µm. 
 
5x
10
3
1x
10
4
2x
10
4
0
100
200
300
400
500
600
Cell Number
Sp
he
ro
id
 D
ia
m
et
er
 / 
µm
***
5x
10
3
1x
10
4
2x
10
4  
0
100
200
300
400
500
600
Cell Number
Sp
he
ro
id
 D
ia
m
et
er
 / 
µm
***
 
 
155 
 
Figure 5-8 Day 21 viability staining- the cross-sectional viable (green; FITC) and dead (red; 
TRITC) fluorescent signal after calcein/ethidium staining in ULA spheroids, with different 
cell seeding densities. Peaks in the graph represent increasing signal. Scale bar 100 µm. 
 
5.2.7.3 Electron microscopy 
SEM supported the diameter values recorded, indicating large, highly regular 
spheroids are produced when using the ULA technique, Figure 5-9. This was 
evident at the early time point of 24 hours and was consistent across all 3 seeding 
densities. 
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 100µm 10µm 2µm 
Figure 5-9 Scanning electron microscopy of spheroids formed by the ULA technique at 24 
hours with different cell seeding densities. Scale bars A1-A2 100 µm, A3 200 µm, B1-B3 10 
µm and C1-C3 2 µm. 
 
TEM demonstrated many intercellular connections between neighbouring cells, 
supporting the formation of a regular spheroid at 24 hours, rather than a 
multicellular aggregate, Figure 5-10. The imaged spheroids appeared healthy with 
multiple organelles, including mitochondria visible. 
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Cell number ULA spheroids at 24 hours 
5 x 103 
  
1 x 10 4 
  
2 x 10 4 
  
Figure 5-10 Transmission electron micrographs of ULA spheroids at 24 hours, with different 
cell seeding densities. Blue arrow demonstrating mitochondria, red arrow inter-cellular 
connections. Scale bar 1 µm. 
 
5.2.8 Magnetic Nanoparticle Technique 
5.2.8.1 Cell Number and spheroid size 
Spheroids were generated and diameters were assessed by light microscopy, using 
3 different cell seeding densities, Figure 5-11. Surprisingly, an increase in 
diameter was not observed with increasing cell seeding density. The two lower 
seeding densities were seen to produce larger spheroids, however, there was no 
significant difference in diameter between the 3 seeding densities. At day 21 of 
culture the two smaller seeding density spheroids appear to have condensed in 
diameter, Figure 5-11-B. However, the largest seeding density remained relatively 
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similar to the early culture time point. No statistically significant difference in 
diameter was observed. Large variability in spheroid diameter was noted at both 
timepoints. 
A
 
B
 
Figure 5-11 Mean spheroid diameter with SD produced at day 3 (A) and day 21 (B) by the 
MNP technique with three different cell seeding densities. A- N= 3, B- 5 x 10 3 and 1 x 104 N= 
3, 2 x 104 N=4. No statistically significant difference was recorded. 
 
5.2.8.2 Magnetic Nanoparticle Spheroid Viability 
Viability staining was performed at day 7 and day 21 of culture, Figure 5-12 and 
Figure 5-13. High levels of ethidium were observed in all spheroid seeding 
densities at both time points. This suggests necrosis within the spheroid at day 7 
of culture. Small healthy spheroids were also present, noted by the calcein 
staining. At day 21 there was also evidence of cell escape from the spheroid mass 
in the 2 x 104 seeding density, with the formation of a monolayer on the well.  
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Figure 5-12 Day 7 viability staining - cross-sectional viable (green; FITC) and dead (red; 
TRITC) fluorescent signal after calcein/ethidium staining in MNP spheroids with different 
cell seeding densities. Peaks in the graph represent increasing signal. Scale bar 200 µm. 
 
 
Figure 5-13 Day 21 viability staining- the cross-sectional viable (green; FITC) and dead (red; 
TRITC) fluorescent signal after calcein/ethidium staining in MNP spheroids with different 
cell seeding densities. Cell escape and monolayer formation is evident in the 2 x 104 seeding 
density. Peaks in the graph represent increasing signal. Scale bar 100 µm. 
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5.2.8.3 Electron Microscopy 
Figure 5-14 demonstrates the SEM images of the MNP generated spheroids. 
Multiple spheroids were produced with varying size for each seeding density, as 
illustrated in Figure 5-14 image A2. The presence of the MNPs on the outside of 
the spheroid were noted, whilst cellular projections were also visible on the 
spheroid surface. Non-circular morphology was produced by this method, in all 
seeding densities. 
Cell 
number  
MNP Spheroids at 24 hours 
5 x 103 A1
 
B1
 
C1
 
1 x 10 4 A2
 
B2
 
C2
 
2 x 10 4 A3
 
B3
 
C3
 
Figure 5-14 Scanning electron microscopy of spheroids formed by the MNP technique at 24 
hours with different cell seeding densities. Black arrows demonstrate MNPs on the surface 
of the spheroids. Red arrows depict cellular projections. A1-A3 scale bar 100 µm, B1-B3 10 
µm and C1-C3 2 µm. 
 
Transmission electron microscopy (TEM) allowed visualisation of MNPs 
internalisation into MSCs and subsequent intracellular localisation, Figure 5-15. 
MNPs were clearly present on the cell surface, within vesicles and free within the 
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cytoplasm, demonstrating their effective uptake into the MSCs. TEM also 
highlighted the cell-cell interactions, with the presence of gap junctions notable. 
Cell 
number 
MNP Spheroids at 24 hours 
5 x 103 
  
1 x 10 4 
  
2 x 10 4 
  
Figure 5-15 Transmission electron micrographs of MNP spheroids at 24 hours, with different 
cell seeding densities. Black arrows depict MNPs present on the cell surface and 
intracellularly- within vesicles and free in the cytoplasm. Red arrows depict inter-cellular 
connections. Scale bar 1 µm. 
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5.3 Discussion 
This chapter has investigated the suitability of three different spheroid forming 
techniques in the culture of BM MSCs. All three techniques are well established 
and have been utilised thoroughly in other areas of in vitro research. A summary 
of the results generated is shown in Table 5-1.  
Table 5-1 Summary of results for 3 spheroid forming techniques. 
Technique 
Spheroid size-
with seeding 
density 
Spheroid size-
with time Viable culture 
Electron 
microscopy 
HD Increases Decreases Yes Aggregate & 
non-circular 
ULA Increases Decreases Yes Circular  
MNP No change Decreases No Non-circular 
 
5.3.1 Hanging Drop technique generates stable spheroids over 72 
hours 
The HD technique is a well-established method of 3D culture in vitro. It has been 
utilised for many different cell types (Kelm et al., 2003). Its advantages include 
its ability to produce easily accessible spheroids and its potential for low cost 
culture if using a standard 96-well plate (Breslin and O’Driscoll, 2013). 
The HD method took noticeably longer to form spheroids than the ULA technique. 
At 24 hours multicellular aggregates were visible, however the morphology was 
greatly improved by day 7. Although slow to form, in comparison to the other 
techniques analysed, the viability was uniformly high across all seeding densities. 
This is comparable with other studies utilising the HD technique (Rimann and Graf-
Hausner, 2012). This method also potentially allows scale up, for producing 
multiple spheroids or drug testing platforms, with the use of multiwell plates 
(Tung et al., 2011). 
Electron microscopy at 24 hours further supported the longer time needed to form 
spheroids with the HD technique. SEM demonstrated an irregular morphology with 
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all seeding densities at 24 hours. However, TEM demonstrated healthy cells with 
evidence of inter-cellular connections forming. As shown in Figure 5-16, spheroid 
formation occurs over three stages; (1) dispersed cells are drawn closer together 
to form loose aggregates; (2) this direct cell-cell contact encourages increased 
cadherin expression, which is accumulated at the cell membranes, and (3) the 
cells are finally compacted into aggregates to form spheroids (Cui, Hartanto and 
Zhang, 2017). Whilst cell-cell contacts are forming within 24 hours, utilising BM 
MSCs with the HD technique, requires more time for the stages of spheroid 
formation to progress. 
 
Figure 5-16 The three stages of multicellular spheroid formation. Initial loose cell 
aggregates encourage direct cell-cell contact, which enable cadherin accumulation and 
spheroid compaction (Cui, Hartanto and Zhang, 2017). 
 
For long-term culture of spheroids, the HD method requires transfer of the 
samples to a non-adherent plate. This allows medium exchange and easier 
visualisation. The step required to transfer can be technically challenging and can 
result in dissociation of the spheroid. It also incurs the extra cost of an additional 
plate. When performing large scale studies, this extra technical step, and cost, 
has the potential to become prohibitive. Furthermore, spheroid size was observed 
to decrease with time in the HD group, from day 3 to day 21 in all seeding 
densities, Figure 5-1, which contributes to the technical challenge described 
above, and has been reinforced previously in the literature (Breslin and O’Driscoll, 
2013). 
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5.3.2 Ultra-Low Attachment technique rapidly produces spheroids 
with consistent morphology and viability 
The ULA method appears to be the quickest to form spheroids, and furthermore 
the least labour and material intensive. Spheroids were observed in the ULA wells 
within 24 hours, with a significant increase in size with increasing cell density. 
This is in keeping with previous research utilising this technique (Metzger et al., 
2011). However, with time, a notable reduction in size occurred, from a mean 
diameter of 502 µm to 272 µm in the 2x 104 seeding density, Figure 5-6. Change in 
spheroid size with long term culture has been reported previously, and may be 
due to the development of a central necrotic core (Ivascu and Kubbies, 2006; 
Mehta et al., 2012). Thus, handling of the spheroids became more difficult with 
time, as there was a greater risk of pipetting and damaging the spheroid. 
Macroscopic spheroids are less likely to be aspirated or dissociated when 
exchanging media and thus a lower stress and more consistent culture is 
achievable (Grässer et al., 2018). 
The morphology of the spheroid produced in the ULA technique was consistently 
the most geometrically circular, when observed by light microscopy and EM. This 
was observed across all cell seeding densities. The low attachment technique is 
well established and has been previously reported to generate reproducible, 
stable spheroids within 24 hours (Raghavan et al., 2016). 
Furthermore, the ULA method produced spheroids which were highly viable at 
both day 7 and 21 of culture, in keeping with literature published utilising other 
cell types, such as fibroblasts and endothelial cells, with the liquid-overlay 
technique (Metzger et al., 2011).  
5.3.3 Magnetic Nanoparticle technique generates spheroids of 
varied size with compromised viability 
The MNP method requires 2 overnight culture steps, therefore additional time to 
generate the spheroids is required using this technique. However, the MNP 
technique of spheroid formation has several unique advantages. As visualised in 
the TEM imaging, the MNPs freely enter the cells. Utilising the MNPs allows for 
cell labelling, either fluorescently or via electron microscopy. Additionally, the 
MNPs can serve as vehicles to allow the delivery of therapeutic substances. For 
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example, MNPs have been functionalised for use in gene silencing and provide 
great potential in regenerative medicine (Conde et al., 2015). GNPs have been 
functionalised with small interfering RNAs to silence protooncogenes (Conde et 
al., 2012), and MNPs have been shown to be able to be guided to the tumour site 
to initiate gene silencing through their delivery of silencing RNA, in a gastric 
cancer mouse model (Namiki et al., 2009). 
Surprisingly, the spheroid size produced by this technique did not increase with 
the cell seeding density. A maximum spheroid diameter was produced using the 
lower cell suspension of 1 x 104 cells; this was supported by the SEM images, Figure 
5-14. The inability for this technique to produce single, larger spheroids may be a 
disadvantage when performing a longer-term culture, where robust, large 
spheroids are practically easier. This is further compounded by the presence of 
multiple spheroids in one well, as opposed to other 3D culture techniques which 
typically result in one spheroid per well.  
It could be argued that the cell seeding densities used in the MNP technique were 
responsible for the failure to form one spheroid as observed in the other 
techniques. Each cell seeding density was pipetted into a large well, with a 
comparatively much greater volume of culture medium. However, this technique 
has been reproduced successfully within the laboratory group (Lewis et al., 2015, 
2017). It would be of interest to vary the well size and culture medium volume to 
observe if an improved morphology was produced.  
Viability staining demonstrated a large presence of dead cells within the spheroid. 
Cell escape from the spheroid and into monolayer formation, was also observed 
(Figure 5-13). This appeared to increase with culture duration and suggests cells 
may be migrating away from areas of cell necrosis. The cause of the necrosis was 
not obvious. At 24 hours viable cells were present within the spheroid, however 
with increasing time their numbers decreased. Research from our laboratory group 
has previously reported on the good viability achieved with this technique, (Lewis 
et al., 2017). However, they used STRO-1 selected or proprietary MSCs, and 
utilised a type 1 collagen gel, for the culture of their spheroid. It is postulated 
that these cell populations may possess improved cellular functions of viability, 
motility and proliferation in comparison to the unselected group.  
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Aggregates and spheroids were formed rapidly once the cells were detached and 
suspended by a magnetic charge. This step, whilst time efficient, may cause cell 
death due to the abnormally close, and fast forming, interactions between the 
cells. The other two techniques saw improved viability, and shared in a common 
a lack of external coercing force. 
The presence of necrosis within spheroid culture is common, and it offers benefits 
to cancer research as it may recreate the in vivo necrotic core of a tumour (Ivascu 
and Kubbies, 2006; Mehta et al., 2012). However, overall viability of the spheroid 
should persist in long term culture. The utilisation of the unselected BM MSCs and 
the MNP technique did not produce an optimal model for spheroid culture. 
5.4 Conclusion 
In this chapter, the ULA method has been identified as being optimal for spheroid 
culture of BM MSCs. Spheroids from this technique were notably healthier and also 
increased in size on increasing cell density. The hanging drop method similarly 
produced healthy spheroids, but was slower to form, and required and required 
additional time and cost for set up. After encouraging results within the 
department, the MNP technique produced disappointing results with abundant 
necrosis and poor morphology. 
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Chapter 6 
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6 Discussion 
6.1 Relevance of results 
Fragility fractures, secondary to OP, represent an enormous burden to 
healthcare services worldwide (Compston, McClung and Leslie, 2019). It is 
evident, due to changing demographics, that our current therapies have proven 
insufficient (Khosla and Shane, 2016; Khosla and Hofbauer, 2017). Furthermore, 
side effects such as atypical femoral fractures and jaw osteonecrosis cause 
serious morbidity and pose great challenges to a patient’s clinician (Shane et al., 
2014). Improvements in therapies for OP would lead to great benefits to society 
and importantly to reduce suffering of millions of patients. 
The results of these experiments have demonstrated several important findings, 
which will hopefully add to the knowledge required to develop targeted 
therapies for OP. 
6.1.1 The functionality of mesenchymal stromal cells from 
patients with neck of femur fractures is impaired 
The literature has many conflicting studies on the capacity and propensity of 
differentiation of MSCs from patients with OP. It is clear that a confounding 
matter in many of these studies is the age of donor used (Sethe, Scutt and 
Stolzing, 2006).  
The results of this study show that even in a small group of patients either 
suffering from OA or a NOF fracture, the functional capacity of MSCs differs. It 
may seem intuitive that MSCs from the NOF group would have decreased potency 
however their capability to commit to the osteogenic lineage was not 
compromised. The theory of adipogenic switch was again, not evident, in 
agreement with previous research of Abdallah & Kassem suggestive of local 
environmental factors playing a crucial role in the bone marrow niche, 
controlling MSC fate and ultimately bone marrow adiposity and strength 
(Abdallah and Kassem, 2012). 
Along with a reduction in differentiation capacity it is of great interest to 
observe significantly different extracellular markers of MSCs in the NOF group. 
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Additionally, these markers are known to signify MSC potency and differentiation 
potential and therefore adds further weight to the argument that dysfunction of 
MSCs plays a role in the development of OP (Rahman et al., 2014; Xu et al., 
2016). Little has been reported in the literature on this topic, and this data 
should provide impetus for further research, and to consider patients who have 
suffered a fragility fracture as potentially having impaired MSC functionality, 
and thus limiting expected treatment benefits. 
6.1.2 microRNA expression of mesenchymal stromal cells is 
dysregulated post neck of femur fracture  
Developing a more sensitive test for the diagnosis of OP is essential in the 
improvement of the management of the disease. Importantly, utilising a 
biomarker which is sensitive to increases in bone health and density would allow 
accurate treatment durations. This is currently not possible and results in often 
many years of drug therapy, with no strong evidence on when to stop, and what 
risk that poses to a patient (Compston, McClung and Leslie, 2019). 
The first utilisation of miRNAs in the management of OP may be their application 
as a biomarker, they will hopefully be applied as a blood sample to diagnose OP 
and identify patients at risk of developing the disease. Currently companies are 
developing this strategy, and panels for the investigation of samples for miRNA 
sample related to bone diseases have been made commercially available 
(TAmiRNA, Austria). A recent cost-utility model simulated the outcomes of 
utilising this method, via TAmiRNA’s osteomiRTM product, in the screening and 
management of OP in women, with favourable outcomes in comparison to DXA 
and the FRAX tool (Walter et al., 2018). 
Corelating miRNA expression to BMD will further our understanding of the role 
miRNAs can play in the current management of OP. This would hopefully allow 
for earlier diagnosis. Kelch et al found 5 miRNAs upregulated in a cohort of OP 
patients showed linear correlation with BMD values. Furthermore, levels of miR-
21-5p expression allowed identified of BMD levels correlating to osteopaenia or 
OP (Kelch et al., 2017). 
 
 
170 
The results of the miRNA expression in the NOF group in chapter 3 show that 
even in a small patient group there is significant dysregulation which cannot be 
solely attributed to the post fracture state (Nugent, 2017). The overlap of 
dysregulated miRNAs with known miRNAs associated with OP indicates their 
high-risk status for developing OP (Materozzi et al., 2018). This data, in a 
patient group without a diagnosis of OP, further highlights the potential utility of 
miRNAs in targeted therapies. 
It will be important for future research assessing miRNA expression in OP to be 
expanded upon to include a diverse range of patients. The main focus has been 
of Caucasian and Asian post-menopausal women (H. Li et al., 2014; Seeliger et 
al., 2014; Panach et al., 2015; Heilmeier et al., 2016). To provide a holistic view 
of the benefits of utilising miRNA expression in the management of OP future 
studies should be expanded to include male patients, multiple ethnicities and 
larger age ranges. 
6.1.3 microRNA manipulation represents an important method of 
differentiation control 
MiRNAs therapies are becoming increasingly close to clinical use, with multiple 
human trials in progress (Bonneau et al., 2019). They hold great promise for 
regenerative medicine, and as stated above, for the management of OP. 
The focus of miRNA research has often been on cancer (T. Yu et al., 2018). As 
such the osteogenic effect of inhibiting miR-31 has not been thoroughly 
investigated, with studies not yet utilising MSCs from the target patient group, 
or tissue source (Deng et al., 2013; Mizoguchi et al., 2013; McCully et al., 2018). 
This is a distinct benefit of the research presented in this thesis, as utilising the 
NOF group allows for the potential of miR-31 inhibition to be put into context. 
The osteogenic benefit of inhibiting miR-31 function has been previously 
described, and miR-31 is recognised as a regulator of osteogenic transcription 
factors osteopontin, osterix and osteocalcin (Deng et al., 2013). It was 
encouraging to see an increase in expression of osterix at day 7 of culture in 
response to the AmiR-31 and osteogenic media condition within the OA group. 
Assessing the effect of miR-31 inhibition has not been reported in the literature 
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in an OP patient group, as such this experiment, whilst ultimately not resulting 
in statistically significant upregulation in osteogenesis at day 7 in the NOF group 
on qRT-PCR or ICW analysis, provides a direction for future research. 
It was of great interest to observe the metabolomic effect of AmiR-31 on MSCs, a 
further area yet to be reported upon in the literature. Utilising metabolomic 
studies has become an increasingly important technique to gain a greater 
understanding of differentiation effects in bioengineering studies (McNamara et 
al., 2012; Tsimbouri et al., 2012). 
The addition of AmiR-31, in comparison to the control basal media condition, 
was predicted to lead to significant increase in molecules and networks related 
to differentiation and osteogenesis, namely glutathione, adenosine triphosphate 
and AKT, section 4.4.2.7 (Mukherjee and Rotwein, 2009; Ciciarello et al., 2013; 
Romagnoli et al., 2013). It was intriguing to note the difference between the 
two patient groups in these networks, with the AmiR-31 seemingly producing a 
stronger pro-differentiation effect in the NOF group. This is perhaps not in 
keeping with the results of the differentiation studies in chapter 1 or ICW 
analysis of osterix expression. It raises questions as to why this metabolomic 
effect is not resultant in a phenotypic change in the NOF group. The time point 
of the metabolomic study may also have importance, with glutathione levels 
noted to decrease after the induction of osteogenesis (Romagnoli et al., 2013). 
MiR-143 has wide ranging physiological roles, and is linked to many diseases, 
from colorectal cancer, type 2 diabetes mellitus and OP (Panach et al., 2015; Li, 
Fan and Chen, 2018; Li et al., 2019). It has been described as both an adipogenic 
and osteogenic differentiation regulator (Xie, Lim and Lodish, 2009; E. Li et al., 
2014). It represents an intriguing miRNA with regards to OP, due to the diseases 
association with increased bone marrow adiposity and reduced BMD (Abdallah 
and Kassem, 2012). MiR-143 expression was observed to be reduced in chapter 3, 
which correlates to published research concerning a genetic form of OP, and 
patients from who had an OP hip fracture (Panach et al., 2015; Mäkitie et al., 
2018).  
The results in chapter 4 demonstrated that miR-143 was pro-adipogenic on 
assessment by ICW, in the OA group only. It was not noted to significantly 
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stimulate differentiation in the NOF group as hypothesised. Adipogenesis was 
chosen to assess the restorative effects of the miR-143 mimic on differentiation. 
Due to its known role in osteoblast differentiation it will be important to assess 
miR-143 manipulation in osteogenic experiments within the NOF group also (E. Li 
et al., 2014). 
6.1.4 ULA technique identified as optimal method for spheroid 
formation in bone marrow derived MSCs 
To improve upon the clinical relativity of the miRNA cultures displayed in 
chapter 4, performing them in a 3D in vitro model would represent a significant 
advancement. Chapter 5 demonstrated the outcomes of three commonly used 
spheroid forming techniques. The importance of 3D culture has become 
increasingly recognised, and reduces the gap between in vitro research and 
human trials (Saleh and Genever, 2011). Utilising MSCs from the OA group it was 
evident that the ULA technique produced spheroids rapidly, with little technical 
difficulty. Furthermore, viability was satisfactory at all time points. 
The ULA technique is a form of liquid overlay spheroid formation, and has been 
utilised successfully for several decades (Carlsson and Yuhas, 1984). It has 
remained a popular method for spheroid culture due to its low cost, low shear 
stress environment, non-requirement of specialized equipment and its ability to 
be upscaled being advantageous for high throughput screening (Costa et al., 
2018). 
The HD technique produced spheroids of good morphology, but is a less 
attractive method for larger, future studies and application to NOF MSCs due to 
its labour intensiveness, cost and difficulties in scaling up the spheroid size. 
These are common criticisms of the HD technique (Breslin and O’Driscoll, 2013; 
Costa et al., 2018). 
The MNP technique benefits from the ability to utilise the nanoparticles to 
deliver bioactive substances, a significant benefit over the other two 
techniques. This functionalisation of nanoparticles, and the ability to deliver 
small interfering RNA accurately to a tissue, provides great interest for 
regenerative medicine (Conde et al., 2015). The ultimate aim of RNA 
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interference (RNAi) is to modulate the phenotype of the tissue affected by the 
disease, whilst minimizing off target and systemic side effects (Conde et al., 
2015).The addition of nanoparticles was previously shown to not compromise cell 
viability or function (Lewis et al., 2015; McCully et al., 2018). Unfortunately, in 
this experiment poor spheroid shape and viability was produced in the MNP 
group. Differing from previous studies utilising this technique in our research 
group, the MSCs were from bone marrow aspirates, and were not proprietary 
MSCs (Lewis et al., 2017). 
The experimentations in this chapter determined the ULA technique to be the 
optimal method for spheroid formation in MSCs from a bone marrow source, and 
provide a platform to be utilised for future studies in the NOF group. 
6.2 Limitations 
The applicability of the results from this research are limited by the small 
sample size. To improve the confidence of these results, performing larger 
experiments with more strict and controlled inclusion criteria would be 
required. Furthermore, increasing the number of technical replicates utilised in 
the metabolomic experiments would provide greater validity. 
To ensure the patients were truly OP a DXA scan would need to be performed. 
Furthermore, using a control group which was not afflicted by a bone disease, 
such as OA would be a significant improvement. This would potentially provide 
clearer distinctions in bone microarchitectural indices on microCT scanning. 
Bone marrow MSCs from patients suffering from OA were utilised as a control 
group, largely to provide an easy source of cells. However, OA is known to 
produce its own dysregulation of miRNA expression and result in changes in the 
microscopic characteristics of cortical and trabecular bone (Jenkins et al., 2013; 
Nugent, 2016). However, the utilisation of bone samples from healthy donors 
would not be without its difficulties, with regards to access to these samples 
and/or cost. 
The ICW and qRT-PCR analysis of miRNA manipulation at day 7 provided a basis 
for understanding the effect on differentiation this has. Utilising further 
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timepoints and more markers of adipogenic and osteogenic differentiation would 
have allowed for improved conclusions to be drawn to the effectiveness of the 
miR-143 mimic and AmiR-31. Performing an analysis of osteogenic differentiation 
in the miR-143 mimic study would also have been an improvement. 
6.3 Future work 
6.3.1 Further interrogation of mesenchymal stromal cell biology 
in patients who have suffered fragility fractures 
As discussed above, the properties and functional capacity of MSCs from OP 
patients requires significant further research. The apparent differences on flow 
cytometry of extracellular markers warrant further interrogation. Expanding this 
experiment would provide further insight to the significance of this finding and 
provide clarity to the extent of its usefulness. 
Conducting a more controlled study with age matched groups would reduce the 
effect on ageing on MSCs. Ideally groups would be: OP, NOF, healthy with a pre-
operative DXA scan to identify their bone status. It is idealistic to have a healthy 
group, with no bone disease, however in practice this would be difficult to 
achieve. Thus, continuing to use an OA group as a control would be the most 
practical option. The experiment would aim to explore differences in extra-
cellular markers of MSCs in OP, and determine if patients at high risk of the 
disease, who have suffered a fragility fracture, express similar profiles. 
The MSCs from the above study would also be used in further differentiation 
studies and in immune suppression assays to determine their functionality. 
6.3.2 Longer culture and assessment of effect of microRNA-31 in 
mesenchymal stromal cells 
The short term metabolomic effect of AmiR-31 was identified with the 7-day 
culture. However, to gain a fuller understanding of the potential usefulness of 
miR-31 as a therapeutic target to increase osteogenesis it would be important to 
scale up this experiment, with a multiple timepoints, both earlier and later, 
greater number of biological and technical replicates. This would be in 
conjunction with further protein and gene level of analysis of differentiation. 
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These conditions would then be applied to a 3D culture. An assessment of 
differentiation would be undertaken via sectioning the spheroids and performing 
immunofluorescent staining. Furthermore, the spheroids could be disaggregated 
and the RNA extracted, to allow qRT-PCR analysis. 
Utilising these conditions, in both monolayer and 3D techniques, could allow for 
the assessment of other miRNAs with potential therapeutic activity. As 
demonstrated with the miR-143 culture, it would not need to be limited to 
osteogenesis. Focussing on local bone marrow niche regulators could provide 
other methods to increase the activity and vitality of MSCs in patients who have 
suffered a fragility fracture. 
6.3.3 Assessing the impact of current osteoporosis therapies on 
microRNA expression 
It is clear that miRNAs provide a potential biomarker and therapeutic targets to 
manipulate osteogenesis (Weilner et al., 2015; Heilmeier et al., 2016; Sun et 
al., 2016), however the effect on their expression from current therapies is yet 
to be fully explored. A recent study has assessed this topic in a rat in vivo model 
of postmenopausal OP, with zoledronate and teriparatide have been observed to 
revert miRNA changes associated with the disease (Kocijan et al., 2020). 
Conducting a culture of human BM MSCs with commonly used drug therapies for 
OP, such as bisphosphonates, would be followed by an assessment of miRNA 
expression. This would ascertain the extent of non-specific targeting already 
occurring with first line therapies. Not only would this provide useful data on 
miRNA expression but would prevent replicating current inappropriate 
therapeutic strategies. 
6.3.4 Application of three-dimensional culture method to 
osteoporotic mesenchymal stromal cells 
The ULA spheroid forming method was proven successful in the OA patient 
group, and is required to be applied to the NOF patient group. This would ideally 
be extended to patient samples who have a pre-operative diagnosis of OP, via 
DXA scanning. The OA group would be utilised as a control for comparison. 
Furthermore, an assessment of differentiation through culture in differentiation 
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media would be performed. At the end of culture an assessment of osteogenesis 
and adipogenesis would be made, to ensure the model remains applicable to 
differentiation experimentation. This would be performed via fixing and 
sectioning the spheroids, prior to performing immunofluorescent staining. 
  
 
 
177 
6.4 Thesis conclusion 
This thesis achieved the aims outlined in Chapter 1. MSCs from patients who 
have suffered a NOF have demonstrated abnormal expression of extracellular 
markers in comparison to OA patients, and decreased differentiation capabilities 
suggestive of impaired MSC function. Furthermore, miRNA expression in this 
group, without a known diagnosis of OP, shows significant dysregulation. By 
targeting two key miRNAs, linked to the pathogenesis of OP, differentiation of 
MSCs was manipulated adding further evidence to the promise of utilising 
miRNAs in the management and treatment of OP. Finally, an optimal technique 
was identified for the 3D culture of MSCs from a bone marrow source, and has 
been prepared for future experiments. 
These results provide further insight into the impaired MSC function in patients 
who have suffered a fragility fracture, and will hopefully help in the future 
development of targeted therapies. 
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